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Functions of muscle mass 
 
The main function of skeletal muscle is to maintain posture and allow movement of the 
human body. In accordance, muscle mass is a strong predictor for muscle strength, physical 
function and athletic performance. The muscle is a highly adaptive tissue that responds 
rapidly to anabolic stimuli, such as food intake and physical activity. Conversely, conditions 
of fasting and immobilization may cause rapid muscle loss. The loss of muscle mass results 
in a loss of muscle strength, physical function and performance. During the lifespan, muscle 
mass decreases progressively, which may lead to frailty and an increased risk of developing 
metabolic diseases later in life (1-3). Therefore, it is important to prevent or attenuate such 
loss of muscle mass. Acknowledging the capacity of skeletal muscle tissue to respond to 
anabolic stimuli, the two main strategies to preserve muscle mass are dietary protein intake 
and physical activity (4). In situations such as injury or illness, implementation of a physical 
activity intervention is not always possible. Therefore, there is a need for nutritional 
intervention strategies to attenuate the loss of muscle mass and strength. In this thesis, the 
effects of different nutritional intervention strategies to attenuate the loss of muscle mass 
are being evaluated in various settings and populations.  
 
Consequences of muscle loss 
 
Athletes 
Along with its well-known health benefits, an inevitable part of participating in sports is the 
risk of injury. Knee injuries occur frequently in many sports, representing 14-33% of all 
injuries (5, 6). Rehabilitation of injury often requires an initial phase of complete 
immobilization of the joint, usually by a plaster cast or a brace (7). Depending on the severity 
of the injury, average recovery time ranges from 9–23 days, with approximately two-thirds 
of the injuries recovering within 7 days (5, 6). Such a short period of muscle disuse (≤7 days) 
already leads to a substantial decline in muscle mass (0.5-1.0% per day) (8, 9), which is 
accompanied by a rapid loss of muscle strength (1-2% per day) and a concomitant decrease 
in physical and athletic performance (8, 9). Furthermore, a decline in muscle mass and 
strength not only prolongs the time needed for an athlete to return to competition level, 
but also increases the recurrence risk for injuries (10-12). Unfortunately, the loss of muscle 
mass occurs at a much faster rate than the regain of muscle mass (13). Even after only 2 
weeks of immobilization, a rehabilitation program of 4 weeks including 3 sessions of 
resistance-type exercise per week is needed to regain the muscle mass that was lost (13). 
When an athlete is unable to participate in such a progressive exercise-based rehabilitation 
program due to pain or other injury-related complications, the recovery may take even 
longer. It is therefore important to find strategies to prevent or attenuate the loss of muscle 
mass and strength during a period of disuse.  
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Older adults  
From the age of ~35 years, muscle mass starts to decline progressively by 0.4-1.0% per year 
(1). The age-related loss of muscle mass and strength in otherwise healthy, older individuals 
is also referred to as sarcopenia. For older adults that already experience this age-related 
decline in muscle mass, a period of bed rest or immobilization due to disease or surgery 
leads to a more rapid decline in muscle mass and strength. The decline in muscle mass and 
strength can result in an increased risk of developing physical disabilities and in the inability 
to maintain daily functioning (14). Consequently, older adults have a higher risk of 
institutionalization and hospitalization and a decreased quality of life after being exposed 
to short periods of bed rest or immobilization.  
The average hospital stay after surgery tends to be short (~7 days) for older patients (15). 
Such short periods of muscle disuse (5 days) have been shown to result in a loss of 
quadriceps cross-sectional area (CSA; reflecting muscle mass) of 1.5±0.7% in older men (16). 
Although 5 days of immobilization results in a greater, 3.5±0.5%, muscle loss in young men 
(8), the relative decline in muscle strength is equivalent in both young and older people (8, 
16). This indicates that muscle loss in older people has an even greater impact on muscle 
strength and physical functioning when compared with younger individuals. Older 
individuals also have more difficulty regaining muscle mass after a period of disuse when 
compared to their younger counterparts. In older men, the loss of 5% muscle mass after 14 
days of immobilization is not regained within 4 weeks of rehabilitation including resistance-
type exercise performed 3 times per week (13). Thus, most older men may not be able to 
fully regain muscle mass that is lost during a short period of muscle disuse. Therefore, 
successive short periods of muscle disuse throughout the lifespan can contribute 
substantially to the loss of muscle mass with aging (Figure 1). 
 
Overweight individuals 
In overweight and obese people, weight loss is generally encouraged to reduce the risk of 
developing chronic diseases. One of the most effective strategies to lose weight is energy 
intake restriction. However, during a period of energy intake restriction, the decline in body 
weight is accompanied by a substantial loss of muscle mass, ranging between 25 and 40% 
of the body weight lost (18, 19). Since muscle mass is a major contributor to the basal 
metabolic rate (20), the decline in muscle mass decreases energy expenditure, thereby 
hindering further weight loss and increasing the risk of weight regain (21, 22). In overweight, 
older adults, excess fat mass can be accompanied by a relatively low muscle mass (23). In 
this condition, a loss of muscle mass during energy intake restriction may offset the benefits 
of body weight loss. Energy intake restriction in older individuals might therefore increase 
the risk of developing sarcopenia, leading to physical disabilities and decreased daily 
functioning (14). As such, it is important to prevent the loss of muscle mass during a period 
of energy intake restriction in older, overweight adults to maximize the physical and 
metabolic benefits of weight loss. 
1
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Figure 1. Proposed model of age-related muscle loss characterized by a progressive decline in muscle 
mass due to short successive episodes of muscle disuse. Adapted from English et al., 2010 (17). 
 
 
Regulation of muscle mass 
 
Skeletal muscle proteins are in a constant state of turnover, being continuously synthesized 
and broken down at a rate of 1-2% per day (24, 25). Muscle protein turnover is crucial for 
the maintenance of muscle protein quality and quantity (26). Skeletal muscle mass is 
maintained when muscle protein synthesis and muscle protein breakdown are in balance. 
Loss of muscle mass occurs during prolonged periods of decreased muscle protein synthesis 
rates, increased muscle protein breakdown rates, or a combination of both. To assess 
dynamic changes in muscle protein synthesis rates, intravenous infusions with stable 
isotope-labelled amino acids are often applied (27-31). Dynamic assessment of muscle 
protein breakdown is technically more challenging. Therefore, more static markers are 
often used, such as protein or mRNA expression of the ubiquitin ligases MAFbx and MuRF1, 
to represent a snapshot assessment of muscle protein breakdown (8, 32). Numerous factors 
influence muscle protein synthesis and breakdown rates, thereby regulating muscle mass 
(33). Among those factors, physical activity, exercise, disuse and nutrition are the most 
important.  
 
Physical activity and exercise 
Physical activity, especially resistance type exercise training, is one of the most effective 
interventions to increase muscle mass or attenuate the loss of muscle mass. A single session 
of resistance-type exercise increases both muscle protein synthesis and muscle protein 
breakdown rates, albeit the latter to a lesser extent (31). Intramuscular mRNA levels of 
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MAFbx, a ubiquitin ligase involved in proteolysis, have been shown to be elevated 
immediately following high intensity exercise, but decreased below basal levels after 24 and 
72h (34). This finding has been supported with the use of stable-isotope techniques, 
showing that muscle protein breakdown is elevated in the initial phase after exercise (up to 
24h), but returned to baseline after 48h (31). It has been speculated that the initial increase 
in muscle protein breakdown after exercise supports the muscle-remodeling processes (35).  
Muscle protein synthesis rates can be increased more than 100% within 3h after an exercise 
session (31). The changes in muscle protein breakdown and muscle protein synthesis rates 
result in an increased muscle protein net balance that persists up to 48h in young adults 
(31). In addition to the increased basal muscle protein net balance, exercise increases the 
anabolic response to food intake. Protein ingestion in close proximity to an exercise session 
results in 15-30% more amino acids being built into muscle protein (36-38). Therefore, 
physical activity represents a key factor in the regulation of muscle mass by increasing 
postabsorptive and postprandial muscle protein synthesis rates. Unfortunately, in many 
clinical situations, physical activity is temporarily not feasible or simply impossible.  
 
Muscle disuse 
A period of muscle inactivity (muscle disuse) results in a rapid decline in muscle mass (8, 9). 
The rate of muscle atrophy appears to be the highest during the initial period of 
immobilization (5-7 days), although a longer duration of muscle disuse results in a greater 
overall decrease in muscle mass (39). For example, by using a full-leg plaster cast, the 
reduction in muscle quadriceps CSA is shown to be 3.5±0.5% in the first 5 days in healthy 
young men, representing 0.7% per day. After 14 days, the same protocol results in a decline 
in quadriceps CSA of 8.4±2.8%, representing 0.6% per day (40). Studies with longer 
durations show a wider range of muscle loss, 0.48-0.75% per day (41, 42). The wider range 
could be due to differences in study population, immobilization protocol or the diet of the 
subjects. Whereas studies with a longer duration (>2 weeks) of muscle disuse aim to 
represent chronic hospitalization and spaceflight, a shorter duration (<14 days) is more 
representative for injury and short periods of disease. The loss of muscle strength during 
disuse not only depends on the decline in muscle mass, but also on neural and metabolic 
changes (43, 44). The decline in muscle strength is usually 1-2% per day in the initial phase 
of disuse (8, 40) resulting in declines up to 50% after 4 weeks (42).  
The loss of muscle mass during disuse occurs after a prolonged period of a negative net 
protein balance. A period of muscle inactivity (muscle disuse) has been shown to decline 
basal rates of muscle protein synthesis by 25-50% in young, healthy individuals (45-51). 
Postprandial muscle protein synthesis rates in response to amino acid infusion or protein 
ingestion were also decreased by 30-70% (40, 45, 52). This reduced capacity to respond to 
anabolic stimuli, now coined anabolic resistance (53, 54), is likely a major contributor to the 
decline in muscle mass during a period of disuse. The dynamic assessment of muscle protein 
breakdown reveals no change during muscle disuse (50, 51), although other studies have 
reported an increase in mRNA expression of the ubiquitin ligases MuRF and MAFbx in the 
1
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initial phase (<10 d) of disuse (8, 48). Given the magnitude of the decline in muscle protein 
synthesis following disuse, several studies indicate that muscle atrophy is almost entirely 
attributed to the decrease in muscle protein synthesis rates (46, 48, 55, 56). Thus, effective 
nutritional compounds to attenuate the loss of muscle mass during muscle disuse should 
focus on stimulating basal and postprandial muscle protein synthesis rates. 
 
Disuse models 
Two models are commonly used to study disuse-induced muscle atrophy, bed rest and limb 
immobilization. Although short-term, single-leg immobilization shows a similar decrease in 
muscle mass compared to bed rest (resp. 5.4±1.0 vs 3.2±0.9%) (57), the models mimic 
different real-life situations. The bed rest model offers a more relevant model from a clinical 
perspective as it represents a period of hospitalization and (some of) its implications. 
However, limb immobilization is a better suited model when focusing on sports injuries and 
local trauma. Moreover, limb immobilization represents a more controlled situation in 
which muscle disuse atrophy can be studied since it isolates the effect of local muscle disuse 
without interference from systemic factors.  
 
Nutrition 
It has been well established that nutrition is an important factor in the regulation of muscle 
mass (58, 59). In a postabsorptive phase, such as during overnight sleep, muscle protein 
breakdown rates exceed muscle protein synthesis rates resulting in a negative protein 
balance. Food intake stimulates muscle protein synthesis and inhibits muscle protein 
breakdown, thereby stimulating post-prandial muscle protein accretion (30). The 
postprandial muscle protein synthetic response to feeding is regulated on various levels, 
ranging from protein digestion and amino acid absorption, the post-prandial rise in 
circulating insulin and subsequent increase in microvascular recruitment, amino acid uptake 
in skeletal muscle tissue, intramuscular anabolic signaling and myofibrillar muscle protein 
synthesis and breakdown (60-62). One of the main driving factors for the postprandial 
stimulation of muscle protein synthesis is the postprandial rise in plasma amino acid 
availability (63). After ingesting a protein containing meal, approximately 50% of the dietary 
protein-derived amino acids become available in the circulation within 6 h (38, 64). About 
20% of the dietary protein derived amino acids released in the circulation are being used as 
precursors for de novo muscle protein synthesis (64). These amino acids have two main 
functions in the muscle; they stimulate muscle protein synthesis while providing the 
precursors for de novo muscle protein synthesis. Essential amino acids (EAA), and leucine in 
particular, have been shown to increase muscle protein synthesis rates more than 30-100% 
compared to the postabsorptive state (65-67). Thus, muscle mass is maintained through 
fluctuations in muscle protein synthesis and breakdown rates such that net muscle protein 
balance remains zero by the end of each day.  
During a prolonged period of reduced energy intake, the loss of muscle mass results from a 
negative net muscle protein balance. After 10 days of a decreased energy intake (-500 
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kcal/d), basal rates of muscle protein synthesis are reduced by 19% (68). In addition, the 
post-prandial rates of muscle protein synthesis in response to protein feeding decreases 
substantially (14-27%) within the first weeks of an energy restricted diet (69-71). Thus, to 
support healthy weight loss, a dietary intervention should aim to maintain basal and 
postprandial muscle protein synthesis rates to attenuate the loss of muscle mass while 
energy intake is reduced.  
 
Nutritional interventions during situations of muscle atrophy 
 
It has often been speculated that nutritional strategies are able to prevent or attenuate the 
decline in muscle mass during situations of muscle atrophy (55, 72, 73). During a period of 
energy intake restriction, an increase in the protein content of the diet has been suggested 
to preserve muscle mass (74-76). Whereas several intervention studies show that increasing 
protein intake during a period of energy intake restriction can alleviate the loss of muscle 
mass or increase the loss of fat mass (69, 74, 77), other studies have failed to confirm these 
findings (78, 79). The discrepancy in the literature may be attributed to differences in the 
selected study population, the applied nutritional intervention and/or compliance of the 
subjects to the diet. To enhance the compliance to the diet, a strictly controlled intervention 
with nutrition provided and consumed under supervision has been shown to be effective 
(80-85). 
An increased intake of protein or essential amino acids has also been suggested to reduce 
muscle loss during periods of disuse (55, 86). Until now, only one study showed that an 
increased intake of essential amino acids could preserve muscle mass during muscle disuse 
(87), whereas most studies did not confirm this finding (16, 88, 89). Therefore, it is 
important to continue our search for other nutritional compounds that could preserve or 
attenuate the loss of muscle mass during muscle disuse. Although multiple nutritional 
compounds have been suggested to work in this setting, few of these compounds have been 
tested in humans in an in vivo muscle atrophy model. Leucine has been shown to be one of 
the most potent stimuli to induce muscle protein synthesis and decrease muscle protein 
breakdown (65-67), however, the effect of leucine supplementation on muscle mass 
preservation during limb immobilization has not been studied. Moreover, nutritional 
compounds that are known to stimulate muscle mass gains in combination with resistance-
type exercise training, like creatine, are suggested to be effective in attenuating the loss of 
muscle mass during disuse (55). While numerous studies have shown that vitamin D 
concentrations are associated with muscle mass and function in elderly and athletic 
populations (90-93), hardly any randomized controlled trials on the effect of vitamin D 
supplementation on muscle mass and function have been performed. It is surprising that, 
despite frequent speculations, most of these compounds have not yet been tested in 
humans. Therefore, in this thesis, we studied the properties of several nutritional 
compounds to prevent or attenuate the loss of muscle mass. 
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Outline of this thesis 
 
The aim of this thesis is to evaluate the impact of nutritional interventions to prevent the 
loss of muscle mass. We performed a series of studies with some of the most promising 
nutritional compounds. For vitamin D, we focused on nutritional status by assessing the 
prevalence of vitamin D deficiency and seasonal fluctuations in athletes (chapter 2). 
Continuing with that, we studied the effects of different vitamin D dosages on the serum 
vitamin D concentration in athletes (chapter 3). Thereafter, we applied limb immobilization 
to assess the effects of creatine (chapter 4), leucine (chapter 5), and nandrolone decanoate 
(chapter 6) administration on preserving muscle mass and strength. In chapter 7, we 
conducted a dietary intervention study to assess the effect of a high protein intake on the 
preservation of muscle mass during prolonged energy intake restriction. Finally, we discuss 
the main findings of the studies and provide general conclusions and directions for future 
research (chapter 8). 
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Abstract  
 
Background: Studies monitoring vitamin D status in athletes are seldom conducted for a 
period of 12 months or longer, thereby lacking insight into seasonal fluctuations.  
Objective: To identify seasonal changes in total 25-hydroxyvitamin D (25(OH)D) concen-
tration throughout the year.  
Methods: Fifty-two, mainly Caucasian athletes with a sufficient 25(OH)D concentration 
(>75 nmol/L) in June were included in this study.  Serum 25(OH)D concentration was 
measured every three months (June, September, December, March, June). Additionally, 
vitamin D intake and sun exposure were assessed by questionnaires at the same time 
points.  
Results: Highest total 25(OH)D concentrations were found at the end of summer (113±26 
nmol/L), whereas lowest concentrations were observed at the end of winter (78±30 
nmol/L). Although all athletes had a sufficient 25(OH)D concentration at the start of the 
study, nearly 20% of the athletes were deficient (<50 nmol/L) in late winter.  
Conclusion:  A sufficient 25(OH)D concentration in summer does not guarantee a suffi-
cient status in winter. Coaches and medical professionals should therefore monitor ath-
letes’ 25(OH)D concentration regularly in order to prevent vitamin D deficiency.  
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Introduction 
 
A sufficient vitamin D status is important for an athlete’s ability to train and perform, since 
vitamin D deficiency has been linked to impaired skeletal muscle function, immune func-
tion and compromised bone health  (1). The prevalence of vitamin D deficiency in athletes 
is estimated to be between 40-60% (2, 3). The reported prevalence depends on the con-
centrations of serum 25-hydroxyvitamin D (25(OH)D) chosen to define vitamin D deficien-
cy, which ranges from 30-75 nmol/L (1, 4, 5). It has been suggested, however, that optimal 
25(OH)D concentrations for exercise performance  should be even higher (75-125 nmol/L) 
(6). As shown by recent studies, a low 25(OH)D concentrations is associated with reduced 
muscle strength (7) and muscle protein synthesis (8). Increasing the serum 25(OH)D con-
centration can improve sprint capacity and vertical jump performance (9), enhance mus-
cular strength recovery following intense exercise (10) and decrease the risk of musculo-
skeletal injuries (11). Total 25(OH)D concentrations are mostly affected by sunlight expo-
sure (12-15), vitamin D intake (12, 14-16), body composition (12, 14), the capacity of the 
skin to synthesize vitamin D (14, 16) and latitude (1, 17). Athletes may differ in several of 
these factors compared to the general population. Namely, vitamin D intake might be 
higher due to a greater overall food intake. Athletes can also have a different level of sun 
exposure, depending on their sports. Furthermore, athletes typically have a lower per-
centage of fat mass, which is known to be involved in the storage of vitamin D (18). Finally, 
athletes have a higher amount of physical activity, which has been shown to have a posi-
tive association with 25(OH)D concentration (12).   
The most important factor that influences total 25(OH)D concentration is the exposure to 
ultraviolet-B (UV-B) radiation. Therefore, 25(OH)D concentrations vary throughout the 
year and the time point at which vitamin D concentrations are measured is decisive for 
whether an athlete is considered vitamin D deficient or not. Highest 25(OH)D concentra-
tions are typically present at the end of summer (September for the northern hemi-
sphere), while the lowest concentrations are typically measured at the end of winter 
(March). Most of the studies reporting 25(OH)D concentration in athletes have been cross 
sectional in nature or assessed 25(OH)D concentration over a maximum of six months (2, 
3, 19). These studies highlight vitamin D deficiency, however, they do not directly evaluate 
seasonal changes in 25(OH)D concentration over the course of the year. Therefore, the 
aim of the present study was to identify seasonal changes in 25(OH)D concentration 
throughout the course of a year in elite athletes. Additionally, factors that are associated 
with a low 25(OH)D concentration, such as sunlight exposure and dietary vitamin D intake, 
were evaluated.   
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Methods 
 
Study population and design 
In early summer, 100 healthy and injury free (sub) elite athletes had their total 25(OH)D 
concentration assessed. Athletes participated on a national or international level in sports 
supported by Netherlands Olympic Committee * Netherlands Sports Confederation 
(NOC*NSF) and were all living in the Netherlands at a latitude of ~52 °N and an altitude 
between -5 and 50 m above sea level.   
Fifty-two athletes with a sufficient 25(OH)D concentration (>75 nmol/L), were selected for 
follow-up. Of those 52 athletes, 22 were male and 30 were female athletes, with a mean 
age of 22±4 years, a mean BMI of 23.0±1.9 kg/m2, and an average number of trainings 
hours of 10±6 per week. Seven athletes trained mainly outdoors (e.g. soccer, road cycling) 
and 45 indoors (e.g. judo, badminton, swimming). Of this group, 48 athletes had a white 
and 4 athletes had a darker skin tone. The 48 athletes with an insufficient 25(OH)D 
concentration were not different from the sufficient athletes based on vitamin D intake, 
body weight, BMI, age, sunlight exposure, sex and indoor/outdoor sports (P>0.05).  
Total 25(OH)D concentration, dietary vitamin D intake and sun exposure were reassessed 
every three months: September (n=45), December (n=43), March (n=35) and June (n=35). 
Due to scheduling problems or illness, not all athletes were sampled at each occasion; 21 
athletes completed all measurements.  
This one-year longitudinal observational follow-up study is part of a larger project which 
assesses the effect of different vitamin D dosages on 25(OH)D concentrations in athletes 
(20). The study was approved by the Medical Ethics Committee of Wageningen University 
(12/09). The design and aim of the study were registered in the NIH clinical trial database 
(ClinicalTrials.gov number: NCT02008201). 
 
Total 25(OH)D concentration, vitamin D intake and sun exposure 
Subjects were fasted for at least three hours before blood samples were collected. Serum 
total 25 hydroxy-vitamin D (25(OH)D) concentration was analyzed with a liquid chroma-
tography–tandem mass spectrometry (LC–MS/MS) assay. Vitamin D deficiency was de-
fined as 25(OH)D concentrations below 50 nmol/L, vitamin D insufficiency was defined as 
25(OH)D concentrations between 50-75 nmol/L and a concentration above 75 nmol/L was 
considered sufficient (4, 6). Dietary vitamin D intake was assessed using a validated 56-
item food frequency questionnaire, specifically developed for measuring vitamin D intake, 
including supplement use (21). Sun exposure was measured by a questionnaire that as-
sessed the time spent outdoors likely representing exposure to sunlight. The questions 
pertained to time spent outdoors during the last 2 weeks to 3 months. The maximal score 
for all questions was 9 points with a lower score reflecting a lower exposure to sunlight. 
The self-reported sun exposure score could range from 0-108 and was used to rank ath-
letes. In the winter months, points were only allocated when the athletes spent time at a 
sunny destination or used a tanning bed. 
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Statistics  
Data represent mean±SD, or unstandardized β coefficients with the 95% confidence inter-
vals (95% CI). Data were analyzed using SPSS version 22.0 (SPSS, IBM Corp., Armonk, NY, 
USA). Results were considered statistically significant at the 0.05 level. Independent t-tests 
were used to assess differences between the insufficient and sufficient athletes and be-
tween male and female athletes at baseline. Linear mixed models analysis was used to 
assess the fluctuations throughout the year with 25(OH)D concentration as dependent 
variable. Subjects were added to the model as a random factor and time as a fixed factor. 
The best fitting covariance matrix was assessed using the Restricted Maximum Likelihood 
(REML) and tested with the Chi-square distribution. The first order autoregressive covari-
ance matrix (AR(1)) was found to be the best fitted covariance matrix. Other factors were 
included based on a significant contribution to the outcome in the linear mixed model, as 
tested by the Satterthwaite test. The following fixed factors were tested: Vitamin D intake, 
sex, age, indoor/outdoor athletes, and exposure to sunlight. BMI and skin colour were 
included as covariates. Interactions with time are only included if they contributed signifi-
cantly to the model, as tested by the Satterthwaite test. For 25(OH)D concentration, only 
sunlight exposure, sex and the interactions sunlight exposure*time and sex*time contrib-
uted significantly to the statistical model and are therefore included to test changes in 
25(OH)D concentration over the year.  
 
Results 
 
Seasonal variation  
As expected, 25(OH)D concentrations varied significantly throughout the year (see Figure 
2.1 and Table 2.1). The highest concentrations were found at the end of the summer sea-
son (September, 113±26 nmol/L), whereas the lowest 25(OH)D concentrations were ob-
served at the end of the winter season (March, 78±30 nmol/L; 36% decrease). Although all 
athletes had a sufficient 25(OH)D concentration at the start of the observational period, 
2% (n=1) had an insufficient 25(OH)D concentration (<75 nmol/L) in September, 23% 
(n=10) in December, 46% (n=16) in March and 6% (n=2) in June the following year. In 
March, 18% (n=6 athletes) even had a 25(OH)D concentration below 50 nmol/L (‘defi-
cient’). Of the 21 athletes who had their 25(OH)D concentration assessed at all time 
points, 9 athletes had 25(OH)D concentrations below 75 nmol/L in March. Of those 9 ath-
letes, 8 athletes improved their 25(OH)D concentration up to 75 nmol/L or above in June. 
Highest sun exposure scores were achieved in September (71±4 points). Lowest scores 
were observed in December and March (14±5 points). Self-reported sun exposure scores 
changed significantly over time (P<0.01). The overall mean intake of dietary vitamin D was 
4.8±3.4 µg/day and did not change over time (P=0.054). 
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Figure 2.1.  Seasonal changes in serum 25(OH)D in nmol/L. Data represent median± 5-95 percentile, 
‘+’ represents the mean. Serum 25(OH)D concentration varies over time as analyzed by linear mixed 
models. 
 
 
Table 2.1. Serum 25-hydroxyvitamin D, dietary vitamin D intake and sun exposure scores over time  
 June September December March June 
Serum 25(OH)D  
(nmol/L) 
100±16 113±26 97±26 78±30 108±26 
Vitamin D intake 
(µg/day) 
4.1±2.2 3.8±2.3 3.1±1.4 3.6±1.8 3.6±1.8 
Sun exposure score 
(AU) 
64±12 71±10 14±5 14±5 67±11 
Data represent mean±SD  
 
Factors associated with low 25(OH)D concentration  
At baseline, male and female athletes did not show a different 25(OH)D concentration 
(P=0.73). However, male and female athletes showed a different change in 25(OH)D con-
centration over time (Sex*Time interaction P<0.01). In September, 25(OH)D concentration 
was 32 nmol/L (95%CI, 14 to 49 nmol/L) higher in female athletes  compared to male ath-
letes (P<0.01). In December, female athletes showed a 25(OH)D concentration of 22 
nmol/L (95%CI, 6 to 38 nmol/L) higher compared to males and in March the difference 
was 39 nmol/L (95%CI, 20 to 58 nmol/L) (all P<0.01). In June 2013, there was no difference 
between female and male athletes (β 13 nmol/L; 95%CI, -16 to 40 nmol/L; P=0.38). The 
self-reported exposure to sunlight also showed a significant interaction with time 
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(P=0.03). The change in 25(OH)D concentration was partly explained by the difference in 
sunlight exposure between December and March.    
 
Sun light and UV index in the Netherlands 
Retrospectively, the number of sun hours in the Netherlands was assessed by using infor-
mation from the Dutch Meteorological Institute (KNMI). The average numbers of sun 
hours in the 3-month period before each measurement were as follows: 181 sun hours in 
June, 205 in September, 73 in December, 89 in March, and 185 hours in June 2013. In the 
Netherlands, the UV index is lower than 0.5 in winter months and maximal 7 in summer 
months (22). Endogenous vitamin D can only be synthesized between March and Novem-
ber (23, 24). 
 
Discussion  
 
The present study demonstrates that 25(OH)D concentrations in athletes show seasonal 
variation, with the lowest concentrations in late winter, confirming earlier observations in 
athletes (19) and in the general population (25). The largest difference of ~36% lower 
concentrations in March compared to September is somewhat smaller than the ~50% 
reductions observed in professional soccer players playing in the English Premier League 
(19) and in British adults (25). The difference in seasonal variation might be explained by 
our selection of athletes with a sufficient vitamin D status at baseline, these athletes show 
possibly a higher 25(OH)D concentration throughout the whole year compared to a ran-
domly selected group of athletes. 
Though all athletes in the follow-up part had a sufficient total 25(OH)D concentration at 
the start of the study, we found 18% of the athletes to be deficient in late winter. Accord-
ing to the literature, an insufficient dietary vitamin D intake, larger body (or fat) mass, 
poor sunlight exposure, dark skin colour and participation in indoor activities could be risk-
factors for a low 25(OH)D concentration in winter (26). However, in our small sample size 
only sunlight exposure and sex affected 25(OH)D concentration over time. Male athletes 
showed a larger decrease in 25(OH)D in winter compared to female athletes, whereas 
female athletes showed a higher 25(OH)D concentration late summer. It is important to 
note that the current study population consisted mainly of Dutch athletes with a white 
skin colour and that the seasonal variation might be different in athletes with a darker skin 
colour. 
Interestingly, a sufficient 25(OH)D concentration in summer does not guarantee a suffi-
cient status in winter. Coaches and medical professionals should therefore monitor ath-
letes’ 25(OH)D concentration regularly in order to prevent vitamin D deficiency.  
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Abstract 
 
Objective: To assess the prevalence of vitamin D deficiency in Dutch athletes and to define 
the required dosage of vitamin D3 supplementation to prevent vitamin D deficiency over 
the course of a year.  
Methods: Blood samples were collected from 128 highly trained athletes to assess total 
25(OH)D concentration. Of these 128 athletes, 54 male and 48 female athletes (18-32 y) 
were included in a randomized, double blind, dose-response study. Athletes with either a 
deficient (<50 nmol/L) or insufficient (50-75 nmol/L) 25(OH)D concentration were randomly 
assigned to take 400, 1 100 or 2 200 IU vitamin D3 per day orally for one year. Athletes who 
had a total 25(OH)D concentration above 75 nmol/L at baseline continued with the study 
protocol without receiving vitamin D supplements. Serum total 25(OH)D concentration was 
assessed every 3 months as well as dietary vitamin D intake and sunlight exposure.  
Results: Nearly 70% of all athletes showed an insufficient (50-75 nmol/L) or deficient (<50 
nmol/L) 25(OH)D concentration at baseline. After 12 months, serum 25(OH)D concentration 
had increased more in the 2 200 IU/d group (+50±27 nmol/L) than the sufficient group 
receiving no supplements (+4±17 nmol/L; P<0.01) and the 1 100 IU/d group (+25±23 nmol/L; 
P<0.05). Supplementation with 2 200 IU/d vitamin D resulted in a sufficient 25(OH)D 
concentration in 80% of the athletes after 12 months.  
Conclusions: Vitamin D deficiency is highly prevalent in athletes. Athletes with a deficient 
or insufficient 25(OH)D concentration can achieve a sufficient 25(OH)D concentration 
within 3 months by taking 2 200 IU/d.  
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Introduction 
 
Vitamin D inadequacy is traditionally defined as a serum total 25-hydroxyvitamin D 
(25(OH)D) concentrations below 50 nmol/L based upon studies concerning bone health and 
calcium metabolism (1). Using this definition, only 40-60% of the athletes have adequate 
total 25(OH)D concentrations (2-4). More recent studies show that low total 25(OH)D 
concentrations are also associated with reduced muscle strength (5) and muscle protein 
synthesis (6), which may impact athletic performance. So far, a limited number of studies 
have investigated the effect of vitamin D supplementation on athletic performance (7-9). 
These studies demonstrate that increasing serum total 25(OH)D concentration improves 
sprint capacity and vertical jump performance (7), enhances muscular strength recovery 
following intense exercise (8) as well as decreases the risk of musculoskeletal injuries (9). 
However, these studies tend to have a small sample size and did not control for covariates 
like physical activity which might explain the positive effects that are found.   
Data from both observational and intervention studies demonstrate improvements in 
athletic performance when serum total 25(OH)D concentrations are above 75 nmol/L (7-
11). However, it is important to note that not all studies have confirmed this finding (3, 12) 
and more well-controlled studies are needed to assess the optimal 25(OH)D concentrations 
specifically for athletic performance. An effective and commonly used strategy to increase 
serum total 25(OH)D concentrations is supplementation with vitamin D3 (13). Although a 
number of dose-response studies have been performed, most have investigated older, non-
athletic populations (14-16). The results from these studies cannot be directly translated to 
athletes considering differences in dietary vitamin D intake (17-19), body composition (20, 
21), sunlight exposure (17, 19) and the age-related capacity of the skin to produce vitamin 
D (22). Moreover, to improve a low total 25(OH)D concentration at the end of the winter 
and to maintain a sufficient 25(OH)D concentration throughout the year, studies need to 
focus on assessing total 25(OH)D concentration during all seasons. Therefore, the current 
study was conducted to 1) assess the prevalence of vitamin D deficiency (< 50 nmol/L) in a 
group of highly trained athletes and 2) identify the dose of vitamin D3 supplementation 
required to achieve and maintain a total 25(OH)D concentration >75 nmol/L throughout the 
course of a year. 
 
Methods 
Subjects 
A total of 128 highly trained athletes were recruited through contacts with their coaches, 
trainers and/or medical doctors. All athletes participated on a national or international level 
in sports supported by Netherlands Olympic Committee * Netherlands Sports 
Confederation (NOC*NSF) and were all living in the Netherlands at a latitude of ~52 °N. 
Athletes were excluded if they had chronic diseases that could influence total 25(OH)D 
concentrations and/or the response to vitamin D supplementation. Athletes were also 
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excluded if they used vitamin D supplements and participants were not allowed to start 
taking supplements during the study. Athletes that used a sun bed or travelled to foreign 
countries were not excluded but this information was monitored by questions in the 
sunlight questionnaire. At baseline, athletes were asked to fill in a training log with the 
amount of training hours per day for one week. 
 
Spring Summer Fall Winter
September 2013
T=6
Start 
supplementation
Total 25(OH)D 
concentration
Vitamin D and 
calcium intake
Sunlight 
exposure
End 
supplementation
Assessment of
December 2013
T=9
March 2014
T=12
June 2013
T=3
March 2013
T=0
  
 
Figure 3.1: Overview of the study design 
 
Design and intervention 
The present study consisted of two parts. The first part was a cross-sectional observation of 
total 25(OH)D concentration at the end of the winter to assess the prevalence of vitamin D 
deficiency in athletes. The second part comprised a dose-response study to compare the 
effect of 3 dosages of vitamin D supplements on total 25(OH)D concentrations in a selection 
of athletes who participated in the first part.  
After providing written informed consent, 58 male and 70 female athletes had their serum 
total 25(OH)D concentration assessed, while concurrently recording vitamin D and calcium 
intake, sun exposure, and general well-being (baseline measurement). Baseline 
measurements were assessed at the end of the winter season (March until April 2013), since 
the winter months are known to impose the highest risk of vitamin D deficiency due to the 
lack of sun exposure (23). From this group, 102 athletes were included in a randomized, 
double-blind, dose-response study for 12 months. Serum 25(OH)D, vitamin D and calcium 
intake and sun exposure were reassessed every 3 months (Figure 3.1). Selected athletes 
were stratified based on their baseline total 25(OH)D concentration as having a deficient 
(<50 nmol/L), insufficient (50-75 nmol/L) or sufficient (>75 nmol/L) total 25(OH)D 
concentration. Those athletes with a deficient (n = 43) and insufficient (n = 46) total 25(OH)D 
concentration were randomized to take 400 (n = 31), 1 100 (n = 29) or 2 200 IU (n = 29) 
vitamin D3 (cholecalciferol) per day for one year (Table 3.1). The sufficient group (n = 13) 
Vitamin D supplementation in athletes 
35 
continued with the study protocol without receiving vitamin D supplements. For subjects 
whose total 25(OH)D concentration reached 125 nmol/L or higher (as measured during the 
3-monthly assessment), the dose was adjusted to a maintenance dose of 400 IU/d to 
prevent possible harmful effects (1). The study was approved by the Medical Ethics 
Committee of Wageningen University (12/09). The design and aim of the study were 
registered in the NIH clinical trial database (ClinicalTrials.gov number: NCT02008201). 
 
Supplements 
Vitamin D supplements (400, 1 100 or 2 200 IU) were taken on a daily basis together with a 
meal to enhance absorption (24). Vitamin D3 was provided by DSM Biotechnology Center 
(Delft, The Netherlands) in capsulated form. Capsules were administered in a double-blind 
manner and provided in blisters. Supplements were tested by independent laboratories for 
the correct dosage and to guarantee the absence of contamination with prohibited 
substances. The HFL Sport Science lab guaranteed the absence of contamination with 
prohibited substances. The dosages were measured by TNO Triskelion BV by the following 
method: Samples are saponified using a 1.5 mol/l potassium hydroxide ethanolic solution. 
The mixture is extracted using diisopropyl ether. The extract is partly evaporated and 
redissolved in methanol. After sterol precipitation and solid phase extraction, the eluate is 
further purified by fractionation with straight phase chromatography. Finally, the resulting 
extract is analyzed by reversed phase chromatography with diode array detection, 
quantifying at 265 nm. Subjects were asked to fill in a calendar to monitor compliance to 
the supplement intake. Also, subjects were asked to hand in all supplement packages. For 
statistical analysis, all subjects were included. The calendar and supplement count data was 
used to explain deviating results of individual subjects. Overall, 4 subjects in the 2200 IU/d 
group displayed deviating 25(OH)D concentrations. For these subjects, the calendar and 
supplement count helped to explain the data.  
 
Table 3.1: Block randomization of vitamin D supplementation 
Vitamin D status Total 25(OH)D concentration (nmol/L) Supplementation 
    1.       400 IU/day 
Deficient < 50 nmol/L 2.       1 100 IU/day 
    3.       2 200 IU/day 
    1.       400 IU/day 
Insufficient 50-75 nmol/L 2.       1 100 IU/day 
    3.       2 200 IU/day 
Sufficient  > 75 nmol/L No supplements 
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Measurements  
 
Serum 25(OH)D 
Subjects were fasted for at least 3 hours before blood samples were collected by 
venipuncture to assess serum total 25(OH)D concentration. After collection, blood tubes 
(SSTTM Tube with Silica Clot Activator) were stored for at least 30 minutes in a dark box to 
allow clotting, after which they were centrifuged for 10 minutes at 1550 G. Serum was 
separated and stored at -80 °C until analysis. Serum 25(OH)D concentrations were analysed 
with a liquid chromatography–tandem mass spectrometry (LC–MS/MS) assay (Online SPE) 
at the VU Medical Centre, Amsterdam. The VU Medical Centre participates in the United 
Kingdom National External Quality Assessment Schemes (UK NEQAS) and the Dutch society 
for quality control in medical laboratories (SKML). The intra-assay and inter-assay CV’s 
(Coefficients of Variability) of this lab were 5-9% and 7-9% respectively. 
 
Safety  
To prevent possible harmful effects of the vitamin D supplements, athletes in the 2 200 and 
1 100 IU/d group who reached total 25(OH)D concentrations higher than 125 nmol/L 
switched to a maintenance dose of 400 IU/d. This occurred in 31 athletes. In only 5 of them, 
total 25(OH)D concentrations dropped below 75 nmol/L (lowest value 47 nmol/L) at the end 
of the winter (T = 12). 
  
Vitamin D and sun exposure questionnaire  
Vitamin D and calcium intake were calculated from a validated 56-item food frequency 
questionnaire (25). Sun exposure was measured by a questionnaire that assessed the time 
spent outdoors likely representing exposure to sunlight. The questions pertained to time 
spent outdoors during the last 2 weeks to 3 months. The self-reported sun exposure score 
could range from 0-108 and was used to rank athletes. Scores obtained at T0, T9 and T12 
were recoded to 0 to accommodate for the absence of cutaneous synthesis of vitamin D 
during the winter months. Body weight and height were also assessed by a questionnaire, 
BMI was calculated as body weight in kg/(height in m)2.  
 
Statistics 
A sample size calculation was performed prior to the start of the study using GPower (26). 
To detect a significant difference in serum 25(OH)D in response to the lowest and middle 
doses of vitamin D supplementation with an 1-beta of >0.80 and an alpha of <0.05, at least 
10 participants per group were required (27). Considering a drop-out rate of 30%, 15 
participants per group were needed. To include a group of 90 subjects with a deficient or 
insufficient total 25(OH)D concentration, we estimated that 120-140 athletes should be 
included at baseline (28). 
Data are presented as means ± standard deviations (SD). Intention to treat analysis was 
applied, meaning that all subjects were included also in case they missed one or more 
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measurements. Baseline characteristics and total 25(OH)D concentrations were normally 
distributed as evaluated by plotting a histogram and the skewness and kurtosis values (all 
between -1.0 and +1.0). To check whether there were baseline differences between the 
groups, a one-way ANOVA was used in combination with a Bonferroni post-hoc test to 
assess differences between specific dosage groups. Linear mixed models analysis in 
combination with a Bonferroni post-hoc test was applied to assess differences between 
groups over time. Supplement dose, time and supplement dose*time were entered as fixed 
factors. Random factors were included based on a significant contribution to the outcome 
in the linear mixed model. The following random factors were tested: Vitamin D intake, 
gender, age, skin colour, indoor/outdoor athletes, baseline 25(OH)D, exposure to sunlight 
and BMI. Only baseline 25(OH)D and exposure to sunlight were significant. Firstly, linear 
mixed models was applied with only exposure to sunlight as random factor to compare 
mean total 25(OH)D concentrations between groups (Table 3.3A). Secondly, exposure to 
sunlight and baseline total 25(OH)D concentrations were included as random factors to 
compare changes over time (Table 3.3B). Data were analysed using SPSS version 21 (SPSS 
Inc Chicago, IL) and effects were considered statistically significant at P<0.05.   
 
Results 
Baseline characteristics 
The total group of 128 subjects had a mean age of 22 ± 3 years and a mean BMI of 22 ± 2 
kg/m2 (Table 3.2). Athletes trained on average 9±4 hours per week. Most athletes had a 
light skin colour (n = 112) and only 16 athletes had a darker skin colour. Athletes competed 
in different sport disciplines, classified as mainly training outdoors (total n = 94): field 
hockey (n = 61), athletics (n = 15), soccer (n = 12), rowing (n = 4), cycling (n = 1), bobsleighing 
(n = 1), or indoors (total n = 34): volleyball (n = 26), synchronized swimming (n = 5) and judo 
(n = 3). 
On average, baseline characteristics of the athletes participating in the dose-response study 
did not differ from those of the total group, nor did the three supplemental groups differ 
from each other, except for gender distribution. The sufficient group included only female 
indoor athletes (Table 3.2).  
During the dose-response study, 12 participants withdrew after T0, another 13 after T3, and 
7 participants withdrew after T6. A total of 40 athletes completed all measurements, of 
which 11 subjects in the 400 IU/d, 7 in the 1 100 IU/d, 12 in the 2 200 IU/d group and 10 in 
the sufficient group; see Figure 3.2 for participant flow.  
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Table 3.2: Baseline characteristics 
  
Total  400 IU/d 1 100 IU/d 2 200 IU/d Sufficient 
(n = 128) (n = 31) (n = 29) (n = 29) (n = 13) 
Age (y) 22 ± 3  21 ± 3 22 ± 3 21 ± 3 23 ± 4 
Gender (M/F) 58/70 18/13 18/11 18/11 0/13 
Body weight (kg) 70 ± 8.8 71 ± 10 73 ± 10 70 ± 7 74 ± 6 
Height (m) 1.78 ± 0.09 1.80±0.09 1.79±0.09 1.77±0.09 1.81±0.06 
BMI (kg/m2) 22 ± 2  22 ± 2 22 ± 2 22 ± 2 23 ± 2 
Indoor/Outdoor 
(n) 
34/94 6/25 6/23 2/27 13/0 
Trainingshours 
per week (h:min) 
8:53 ± 3:39 7:26 ± 2:42 8:08 ± 2:37 7:51 ± 2:38 7:51 ± 2:38 
Self-reported 
sunlight exposure 
(scores 1-108) 
13.0 ± 6.3 12.1 ± 5.8 13.6 ± 7.2 13.7 ± 6.4 12.0 ± 5.9 
Skin colour (light 
vs darker) 
112/16 27/4 24/5 25/4 12/1 
Data represent means±SD. The sufficient group included only female and indoor athletes and showed a 
higher average training load. Furthermore, no differences between groups were found by one-way 
ANOVA. BMI: Body Mass Index. 
 
Baseline serum 25(OH)D 
Baseline mean total 25(OH)D concentration was 64 ± 26 nmol/L in all athletes and 64 ± 21 
nmol/L in the athletes who completed all measurements (n=40). Of the total group, 43 
athletes had a deficient (< 50 nmol/L), 46 athletes had an insufficient (50-75 nmol/L) and 39 
athletes had a sufficient (> 75 nmol/L) baseline total 25(OH)D concentration. This means 
that 70% of all athletes showed an insufficient or deficient total 25(OH)D concentration at 
baseline (the end of the winter season). A higher percentage of male athletes were vitamin 
D deficient or insufficient as compared to female athletes (average 25(OH)D for men and 
women 46±19 and 78±21 nmol/L respectively; P<0.01).  
 
 
 
 
 
 
 
 
 
Figure 3.2: Participant flow chart   
Included T=0
(n = 102)
T=3
(n = 72)
T=6 
(n = 72)
T=9
 (n = 61)
T=12
(n = 61)
Baseline
(n = 128)
No follow up 
(n = 26)
Drop out 
(n = 12)
Missing 
(n = 18)
Missing 
(n = 5)
Drop out 
(n = 7)
Missing 
(n = 9)
Missing 
(n = 9)
Drop out 
(n = 13)
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Serum 25(OH)D over time  
Overall, the three vitamin D dosage groups showed different effects over time 
(time*treatment interaction P<0.01) as can be seen in Table 3.3. 
At 3 months, serum total 25(OH)D concentration was 80±17 for the 400 IU/d group, 79±18 
nmol/L in the 1 100 IU/d group, 94±19 nmol/L in the 2 200 IU/d group and 100±22 nmol/L 
for the sufficient group. The increases from baseline were not different between 
supplementation groups (P>0.05). However, all three supplemental groups increased total 
25(OH)D concentration more compared to the sufficient group (P=0.049 for the 400 IU/d 
group, P=0.01 for the 1 100 IU/d group and P<0.01 for the 2 200 IU/d group). In the 2 200 
IU/d group, a sufficient total 25(OH)D concentration was achieved in 85% of the athletes 
within 3 months. A sufficient total 25(OH)D concentration was achieved in 50% and 57% of 
the athletes within the first 3 months in the 1 100 IU/d and 400 IU/d group, respectively. 
At 6 months, in late summer, peak total 25(OH)D concentrations were achieved in all four 
groups. The 2 200 IU/d group showed the highest mean of 144±33 nmol/L, which was 
significantly different from the 400 (P<0.01) and 1 100 (P=0.03) IU/d groups. The sufficient 
group had a mean total 25(OH)D concentration of 129±32 nmol/L, the 400 IU/d group had 
a mean total 25(OH)D concentration of 111±31 nmol/L, and the 1 100 IU/d group had a 
mean total 25(OH)D concentration of 119±27 nmol/L. In the 1 100 and 2 200 IU/d and in 
the sufficient group, all athletes had total 25(OH)D concentrations above 75 nmol/L. In the 
400 IU/d group, 86% of the athletes achieved a sufficient total 25(OH)D concentration.  
At 12 months, all groups that received vitamin D supplements had higher total 25(OH)D 
concentrations as compared to baseline (P<0.01). The difference was more pronounced in 
the 2 200 IU/d group (+50±27 nmol/L) than in both the sufficient group (+4±17 nmol/L; 
P<0.01) or the 1 100 IU/d group (+25±23 nmol/L; P=0.049), while the difference tended to 
be higher compared to the 400 IU/d group (+28±24 nmol/L; P=0.06). The 2 200 IU/d group 
had a total 25(OH)D concentration of 100±27 nmol/L, the 1 100 had 76±29 nmol/L, the 400 
IU/d group had 81±26 nmol/L and the sufficient group had a total 25(OH)D concentration 
of 96±22 nmol/L. After 12 months of supplementation, 80% of the athletes in the 2 200 IU/d 
group achieved a sufficient total 25(OH)D concentration. In the 1 100 IU/d group, only 43% 
of the athletes achieved a sufficient total 25(OH)D concentration, whereas in the 400 IU/d 
group, this percentage was 63%.  
 
Vitamin D intake 
The average baseline dietary vitamin D intake was 4.2 ± 2.6 mcg per day (i.e. 168±104 IU/d). 
Dietary vitamin D intake did not affect total 25(OH)D concentration (P=1.00). Dietary 
vitamin D intake did not significantly change over time (P=0.28).  
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Table 3.3: Total 25(OH)D concentrations in athletes receiving 400; 1 100 or 2 200 IU vitamin D3 per 
day 
    
March  June September December March 
T=0 T=3 T=6 T=9 T=12 
A       
 Sufficient group 95 ± 12 100 ± 22 129 ± 32 102 ± 24  96 ± 22 
 n 13 12 11 11 11 
 400 IU/d 50 ± 16P 80 ± 17P 111 ± 31# 85 ± 22*# 81 ± 26* 
 n 31 23 22 19 16 
 1 100 IU/d 49 ± 16P 79 ± 18P 119 ± 27*# 85 ± 25*# 76 ± 29*# 
 n 29 18 16 12 14 
 2 200 IU/d 50 ± 15P 94 ± 19  144 ± 33* 120 ± 28* 100 ± 27* 
  n 29 19 23 19 20 
B       
 Sufficient group - 5 ± 22 37 ± 30# 10 ± 20# 4 ± 17# 
 n - 12 11 11 11 
 400 IU/d - 27 ± 22P 56 ± 30# 32 ± 22# 28 ± 24 
 n - 23 22 19 16 
 1 100 IU/d - 33 ± 19P 70 ± 30# 37 ± 24# 25 ± 23# 
 n - 18 16 12 14 
 2 200 IU/d - 42 ± 16P 94 ± 30P 67 ± 27P 50 ± 27P 
  n - 19 23 19 20 
Data represent means±SD. Part A represents the average 25(OH)D concentration for each time point. 
Linear mixed models was applied to compare mean 25(OH)D levels between groups. Part B represents 
the change in 25(OH)D concentrations from baseline (T=0). Changes over time are analyzed by Linear 
mixed models with correction for baseline 25(OH)D concentrations. *Significantly different from T0, 
#Significantly different from 2 200 IU/d at the same time point, PSignificantly different from the 
sufficient group at the same time point. 
 
Sun exposure  
Self-reported sun exposure scores varied from 0 points in winter till 84 points in summer 
(T=6 months). Scores only varied at 3 months between groups: the 400 IU/d group showed 
a higher score compared to the 1 100 IU/d group (56±10 vs 48±8 points; P=0.02) and 
compared to the sufficient group (45±7 points; P<0.01), but not to the 2.220 IU/d group 
(53±9 points). No group differences were observed at 6 months. 
 
Discussion 
 
The aims of the current study were firstly to assess the prevalence of vitamin D deficiency 
in highly trained athletes, and secondly to identify the dosage of vitamin D3 
supplementation required to achieve and maintain a sufficient total 25(OH)D concentration 
throughout the year. We observed that only 30% of the highly-trained Dutch athletes had a 
sufficient total 25(OH)D concentration (> 75 nmol/L) at the end of the winter. A 
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considerable 34% of the athletes showed a deficient total 25(OH)D concentration (<50 
nmol/L) and 30% of the athletes were vitamin D insufficient (50-75 nmol/L). This 
observation is in line with other studies showing a prevalence of vitamin D deficiency 
ranging from 40-60% (2-4) and sufficient total 25(OH)D concentrations in ~44% of the 
athletes (28-30). Supplementing athletes with 2 200 IU/d was the most effective dosage to 
achieve and maintain a sufficient total 25(OH)D concentration throughout the year.  
The current study defined vitamin D deficiency as serum total 25(OH)D concentrations 
below 50 nmol/L, based upon data considering bone health and calcium metabolism (1). 
Many other studies use the same definition (2, 30, 31), while other researchers consider 
total 25(OH)D concentrations below 25 or 30 nmol/L as vitamin D deficiency (4, 13). If the 
current study would have interpreted the data according to the latter definition, only 6% of 
the athletes would be vitamin D deficient at baseline. The classification of vitamin D 
sufficiency is also under debate (28). We chose to define total 25(OH)D concentrations 
above 75 nmol/L as sufficient since these values are commonly used in athletic populations 
(2, 29, 32) and are considered to have a positive effect on training ability and sports 
performance (7-9). Using this cut-off, 70% of the athletes had an insufficient total 25(OH)D 
concentration.  
Cashman and colleagues calculated that ~400 IU/d of vitamin D would result in only 50% of 
the population reaching 25(OH)D concentrations of >50 nmol/L. According to their study, 
dosages of at least 800 IU/d were needed to ensure that 50% of the population would 
maintain >80 nmol/L 25(OH)D, and 97.5% of the adult population would maintain total 
25(OH)D concentrations of >50 nmol/L during winter (15, 33, 34). Thus, vitamin D intakes 
that are described to maintain adequate total 25(OH)D concentrations, may not suffice to 
correct a low status (15, 33, 34). In the present study, all vitamin D dosages (400; 1 100; 2 
200 IU/d) increased total 25(OH)D concentrations from baseline to 12 months. Supplements 
containing 2 200 IU/d were shown to be the most effective in preventing vitamin D 
deficiency throughout the year, resulting in 85% of the athletes achieving a sufficient total 
25(OH)D concentrations after 3 months and 80% maintaining a sufficient total 25(OH)D 
concentration after 12 months. If the current study would have used a total 25(OH)D 
concentration below 50 nmol/L for selecting the dosage to achieve and maintain sufficient 
25(OH)D levels , a dosage of 400 IU/d would be enough for all athletes to increase a low 
25(OH)D concentration to >50 nmol/L within 3 months. After 12 months, 89% of the 
athletes in the 400 IU/d group was able to increase 25(OH)D concentration above 50 
nmol/L, in the 1 100 IU/d group, this was 79% and in the 2 200 IU/d group, this was 100%. 
The results of the current dose-response study show that in 4 athletes randomized to take 
supplements with 2 200 IU/d, total 25(OH)D concentrations dropped or remained below 75 
nmol/L at 12 months (ranging from 43-73 nmol/L). Of those 4 athletes, 2 athletes had their 
supplemental dose reset to 400 IU/d after reaching a total 25(OH)D concentration above 
125 nmol/L. The 2 other athletes showed poor compliance by taking less than 75% of the 
provided supplements. Therefore, we presume that daily intake of 2 200 IU/d would be high 
enough for all athletes to reach and maintain a sufficient total 25(OH)D concentration 
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during the course of a year. In all subjects receiving 400 IU/d from 6 months onwards, only 
10% dropped their total 25(OH)D concentration under 75 nmol/L at 12 months. This shows 
that supplementation with 400 IU/d is adequate to maintain a sufficient total 25(OH)D 
concentration once serum total 25(OH)D concentrations rise above 125 nmol/L. Therefore, 
it is unnecessary to take a high dose of 2 200 IU/d throughout the whole year.  
Exceedingly high total 25(OH)D concentrations are considered as detrimental to health (35, 
36). Upon starting the study, literature suggested that the safe upper limit of 25(OH)D was 
125 nmol/L (1). To keep total 25(OH)D concentrations under this upper limit, subjects with 
total 25(OH)D concentrations above 125 nmol/L had their dosage adjusted to a 
maintenance dose of 400 IU/d. Currently, total 25(OH)D concentrations up to 220-250 
nmol/L are generally considered as safe (13, 37). If the current study had used an upper 
level of 250 nmol/L instead of 125 nmol/L, more athletes would have taken 2 200 or 1 100 
IU/d during the entire intervention period. As a consequence, the percentage of athletes 
with a sufficient total 25(OH)D concentration after 12 months would likely have been higher 
in the 1 100 and 2 200 IU/d groups. Along with increasing the safe upper level of 25(OH)D, 
the upper daily intake level was also newly set to 4,000 IU/d (38). However, the present 
study supports that long-term use of such high amounts is not necessary to achieve and 
maintain total 25(OH)D concentrations above 75 nmol/L in healthy young athletes.  
The current dose-response study was conducted in a group of 102 young, highly-trained, 
healthy male and female athletes. This study population is an underrepresented group in 
current dose-response studies as most studies are done in older populations (14-16). 
However, the lifestyle and characteristics of athletes inhibit the direct translation from 
other study populations as age might affect sun exposure behavior and/or the ability of the 
skin to produce vitamin D (39). Despite the higher dietary vitamin D intake compared to the 
average Dutch population (3.2 ±2.2 mcg/d) (40), athletes are at high risk of vitamin D 
deficiency in the winter as shown in the current study. This vitamin D deficiency might 
hinder optimal sports performance. Therefore, it is important to measure total 25(OH)D 
concentration in athletes at the end of the winter and recommend athletes with a low total 
25(OH)D concentration to take vitamin D supplements.     
One of the strengths of the current dose-response study is the large sample size of 102 male 
and female athletes. Elite athletes are generally hard to reach as research participants and 
are therefore an underrepresented group in current literature. The number of elite athletes 
in the current study exceeds most of the previous dose-response studies. In addition, the 
follow-up period of 12 months allowed us to assess the effect of supplements throughout 
all seasons. However, the large group of athletes and the long follow-up period resulted in 
a relatively high number of drop-outs and missing values (Figure 3.2). Another strength of 
the current dose-response study is the inclusion of the self-reported sunlight exposure. 
Although an objective measure of sunlight exposure (for example a dosimeter) would 
possibly show a more precise estimate of the UVB-exposure, we were able to assess factors 
as sun bed use, time spent outside and clothing habits. The development of a standardized 
sunlight questionnaire or the use of a dosimeter would be valuable for studies focusing on 
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vitamin D intake and/or total 25(OH)D concentrations. Also, data on the effect of vitamin D 
supplements on athletic performance and general agreement on the definitions for vitamin 
D deficiency, insufficiency and sufficiency, would be valuable for future studies. 
In conclusion, vitamin D deficiency is highly prevalent among Dutch elite athletes. Athletes 
with a deficient or insufficient total 25(OH)D concentration can achieve a sufficient total 
25(OH)D concentration within 3 months by taking 2 200 IU/d. After reaching a high total 
25(OH)D concentration (> 125 nmol/L), vitamin D supplementation of 400 IU/d is adequate 
to maintain a sufficient total 25(OH)D concentration. 
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Abstract 
 
Background A short period of leg immobilization leads to rapid loss of muscle mass and 
strength. Creatine supplementation has been shown to increase lean body mass in active 
individuals and can be used to augment gains in muscle mass and strength during prolonged 
resistance type exercise training.  
Objective To investigate whether creatine loading can attenuate the loss of muscle mass 
and strength during short-term leg immobilization.  
Methods Thirty healthy, young men (aged 23±1 y; BMI 23.3±0.5 kg·m-2) were randomly 
assigned to either a creatine (CR) or a placebo group (PLA). Subjects received placebo or 
creatine supplements (20 g/d) for 5 days before one leg was immobilized by means of a full-
leg cast for 7 days. Muscle biopsies were taken before creatine loading, prior to and 
immediately after leg immobilization and after 7 days of subsequent recovery. Quadriceps 
cross-sectional area (CT scan) and leg muscle strength (1-RM knee extension) were assessed 
before and immediately after immobilization and after one week of recovery. Data were 
analyzed using repeated measures ANOVA. Data is represented consistently as mean±SEM. 
Results Quadriceps muscle cross sectional area had declined by 465±59 and 425±69 mm2 
(P<0.01) in the CR and PLA group, respectively, with no differences between groups 
(P=0.76). Leg muscle strength decreased from 56±4 to 53±4 kg in the CR and from 59±3 to 
53±3 kg in the PLA group, with no differences between groups P=0.20). Muscle fiber size did 
not change significantly over time in either group (P>0.05). When non-responders to 
creatine loading were excluded (n=6), responders (n=8; total creatine content increasing 
from 70 to 106 mmol·kg−1) showed similar findings with no signs of preservation of muscle 
mass or strength during immobilization. During the subsequent recovery phase, no 
differences in muscle mass or strength were found between the two groups (P>0.05). 
Conclusion Creatine supplementation prior to and during leg immobilization does not 
prevent or attenuate the loss of muscle mass or strength during short term muscle disuse. 
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Introduction 
 
Recovery from injury or illness often requires a period of inactivity. Even short periods of 
disuse lead to a substantial loss of skeletal muscle mass and strength (1, 2). The loss of 
muscle mass and strength is associated with a longer recovery period and with a higher risk 
of injury reoccurrence (3, 4). Moreover, periods of disuse result in reduced insulin sensitivity 
(5, 6), a decline in basal metabolic rate (7) and an increase in body fat mass (8). These factors 
impair physical functioning and decline metabolic health, causing even more health 
concerns. Therefore, strategies are warranted to prevent the loss of muscle mass and/or 
strength during short periods of disuse due to injury or hospitalization.  
During the nineties, creatine supplements became a popular ergogenic aid for athletes. 
Creatine monohydrate supplementation can increase the phosphocreatine/creatine ratio in 
skeletal muscle tissue, thereby increasing the capacity for rapid ATP resynthesis during 
repeated high-intensity exercise tasks (9-11). In accordance, creatine supplementation was 
shown to effectively augment athletic performance during various exercise tasks 
characterized by repeated, high intensity exercise and has since become common practice 
among many athletes (12-14) . Besides increasing high-intensity exercise performance, 
creatine supplementation has also been reported to increase muscle mass and strength in 
the presence as well as in the absence of prolonged resistance type exercise training (9, 15, 
16). The increase in lean mass following creatine supplementation has, at least partly, been 
attributed to water retention in muscle tissue (11, 17). The greater osmotic pressure 
following the increase in creatine content has been suggested to result in muscle cell 
swelling, which is considered a key stimulus for cell growth (11, 18).  
Consequently, it has been hypothesized that creatine loading prior to immobilization may 
help to prevent muscle loss during a short period of disuse (19). So far, only two studies 
have assessed the clinical benefits of creatine supplementation during immobilization to 
prevent or attenuate disuse atrophy (20, 21). Whereas creatine supplementation 
attenuated muscle loss during a 1-wk arm immobilization (20), no effect was observed 
during a 2-wk leg immobilization period (21). Since both studies did not include a creatine 
loading phase to allow an increase in muscle creatine content before immobilization (20, 
21), it remains to be determined whether creatine loading prior to (leg) immobilization can 
preserve muscle mass and strength in humans.  
We hypothesized that creatine loading prevents or attenuates the loss of muscle mass and 
strength during one week of leg immobilization. To test our hypothesis, we selected 30 
young males to participate in a study in which they were subjected to 7 days of single-leg 
immobilization. Subjects received either placebo or creatine supplements from 5 days prior 
to immobilization until the end of the study. To assess the effect of creatine loading, muscle 
biopsies were taken at baseline and after 5 days of creatine loading (20 g/d). Before and 
after 7 days of immobilization as well as after 7 days of subsequent recovery, we assessed 
muscle mass and strength. In addition, muscle biopsies were taken to assess muscle fiber 
characteristics.  
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Methods 
 
Subjects 
After screening, thirty healthy, young men (age: 23±1 y; body mass index: 23.3±0.5 kg·m-2) 
were included in the study. Exclusion criteria included a (family) history of thrombosis, any 
back/leg/knee/shoulder complaints which could interfere with the use of crutches, and any 
co-morbidities interacting with mobility or muscle metabolism of the lower limbs (e.g. 
arthritis, spasticity/rigidity, all neurological disorders and paralysis). None of the subjects 
reported to have performed progressive resistance type exercise training, used creatine 
supplements, anti-coagulants, corticosteroids, growth hormone, testosterone, 
immunosuppressants or exogenous insulin over the previous 6 months. During the 
screening, subjects gave written informed consent after they were fully informed about the 
nature and possible risks of the experimental procedures. The study was approved by the 
Medical Ethics Committee of the Maastricht University Medical Centre+ and performed in 
accordance with the Declaration of Helsinki.  
 
Experimental design  
The present study was a double-blind, placebo-controlled intervention trial with 30 subjects 
randomly allocated into either the placebo (PLA; n=15) or the creatine (CR; n=15) 
supplemented group (Figure 4.1). All subjects reported to the laboratory following an 
overnight fast on 4 occasions. Standardized meals (2.9 MJ; providing 51 energy percent 
(En%) as carbohydrate, 32 En% as fat, and 17 En% as protein) were consumed the evening 
prior to all 4 test days. On the first test visit (baseline), body weight was assessed after which 
a muscle biopsy sample was taken from the vastus lateralis muscle. Subjects started with 
the creatine or placebo supplements directly after the baseline test. Five days after the 
baseline test, the subjects came in for the pre-immobilization test. During the pre-
immobilization test, a second muscle biopsy was taken to assess the effect of creatine 
loading on muscle creatine content and a baseline assessment of muscle mass (CT scan 
upper legs) and knee extension strength (one-repetition maximum (1-RM)) were 
conducted. Two days after the pre-immobilization test, one leg was immobilized by means 
of a full leg cast for 7 subsequent days. On the day of the cast removal and after 7 days of 
recovery, another muscle biopsy was taken and muscle mass and strength assessments 
were repeated.  
 
Measurements 
Body weight was measured with a digital balance with an accuracy of 0.1 kg (SECA GmbH, 
Hamburg, Germany). Muscle biopsies were taken from the middle region of the vastus 
lateralis muscle under local anaesthesia, ~15 cm above the patella and ~3 cm below entry 
through the fascia, using the percutaneous needle biopsy technique (22). All biopsies were 
taken from the leg that was subsequently immobilized. Muscle samples were dissected 
carefully and freed from any visible non-muscle material and were immediately frozen in 
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liquid nitrogen (biochemical analyses), or in liquid-nitrogen cooled isopentane 
(histochemical analyses). Subsequently, muscle samples were stored at -80 °C until further 
analysis.  
Muscle mass was assessed with a single slice CT-scan (Philips Brilliance 64, Philips Medical 
Systems, Best, the Netherlands) to assess cross-sectional area (CSA) of the quadriceps 
muscle. The scanning characteristics were as follows: 120 kV, 300 mA, rotation time of 0.75 
s, and a field of view of 500 mm. With subjects lying supine with their legs extended and 
feet secured, a 3 mm thick axial image was taken 15 cm proximal to the top of the patella. 
The precise scan position was marked with semi-permanent ink for the duration of the 
intervention period to ensure accurate repeated measurements. For analysis, muscle area 
of the legs was selected between -29 to 150 Hounsfield units (23), after which the 
quadriceps muscle was selected by manual tracing using ImageJ software (version 1.49p, 
National Institute of Health, Maryland, USA) (24-26). As a measure of muscle strength, 
maximal leg strength was assessed by 1-RM (5) for each leg individually on a knee extension 
machine (Technogym, Rotterdam, The Netherlands), as described in more detail previously 
(27). In short, during the screening visit, subjects started with a warm-up on a cycle 
ergometer. After demonstration of the lifting technique, a familiarization trial was 
performed to ensure proper execution of the exercise protocol. The maximum amount of 
repetitions measured for a certain load was used to estimate the 1-RM: 1-RM 1⁄4 
load/(1.02787 0.0278*reps) (28). This estimate was used during the following visits to 
determine the initial load for the actual 1-RM test. During the actual 1-RM test, the load 
was set at ~90% of the estimated 1-RM and was increased by 2.5-5.0% after each successful 
lift until failure. 
 
Muscle biopsy
1RM
CT scan
Loading 
(20 g/d)
7d immobilization 7d recovery
Maintenance
5 g/d
5d
 
Figure 4.1: Schematic overview of the study design 
 
Supplements  
The PLA group received a placebo supplement consisting of 7.5 g maltodextrin (AVEBE, 
Veendam, The Netherlands) and 7.5 g of dextrose monohydrate (AVEBE). The CR group 
received the same supplement with the addition of 5 g creatine monohydrate (Creapure 
AlzChem, Trostberg, Germany). The creatine supplements could not be distinguished from 
the placebo supplement with respect to colour, taste, smell or appearance. All subjects 
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were instructed to dissolve the supplement in lukewarm tap water prior to ingestion. During 
the first 5 days of creatine loading, subjects consumed 4 supplements per day (providing a 
total of 20 g creatine per day for the CR group) at  breakfast, lunch, dinner and immediately 
prior to going to bed (approximately 5 h intervals between supplements). Thereafter, 
subjects continued with one supplement per day as a maintenance dose (containing 5 g 
creatine per day for the CR group) during the subsequent immobilization and recovery 
period. The applied creatine supplementation protocol was designed according to the 
guidelines on creatine supplementation set by the American College of Sports Medicine 
(29).  
 
Limb immobilization  
Two days after the pre-immobilization test, subjects attended the Casting Room at 
Maastricht University Medical Centre at 08.00 am to have a full leg cast fitted to induce 
knee immobilization. The leg to be immobilized was randomized and counter-balanced 
between left and right. The circular leg cast extended from 10 cm above the ankle to 
approximately 25 cm above the patella. The knee was casted at a 30o angle of flexion to 
prevent subjects from being able to perform any weight bearing activities on the casted 
limb. Subjects were provided with crutches for proper ambulation. Throughout the 
immobilization period, subjects were instructed to perform a series of daily simple ankle 
exercises (i.e. plantar and dorsal flexion, and circular movements of the entire foot) to keep 
the calf muscle pump activated in the immobilized leg, thereby minimizing the risk of 
developing deep vein thrombosis. Prior to the start of the third test visit, subjects visited 
the Casting Room to have the cast removed. Following cast removal, subjects were 
transported by wheelchair to prevent any weight bearing on the immobilized leg until the 
muscle biopsy sample was collected. 
 
Diet and physical activity 
Subjects were asked to maintain habitual dietary intake during the entire intervention 
period. To check for any deviations, the participants completed dietary intake records, 
including food sources, estimation of the portion size using household measures and the 
timing of intake. Dietary intake records were completed before and during the 
immobilization period on 2 weekdays and 1 weekend day. DieetInzicht software (7), based 
on the Dutch food composition table (NEVO table) 2011, was used to analyze dietary intake 
records. Alcohol intake was allowed until 48 h before every test visit. Subjects refrained 
from any heavy physical exercise during the entire intervention period. Therefore, a 3-day 
activity journal was completed by the participants on the same days as the dietary intake 
records.  
 
Muscle total creatine analysis 
One fraction of the muscle sample (approximately 50 mg wet tissue) was freeze-dried and 
pulverized. Muscle creatine and phosphocreatine content were analyzed as described by 
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Harris et al. (30). After adding perchloric acid (250 μL PCA 1M), muscle samples (10 mg dry 
muscle) were centrifuged, KHCO3 (105 μL, 2M) was added to neutralize samples, after 
which samples were centrifuged again. Supernatants were used for spectrophotometric 
determination of creatine and phosphocreatine content on the Cobas Fara (Roche, 
Switzerland). The biochemically determined metabolite concentrations for each muscle 
sample were expressed as millimoles per kilogram dry weight.  
 
Histochemical analysis 
Part of each muscle biopsy sample was frozen in liquid nitrogen cooled isopentane. These 
samples were cut into 5-μm thick cryosections using a cryostat at -20 °C. Muscle biopsies 
were stained for muscle fiber typing and used to assess muscle fiber type composition and 
type I and II muscle fiber size as described in detail previously (31). In short, slides were 
incubated with primary antibodies directed against myosin heavy chain (MHC)-I (A4.840, 
dilution 1:25; Developmental Studies Hybridoma Bank, Iowa City, IA, USA) and laminin 
(polyclonal rabbit antilaminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands). Goat 
anti-mouse IgM AlexaFluor555 and goat anti-rabbit IgG AlexaFluor647 were applied as 
secondary antibodies (dilution 1:500 and 1:400; Molecular Probes, Invitrogen, Breda, the 
Netherlands). Images were captured with a fluorescent microscope and analyzed for muscle 
cross-sectional area and fiber type distribution using ImageJ software. 
 
Statistics 
All data are expressed as means±SEM. The sample size was based upon a power calculation 
with an expected difference in the loss of quadriceps CSA of 40 % between the PLA and CR 
group (respectively 5 vs 3 % loss of quadriceps CSA) (32). With a power of 80% and a 
significance level (α) of 0.05, at least 13 participants are required per group. Thirty subjects 
were included to allow for drop-outs. 
An independent t-test was used to assess differences in baseline characteristics between 
subjects in the PLA and CR group. Our main objective focused on the differences between 
the PLA and CR group during immobilization. A two-way repeated measures ANOVA with 
time (pre-immobilization vs post-immobilization) as within-subjects factor, and treatment 
(CR and PLA group) as between-subjects factors was used to compare changes in quadriceps 
CSA, muscle strength and muscle fiber characteristics during immobilization. Thereafter, a 
two-way repeated measures ANOVA was conducted with time (post-immobilization vs post-
recovery) as within-subjects factor to test the differences between the PLA and CR groups 
during the recovery week. A third repeated measures ANOVA with all 3 time points (pre-
immobilization, post-immobilization and post-recovery) was conducted to test whether the 
PLA and CR group responded differently throughout the whole study period. For muscle 
fiber characteristics, a second within-subjects factor was added (type I vs type II fibers).  
The effects of the creatine loading phase on muscle free creatine, phosphocreatine and 
total creatine, as well as body weight were tested using a two-way repeated measures 
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ANOVA with time (all time points; and baseline vs pre-immobilization separately) as within-
subjects factor and treatment (CR and PLA group) as between-subjects factors.  
In case of a significant time x treatment interaction, paired t-tests were performed in the 
CR and PLA groups separately, with Bonferroni correction when appropriate (i.e. more than 
2 time points). Data were analyzed using SPSS version 21 (SPSS, IBM Corp., Armonk, NY, 
USA). Results were considered statistically significant in case P<0.05.  
 
Results 
 
Subjects 
Baseline subjects’ characteristics did not differ between the PLA and CR groups (quadriceps 
CSA 7712±324 and 8194±263 mm2; P=0.26, and leg muscle strength 56±4 and 59±3 kg; 
P=0.47 respectively) (Table 4.1). Three subjects withdrew prior to immobilization due to 
time constraints. From the 30 participants, 27 completed the study (PLA: n=13; CR: n=14).  
 
Table 4.1: Subjects’ baseline characteristics 
 Placebo group (n=13) Creatine group (n=14) 
Age (years) 23±1 23±1 
Body weight (kg) 73±3 75±2 
Height (m) 1.76±0.03 1.81±0.02 
BMI (kg·m-2) 23.5±0.9 23.0±0.5 
1RM (kg) 55±4 59±3 
Quadriceps CSA (mm2) 7712±324 8194±263 
Data are expressed as the means±SEM. No differences are found between groups (P>0.05). BMI: body 
mass index (kg·m-2), CSA: cross-sectional area. 
 
Creatine loading 
Muscle tissue free creatine, phosphocreatine, and total creatine content are displayed in 
Table 4.2. At baseline, total muscle creatine content averaged 89±5 mmol·kg of dry muscle−1 
(mmol·kg−1), with no differences between the PLA and CR group (88±4 vs 90±9 mmol·kg−1, 
respectively; P=0.68). Despite similar baseline values, an overall treatment effect was 
observed when all time points were included in the analysis, showing that muscle creatine 
content was greater in the CR vs PLA group (P=0.03). When focusing on the loading phase, 
a significant main effect of time (P=0.049) was observed, showing an increase in total 
creatine content. Although the time x group interaction did not reach statistical significance 
(P=0.066), this increase in total muscle creatine content appeared to be driven by an 
increase in the CR group (from 90±9 to 107±4 mmol·kg−1 following 5 days of loading), with 
no apparent changes in muscle total creatine contents in the PLA group (from 88±4 to 90±3 
mmol·kg−1). In accordance, a significant time x treatment interaction was observed for 
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muscle free creatine content (P=0.011), with post-hoc analyses showing a significant 
increase in the CR group (P<0.001) with no changes over time in the PLA group (Table 4.2). 
In the CR group (n=14), 6 subjects did not show an increase in total muscle creatine content 
exceeding 10 mmol creatine·kg−1 and could, therefore, be considered non-responders to 
creatine loading (10). In agreement with previous findings (10, 33), these non-responders 
showed higher baseline muscle creatine contents when compared to most responders 
(121±8 vs 70±9 mmol·kg−1; P<0.01). The individual responses to creatine loading are 
presented in Figure 4.2. In the responders to creatine loading, we observed a significant 
increase in total creatine content in muscle from 70±9 to 106±6 mmol·kg−1 (P<0.01).  
During the loading phase, body weight increased more in the CR compared to the PLA group 
(time x treatment interaction P=0.02). Body weight increased from 73.7±2.2 to 74.4±2.3 kg 
the CR group (P=0.01), with no changes observed in the PLA group (71.2±2.8 to 71.4±2.8 kg; 
P=0.39). Within the CR group, greater increases in body weight were observed in the 
responders to creatine loading compared with the non-responders (P=0.03). Individual 
changes in body weight in the responders and non-responders in the creatine group are 
presented in Figure 4.3.  
 
Table 4.2: Muscle creatine content 
 Placebo group (n=13) Creatine group (n=13) 
 Baseline Pre-
immobili
zation 
Post-
immobili
zation 
Recovery Baseline Pre-
immobili
zation 
Post-
immobili
zation 
Recovery 
 
 
Free Cr 40±2 44±4 48±4 40±3 34±1 48±4# 53±3# 52±3# 
CrP 48±4 45±4 40±4 55±5 55±10 59±6 45±5 52±5 
Total Cr  88±4 90±3 87±3 95±4 90±9* 107±4* 98±6* 104±4* 
Data are expressed as the means±SEM. Free Cr (Creatine), CrP (creatine phosphate), and total Cr content 
are expressed in mmol·kg of dry muscle−1. Independent t-tests showed no differences between treatments 
at baseline. Repeated measures ANOVA (time x treatment) showed: #Significant time x treatment 
interaction (P=0.01) for Free Cr; Bonferroni corrected post-hoc showed a significant increase compared 
with baseline in the creatine group only (all P≤0.01). *Significant treatment effect (P=0.03) for Total Cr. 
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Figure 4.2: Individual changes in total muscle creatine at baseline and after 5 days of creatine loading 
in the CR group. The responders to creatine supplementation (n=8) were defined as subjects who 
showed an increase in total muscle creatine exceeding 10 mmol·kg−1 (10). The  non-responders (n=6) 
were defined as those subjects that showed no increase in muscle total creatine content or an 
increase less than 10 mmol creatine·kg−1 (10). 
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Figure 4.3: Individual changes in body weight in the responders and non-responders following 5 days 
of creatine loading. Body weight changes are calculated as post-loading minus baseline values.  
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Muscle mass 
Leg immobilization resulted in a significant decline in muscle cross-sectional area of the 
quadriceps muscle (P<0.01) with no differences between groups (Figure 4.4; time x 
treatment interaction P=0.76). Quadriceps CSA decreased by 5.5±0.8 % (from 7712±324 to 
7287±305 mm2) in the PLA group. In the CR group, quadriceps CSA decreased by 5.6±0.8 % 
(from 8194±263 to 7729±245 mm2). During the subsequent recovery phase, quadriceps CSA 
increased by 2.0±0.6 and 1.1±0.7 % in the PLA and CR group respectively (P<0.01), with no 
differences between groups (time x treatment interaction P=0.52).  
In agreement with the changes in quadriceps CSA, the CSA of the whole thigh muscle 
decreased during immobilization in both the PLA (3.6±0.7 %) and CR (3.7±0.6 %) groups, 
with no differences between groups (P=0.76). During the recovery week, whole thigh 
muscle CSA of the total group increased by 1.2±0.4 % (P<0.01), with no differences between 
groups (time x treatment interaction P=0.52).  
In the non-immobilized leg, quadriceps muscle CSA did not change differently in the PLA or 
CR group during immobilization (respectively -8±33 and 41±48 mm2; time x treatment 
interaction P=0.41) or subsequent recovery (respectively +62±44 and +94±47 mm2; time x 
treatment interaction P=0.63). The responders to creatine loading showed a similar change 
in quadriceps muscle CSA compared to the non-responders to creatine loading during 
immobilization (respectively -446±88 and -489±79 mm2) or recovery (respectively +85±41 
and +106±122 mm2). 
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Figure 4.4: Changes in cross-sectional area (CSA) of the quadriceps muscle in the Creatine and Placebo 
group following 7 days of one-legged knee immobilization and 7 days of subsequent recovery. Data 
were analyzed by two-way repeated measures ANOVA with time as within-subjects factor, and 
treatment (CR and PLA group) as between-subjects factors. Data are expressed as means±SEM. 
Immobilization resulted in a significant decline in quadriceps CSA in both groups (*), with no 
differences between groups. Quadriceps CSA increased during the recovery week (*), with no 
differences between groups. 
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Knee extension strength 
One repetition maximum (1-RM) decreased significantly during leg immobilization (P<0.01), 
with no differences between groups (Figure 4.5; time x treatment interaction P=0.20). 1-
RM decreased by 5.6±2.2 % (from 56±4 to 53±4 kg) in the PLA group. In the CR group, 1-RM 
decreased by 9.2±3.1 % (from 59±3 to 53±3 kg). During the subsequent recovery week, 1-
RM did not increase in either group and no differences were found between the two groups 
(time x treatment interaction P=0.32). The responders and non-responders to creatine 
loading showed a similar change in 1-RM during immobilization (respectively -5±3 and -8±2 
kg) and recovery (respectively +1±2 and +3±1 kg). 
1-RM in the non-immobilized leg increased during the immobilization period by 3.0±1.5 % 
(from 61±2 to 63±2 kg; P=0.03), with no differences between the PLA and CR group (time x 
treatment interaction P=0.90). 1-RM in the non-immobilized leg did not change during the 
subsequent recovery week (P=0.57).  
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Figure 4.5: Changes in the one-repetition maximum (1-RM) leg muscle strength in the Creatine and 
Placebo group, following 7 days of one-legged knee immobilization and 7 days of subsequent 
recovery. Data were analyzed by two-way repeated measures ANOVA with time as within-subjects 
factor, and treatment (CR and PLA group) as between-subjects factors. Data are expressed as 
means±SEM. Immobilization resulted in a significant decline in muscle strength in both groups (*), 
with no differences between groups. Muscle strength did not change during the recovery week, with 
no differences between groups.  
 
Muscle fiber characteristics 
Muscle fiber characteristics are presented in Table 4.3. At baseline, type I and II muscle fiber 
size averaged 6458±334 and 7263±375 μm2, respectively (P=0.01), with no differences 
between groups. No significant changes in type I or II muscle fiber size were observed 
following leg immobilization or during subsequent recovery. The proportion of type I and 
type II muscle fibers was 39±3 and 61±3 %, respectively, before the loading period. No 
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changes in muscle fiber type composition were observed over time or between groups. No 
differences were observed in fiber size between responders and non-responders to creatine 
loading, and no changes were observed over time in either group. 
 
Diet and physical activity 
Baseline daily energy intake was 8.2±0.4 MJ per day, with no differences between groups 
(P=0.26). Dietary protein intake averaged 1.1±0.1 g·kg-1 body weight per day, with no 
differences between groups (P=0.61). Neither daily energy nor protein intake changed 
significantly during the subsequent immobilization and recovery period.  
 
Discussion 
 
The present study shows that 7 days of one-legged knee immobilization results in a 
substantial decrease in muscle mass and strength in healthy, young men. Creatine loading 
prior to immobilisation and creatine supplementation during immobilisation did not 
attenuate the loss of muscle mass or strength during immobilization. In addition, creatine 
supplementation failed to accelerate muscle mass or strength regain during one week of 
subsequent recovery. 
Short-term disuse leads to substantial losses in muscle mass and strength. The current study 
demonstrates that merely 7 days of disuse leads to 5.5±0.5 % loss of muscle mass (Figure 
44.), representing 0.8 % loss of muscle mass per day. This muscle loss is in line with earlier 
work (1, 32, 34) and underlines the impact that even short periods of disuse can have. 
Besides the loss of muscle mass, muscle strength declined by 7.6±2.0 % (Figure 4.5). Similar 
declines in muscle strength (1-2 % per day) have been reported previously by our laboratory 
as well as others (1, 32, 34). The loss of muscle mass and strength during disuse is associated 
with a longer recovery period, a higher risk of injury reoccurrence, and a decline in 
metabolic health (3-6). Hence, short-term disuse atrophy is of high clinical relevance and 
effective strategies are needed to preserve muscle mass and strength during short periods 
of disuse or bed rest due to injury or hospitalization (35). 
We hypothesized that creatine loading prior to disuse, thereby increasing muscle creatine 
content, attenuates the loss of muscle mass and strength. Therefore, the creatine group 
consumed 20 g creatine per day during the 5 day loading phase, which allowed total 
creatine content in muscle to increase by 19 %. This loading and maintenance 
supplementation scheme has previously been shown to increase muscle free creatine and 
creatine phosphate (9, 11) and is in accordance with the guidelines of the American College 
of Sports Medicine (29). In the present study, 8 subjects showed an increase in total creatine 
content of more than 20 %. In the creatine supplemented group, 6 subjects did not show a 
substantial increase in muscle creatine content (Figure 4.2). These subjects, not showing 
differences in muscle creatine content exceeding 10 mmol·kg−1, were defined as non- 
responders (10). It has been well established that 15-30 % of the people who take creatine 
supplements do not experience increases in total muscle creatine contents (9, 10, 33). 
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Such non-responders to creatine supplementation typically show high(er) baseline muscle 
creatine contents, potentially preventing further increases in muscle creatine content (9, 
10, 33).In agreement, our non-responders showed substantially greater baseline creatine 
contents when compared to the responders (108±14 vs 70±9 mmol·kg−1 respectively; 
P=0.04). We also observed an increase in body weight in the responders to creatine 
supplementation ranging from 0.4-1.9 kg, which is in line with previous studies (9, 10, 29). 
The increase in body weight with creatine loading has been found to result from water 
retention due to the increased cellular osmolarity (11, 17)  or from the increase in fat free 
mass (9, 15, 16). The fact that the individuals with an increase in muscle total creatine 
content also show an increase in body weight supports the fact that these subjects are 
responders to creatine supplementation. Despite the effective creatine loading, the greater 
muscle creatine contents did not result in the preservation of muscle mass or strength 
during 7 days of single-leg immobilization. When only the responders to creatine 
supplementation were included in the analyses, similar findings were observed. In addition 
to the changes in muscle quadriceps cross-sectional area, we also assessed potential disuse 
atrophy on a muscle fiber level in the vastus lateralis muscle. Average type I and type II 
muscle fibers cross-sectional areas showed no net changes following immobilization in both 
the placebo and creatine group (Table 4.3). The absence of a detectable decline in muscle 
fiber size following short-term immobilization has been reported previously (2) and is 
attributed to the substantial inter- and intra-subject variation in muscle fiber sizes (36). Of 
course, the vastus lateralis muscle does not per se represent the entire quadriceps muscle. 
Furthermore, a muscle biopsy sample taken from the mid region of the vastus lateralis does 
not necessarily represent the entire muscle. Therefore, we can only assume that the 
presented data extend to all upper and/or lower leg muscle. 
Though the current study focused on the impact of creatine loading on the decline in muscle 
mass and strength during immobilization, we also assessed changes in muscle mass and leg 
strength during the acute stages of recovery from disuse. After one week of recovery, we 
observed a 1.5±0.5 % regain in skeletal muscle mass. Although significant, this increase in 
muscle mass represents only 26% of the muscle mass that was lost during the 7 day 
immobilization period. Thus, to regain all muscle mass after a period disuse, much more 
time will be required for rehabilitation than the duration of the disuse period itself. 
Interestingly, no detectable regain in leg strength was observed after the first week of 
recovery. Creatine supplementation did not affect muscle mass or leg strength regain. 
Previously, Hespel et al. showed greater muscle regain following a period of disuse when 
creatine was supplemented during a more prolonged period of rehabilitation, which 
included a 10 week resistance type exercise training program (21). Clearly, though we show 
that creatine supplementation does not preserve muscle mass during disuse or support 
muscle regain during the acute stages of recovery form disuse, it may still be of benefit to 
support muscle mass and strength regains during more prolonged, active rehabilitation. We 
hypothesised that creatine loading prior to and during immobilisation would prevent or 
attenuate muscle loss during a short period of immobilisation. The increase in muscle 
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Table 4.3: Muscle fiber characteristics in the placebo and creatine group 
  Placebo group (n=13) Creatine group (n=13) 
 Fiber 
type 
Baseline Pre-
immobilizat
ion 
Post-
immobilizat
ion 
Recovery Baseline Pre-
immobilizat
ion 
Post-
immobilizat
ion 
Recovery 
Muscle fiber CSA (μm2) I 5991±391 6034±501 6620±508 6078±406 6965±521 6898±502 6935±607 6813±408 
 II* 6671±355 7202±640 7540±587 7028±469 7855±633 7434±456 7630±865 7471±534 
Fiber type distribution 
(%) 
I 
 
35±3 38±4 33±3 39±4 42±4 46±3 38±5 46±4 
 II* 65±3 62±4 67±3 61±4 58±4 54±3 62±5 54±4 
Fiber type distribution 
(% area) 
I 
 
33±3 34±4 31±3 36±4 40±5 44±3 37±5 44±5 
 II* 67±3 66±4 69±3 64±4 60±5 56±3 63±5 56±5 
Values are means ± SEMs. CSA, cross-sectional area. No differences were found between the Placebo and Creatine group for all variables on all time points. 
*Muscle fiber CSA and fiber type distribution (in % and % area) were different between type I and type II muscle fibers on all time points. 
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creatine content following creatine loading creates an osmotic potential that forces water 
in the muscle, causing muscle cells to swell (18). Increases in cell volume and the impact on 
cell volume homeostasis have been associated with muscle anabolism (18). Despite the 
successful creatine loading prior to the immobilization period, the greater muscle creatine 
content did not prevent or attenuate the decline in muscle mass or strength that is typically 
observed during hort term disuse. Therefore, in spite of frequent speculation on the clinical 
advantage of creatine supplementation during disuse, we have to remove creatine from the 
list of potential nutritional or pharmaceutical compounds that may help to prevent disuse 
atrophy. Of course, creatine supplementation can still provide an ergogenic advantage in 
anaerobic energy provision required during exhaustive, intermittent type exercise. As such, 
creatine supplementation may be used during clinical rehabilitation to augment the skeletal 
muscle adaptive response to prolonged resistance type exercise training. However, it should 
be noted that muscle loss during disuse occurs at a rate that is several-fold greater than 
muscle (re)gain during resistance type exercise training. Therefore, it is imperative that we 
continue our endeavor o identify nutrition l or pharmaceutical compounds that may 
prevent or attenuated disuse atrophy (35).  
In conclusion, creatine supplementation prior to and during leg immobilization does not 
prevent or attenuate the loss of muscl  mass or strength during short term muscl  disuse 
in humans. 
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cell volume homeostasis have been associated with muscle anabolism (18). Despite the 
successful creatine loading prior to the immobilization period, the greater muscle creatine 
content did not prevent or attenuate the decline in muscle mass or strength that is typically 
observed during short term disuse. Therefore, in spite of frequent speculation on the clinical 
advantage of creatine supplementation during disuse, we have to remove creatine from the 
list of potential nutritional or pharmaceutical compounds that may help to prevent disuse 
atrophy. Of course, creatine supplementation can still provide an ergogenic advantage in 
anaerobic energy provision required during exhaustive, intermittent type exercise. As such, 
creatine supplementation may be used during clinical rehabilitation to augment the skeletal 
muscle adaptive response to prolonged resistance type exercise training. However, it should 
be noted that muscle loss during disuse occurs at a rate that is several-fold greater than 
muscle (re)gain during resistance type exercise training. Therefore, it is imperative that we 
continue our endeavor to identify nutritional or pharmaceutical compounds that may 
prevent or attenuated disuse atrophy (35).  
In conclusion, creatine supplementation prior to and during leg immobilization does not 
prevent or attenuate the loss of muscle mass or strength during short term muscle disuse 
in humans. 
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Abstract 
 
Background: Short successive periods of reduced physical activity occur throughout life and 
contribute substantially to the loss of skeletal muscle mass with aging. Muscle mass 
maintenance during short periods of disuse is required to prevent functional decline and 
maintain metabolic health. 
Objective: To assess whether daily leucine supplementation during a short period of disuse 
can attenuate subsequent muscle loss in vivo in humans. 
Methods: Thirty healthy (22 ± 1 y) young males were subjected to 7 days of one-legged knee 
immobilization by means of a full leg cast with (LEU, n=15) or without (CON, n=15) daily 
leucine supplementation (2.5 g leucine 3 times daily). Prior to and immediately after 
immobilization, quadriceps muscle cross-sectional area (CT) and leg strength (1-RM) were 
assessed. Furthermore, muscle biopsies were taken in both groups before and after 
immobilization to assess changes in type I and type II muscle fiber CSA  
Results: Quadriceps muscle cross sectional area (CSA) declined in the CON and LEU group 
(P<0.01), with no differences between the two group (respectively from 7603±301 to 
7156±279 mm2 vs 7643±317 to 7164±328 mm2; P=0.77). Leg muscle strength decreased 
from 56±4 to 53±4 kg in the CON group (P=0.03) and from 63±3 to 55±2 kg in the LEU group 
(P<0.01), with no differences between groups (P=0.052). Type I and II muscle fiber size did 
not change significantly over time and no differences are found between groups (P>0.05).  
Conclusion: Fortification of the three main meals with free leucine (7.5 g/d) does not 
attenuate the loss of muscle mass or strength during a short period of leg immobilization.  
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Introduction 
 
Aging is associated with progressive loss of skeletal muscle mass and strength. This loss of 
muscle mass and strength leads to a decline in functional capacity and predisposes to the 
development of chronic metabolic diseases [1]. Though the mechanisms responsible for 
age-related muscle mass loss remain to be elucidated, it is clear that an inadequate protein 
intake and reduced level of physical activity play a key role [2]. Recently, it has been 
suggested that age-related muscle loss may be largely attributed to the muscle loss that 
occurs during short successive periods of muscle disuse throughout the lifespan [3-5]. 
Merely a few days of immobilization [6-10] or bedrest [11-13] can already result in 
substantial muscle and strength loss in older individuals. Furthermore, it has been reported 
that older individuals have a reduced capacity to regain skeletal muscle mass that was lost 
during a period of disuse [14]. As a consequence, our group and others have started to look 
for strategies to prevent or attenuate muscle loss during such short periods of muscle disuse 
to support healthy aging. 
Muscle mass is regulated by the fluctuations in muscle protein synthesis and breakdown 
rates [15, 16]. The loss of muscle mass during a period of disuse has been attributed to a 
decline in both basal muscle protein synthesis [11, 17-21] and a blunted muscle protein 
synthetic response to protein ingestion [21-24]. Furthermore, a rapid increase in muscle 
protein breakdown rate has been suggested to occur during the early stages of muscle 
disuse [2, 25-27]. Protein ingestion forms a key anabolic stimulus with a rapid increase in 
muscle protein synthesis rates and an inhibition of proteolysis following the postprandial 
rise in plasma amino acid concentrations. It has been well established that the postprandial 
increase in muscle protein synthesis is attributed to the rise in plasma essential amino acids 
concentrations [28, 29], with the rise in circulating leucine being of particular relevance [30-
35]. Leucine administration has been shown to stimulate muscle protein synthesis by direct 
or indirect activation of many key regulatory proteins in the mTOR pathway [36-39]. 
Furthermore, leucine has been shown to have strong anti-proteolytic properties [40], either 
directly or via its insulinotropic properties [41, 42]. We hypothesize that providing 
additional free leucine with each main meal may compensate for anabolic resistance and, 
as such, prevent or attenuate muscle mass loss during a short period of immobilization.  
In the present study, we subjected 30 healthy, young men to 7 days of one-legged knee 
immobilization. One group (n=15) was supplemented with 2.5 g of leucine three times daily 
during immobilization (7.5 g/d in total), whereas the other group (n=15) ingested a control 
supplement. Skeletal muscle mass and function were assessed before and after 
immobilization, and muscle biopsies were collected to assess changes in muscle fiber size.  
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Methods 
 
Subjects 
Thirty young (18-35 y) healthy males (18.5 < BMI < 30 kg/m-2) participated in this 
randomized controlled trial. Participants’ characteristics are presented in Table 5.1. All 
subjects were screened and excluded in case one or more of the following criteria were 
met: a history of thromboembolic events, smoker, currently participating in progressive 
resistance type exercise training,  back/leg/knee/shoulder complaints that could interfere 
with the use of crutches, systematic use of corticosteroids, anabolic steroids, growth 
hormone, testosterone, immunosuppressants, insulin, or blood glucose lowering 
medication, pre-existing renal disease or potential risk for renal dysfunction (diabetes, 
hypertension, reduced glomerular filtration rate), liver disease, heart failure or migraines. 
All participants were informed about the purpose of the study, the experimental 
procedures, and all its possible risks prior to providing written consent to participate. This 
study was approved by the Medical Ethics Committee from the Academic Hospital 
Maastricht and Maastricht University (MUMC+). The procedures followed were in 
accordance with the ethical standards of the responsible institutional or regional committee 
on human experimentation or in accordance with the Declaration of Helsinki of 1975 as 
revised in 1983. 
 
Experimental outline 
 After inclusion into the study, subjects were allocated to either the control (CON, n=15) or 
the leucine (LEU, n=15) supplemented group. Both groups were subjected to 7 days of 
muscle disuse induced by means of a full leg cast. The immobilized leg was randomly 
allocated and counter-balanced between left and right. Two days prior to casting and 
directly after cast removal, a series of measurements were performed. Single-slice 
computed tomography (CT) scans were performed at the mid-thigh of both legs. In addition, 
a single muscle biopsy from the immobilized leg and a venous blood sample were collected. 
Leg extension strength was assessed  (1 repetition maximum) for both legs separately. 
 
Pretesting/ screening 
Body weight and height were measured using a digital balance and a stadiometer to 
calculate BMI. A medical questionnaire was filled in to assess whether subjects met the 
inclusion criteria. Subsequently, a familiarization session on the leg extension machine 
(Technogym, Rotterdam, the Netherlands) was performed as described previously [43, 44].  
 
Measurements 
Subjects participated in two identical experimental test days, before and immediately after 
the immobilization period. Two days prior to the immobilization period, subjects arrived at 
the laboratory at 08.00 am after an overnight fast, and body weight was measured with a 
digital balance with an accuracy of 0.1 kg (SECA GmbH, Hamburg, Germany). Thereafter, a 
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single-slice CT scan (Philips Brilliance 64; Philips Medical Systems, Best, the Netherlands) 
was performed to assess quadriceps muscle and whole thigh muscle cross-sectional area 
(CSA) in both legs. The scanning characteristics were as follows: 120 kV, 300 mA, rotation 
time of 0.75 s and a field of view of 500 mm. With subjects lying supine with their legs 
extended and feet secured, a 3-mm thick axial image was taken 15 cm proximal to the top 
of the patella. The precise scan position was marked with semi-permanent ink for the 7 days 
of immobilization to ensure accurate repeat measurements at the second test day. Muscle 
area of the thigh was selected between -29 and 150 Hounsfield units, after which the 
quadriceps muscle was selected by manual tracing using ImageJ software (version 1.46d; 
National Institute of Health, Bethesda, MD, USA) [45]. Subsequently, a blood sample was 
taken from the antecubital vein by venipucture. After collection, EDTA-containing blood 
tubes were immediately centrifuged at 1000 X g for 10 minutes at 4 °C. Aliquots of plasma 
were frozen in liquid nitrogen and stored at -80 °C until analysis. 
 Thereafter, a muscle biopsy was collected from the leg that was subsequently immobilized 
by using the percutaneous needle biopsy technique [46]. Muscle biopsy samples were 
obtained from the middle region of the vastus lateralis, ~1–3 cm below the level that the 
CT scan was performed, and ~3 cm below entry through the fascia,. Any visible non-muscle 
tissue was removed immediately, after which the biopsy sample was embedded in Tissue-
Tec (Sakura Finetek, Zoeterwoude, the Netherlands) before being frozen in liquid nitrogen-
cooled isopentane.. Muscle samples were subsequently stored at -80 °C until further 
analyses.  
After consuming breakfast, subject’s single-leg one repetition maximum (1-RM) was 
assessed on a leg extension machine. The estimations obtained during the screening visit 
were used to determine 1-RM [44]. Finally, subjects were instructed on, and familiarized 
with, the use of crutches.  
On the second test day, post-immobilization, the cast was removed before the 
measurements described above (CT scan, muscle biopsy, blood draw and 1-RM leg strength) 
were performed.  
  
Limb immobilization protocol 
Two days after the first test day, subjects reported at 8 am at the Casting Room at 
Maastricht University Medical Centre, to have a full leg cast fitted. The casting procedure 
has been described previously [43, 47]. In short, the circular leg cast extended from 10 cm 
above the ankle to ~25 cm above the patella. The knee was casted at a 30° angle of flexion 
to prevent subjects performing any weight bearing activities with the casted leg. Subjects 
were provided with crutches for proper ambulation. All subjects were instructed to perform 
a series of simple ankle exercises (i.e. plantar and dorsal flexion, and circular movements of 
the entire foot) to keep the calf muscle pump activated in the immobilized leg, thereby 
minimizing the risk of developing deep vein thrombosis. After 7 days of immobilization and 
prior to the start of the second test day, subjects visited the Casting Room to have the cast 
removed. Immediately after the cast-removal, subjects were taken by wheelchair to the 
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laboratory to prevent any weight bearing activities prior to the CT scan and muscle biopsy 
collection.  
 
Leucine supplementation 
Subjects in the LEU group were supplemented with free crystalline leucine (BUFA, Uitgeest, 
The Netherlands) for 1 week, starting at the first day of immobilization. The leucine was 
provided in capsules (0.5 g free leucine per capsule). The supplementation protocol 
consisted of 7.5 g leucine per day; i.e. 2.5 g with each main meal (breakfast, lunch, and 
dinner), thus three times per day 5 capsules during the immobilization week.  
 
Dietary intake and physical activity records 
On the evening prior to both test days, subjects received a standardized meal containing 
2.9 MJ providing 51 energy% (En%) as carbohydrate, 32 En% as fat and 17 En% as protein. 
Subjects were asked to maintain their habitual food intake during the study and to refrain 
from consuming alcohol in the 48 h leading up to a test day. All volunteers refrained from 
any sort of heavy physical exercise from 48 h before the first test until the end of the study.  
 
Blood analyses 
Plasma leucine concentration was determined by GC-MS (Agilent 7890A GC/5975C; MSD, 
Little Falls, DE). Specifically, the internal standard of [U-13C6]-Leucine was added to the 
samples. Plasma was deproteinized on ice with dry 5-sulfosalicylic acid. Leucine was purified 
using cation exchange AG 50W-X8 resin (mesh size: 100-200, ionic form: hydrogen (Bio-Rad 
Laboratories, Hercules, CA)) columns and converted to its tert-butyl dimethylsilyl (TBDMS) 
derivative before analysis by GC-MS. The leucine concentration was determined using 
electron impact ionization by monitoring ions at mass/charge (m/z) 302 and 308 for 
unlabeled and [U-13C6]-Leucine, respectively. Standard regression curves were applied from 
a series of known standard concentration values against the measured values to assess the 
linearity of the mass spectrometer.  
 
Muscle analyses  
Frozen muscle biopsies were cut into 5-µm-thick cryosections using a cryostat at -20 °C, and 
thaw mounted on uncoated pre-cleaned glass slides. Samples from pre- and post-
immobilization were mounted together on the same glass slide. Care was taken to properly 
align the samples for cross-sectional fiber analyses. Muscle biopsies were stained for muscle 
fiber typing (FT). First antibodies were directed against laminin (polyclonal rabbit 
antilaminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands) and myosin heavy chain 
(MHC)-I (A4.840, dilution 1:25; Developmental Studies Hybridoma Bank, Iowa City, IA, USA). 
Appropriate secondary antibodies were applied: goat anti-rabbit IgG AlexaFluor647 and 
goat antimouse IgM AlexaFluor555 (dilution 1:400 and 1:500, respectively; Molecular 
Probes, Invitrogen, Breda, the Netherlands). All primary and secondary antibodies were 
diluted in 0.1% bovine serum albumin (BSA) in 0.1% Tween–phosphate-buffered saline 
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(PBS). All incubations took place at room temperature. Staining procedures are described 
before [48].  
Images were visualized and automatically captured at 109 magnification with a fluorescent 
microscope equipped with an automatic stage (IX81 motorized inverted microscope; 
Olympus, Hamburg, Germany) EXi Aqua CCD camera (Q Imaging, Surrey, Canada). 
Micromanager 1.4 software was used for image acquisition [49]. Quantitative analyses were 
carried out using Image J software package (version 1.45d, National Institute of Health; 
[45]). All image recordings and analyses were performed by an investigator blinded to 
subject coding. Mean muscle fiber size was calculated for the type I and type II muscle fibers 
separately. To assess fiber circularity, form factors were calculated by using the following 
formula: (4π·CSA)/(perimeter)2. Fiber circularity did not change over time or between 
groups. Mean numbers of 274±25 and 306±28 fibers were analyzed in pre- and post-
immobilization samples, respectively. 
 
Statistics 
All data are expressed as mean ± SEM. Baseline values between groups were compared by 
means of an independent samples t-test. Pre- versus post-immobilization data were 
analyzed using Repeated Measures ANOVA with treatment (CON vs LEU) as between-
subjects factor and time (pre- vs post-immobilization) as within-subjects factor. Fiber type 
(type I vs type II) was added to the test as a within-subjects factor when performing the 
statistical analyses for the muscle data. A P-value of <0.05 was used to determine 
significance. All data were analyzed using SPSS version 22.0 ( SPSS, IBM Corp., Armonk, NY, 
USA). 
 
Results 
 
Subjects and dietary intake 
Subjects’ characteristics are provided in Table 5.1. The mean age of the subjects was 22±1 
y with an average BMI of 23.1±0.5 kg·m-2. Baseline subjects’ characteristics did not differ 
between the CON and LEU groups (quadriceps CSA 7603±301 and 7643±317 mm2 (P=0.93), 
and leg muscle strength 56±4 and 63±3 kg (P=0.16), respectively). Three subjects withdrew 
prior to immobilization due to time constraints. From the 30 participants, 27 completed the 
study (CON: n=13; LEU: n=14).  
 
Muscle mass and strength  
Quadriceps muscle cross-sectional area (CSA) is displayed in Figure 5.1. At baseline, no 
differences were observed in quadriceps or muscle CSA between groups (P=0.93). Seven 
days of immobilization caused significant muscle atrophy of the quadriceps (time effect, 
P<0.01; from 7603±301 to 7156±279 mm2 vs 7643±317 to 7164±328 mm2 in the CON and 
LEU group, respectively). No differences were observed between the CON and LEU group 
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(interaction effect P=0.77). Leg muscle strength data are presented in Figure 5.2. Maximal 
leg strength had decreased during immobilization from 56±4 kg to 53±4 kg in the CON group 
(P=0.03) and from 63±3 kg to 55±2 kg) in the LEU group (P<0.01). No significant differences 
were observed between the CON and LEU group (interaction effect; P=0.052). 
 
Table 5.1: Subjects’ characteristics 
 Leucine Placebo 
Age (y) 21±1 22±1 
Body mass (kg) 73.5 ± 1.9 73.4 ± 2.8 
Height (m) 1.80 ± 0.02 1.77 ± 0.02 
BMI (kg·m-2) 22.7 ± 0.6 23.5 ± 0.8 
Leg strength (kg) 63±3 56±4 
Whole-thigh CSA (mm2) 14417±537 14204±469 
Quadriceps CSA (mm2) 7691±299 7603±301 
Data are expressed as the means±SEM. Baseline characteristics are not different between groups. 
 
Plasma analyses  
Post-absorptive plasma leucine concentrations did not change in the LEU (154±5 and 160±4 
μmol.L-1 before and after supplementation respectively; P=0.34) and in the CON group 
(156±5 and 150±6 μmol.L-1 before and after supplementation respectively; P=0.23). No 
differences in post-absorptive plasma leucine concentrations were observed between the 
CON and LEU group (P=0.13). 
 
Muscle fiber characteristics  
Muscle fiber characteristics are displayed in Table 5.2. At baseline, no differences between 
groups were observed for any of the variables. No measurable decline in muscle fiber CSA 
was observed following 7 days of immobilization (P≥0.05). Muscle fiber type distribution (in 
% and % area) did not change during 7 d of immobilization (P≥0.05) and no differences were 
observed between groups (P≥0.05). Muscle fiber CSA and fiber type distribution (in % and 
% area) were different between type I and type II muscle fibers on all time points (P≤0.01).  
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Figure 5.1A: Cross-sectional area (CSA) of the quadriceps muscle in the Control and Leucine group 
before and after 7 days of one-legged knee immobilization. Figure 5.1B: Individual changes in 
quadriceps CSA following 7 days of one-legged knee immobilization. Data were analyzed using 
repeated measures ANOVA. Data are expressed as means±SEM. Immobilization resulted in a 
significant decline in quadriceps CSA in both groups (*), with no differences between groups.  
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Figure 5.2A: One-repetition maximum (1-RM) leg muscle strength in the Control and Leucine group 
before and after 7 days of one-legged knee immobilization. Figure 5.2B: Individual changes in 1-RM 
leg muscle strength following 7 days of one-legged knee immobilization. Data were analyzed using 
repeated measures ANOVA. Data are expressed as means±SEM. Immobilization resulted in a 
significant decline in muscle strength in both groups (*), with no differences between groups.  
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Table 5.2: Muscle fiber characteristics in the control and leucine group   
 Control group (n=13) Leucine group (n=11) 
 Fiber 
type 
Pre-
immobilization 
Post-
immobilization 
Pre-
immobilization 
Post-
immobilization 
Muscle fiber  I 6105±588 6857±571 5781±354 6196±415 
CSA (μm2) II* 7420±741 7954±614 6033±482 6589±509 
Fiber type  I 39±4 35±3 39±5 41±5 
distribution (%) II* 61±4 65±3 61±5 59±5 
Fiber type  I 35±4 32±3 38±4 40±5 
distribution  
(% area) 
II* 65±4 68±3 62±4 60±5 
Values are means ± SEMs. CSA, cross-sectional area. No differences over time were found between the 
Control and Leucine group. *Muscle fiber CSA and fiber type distribution (in % and % area) were different 
between type I and type II muscle fibers on all time points 
 
Discussion 
In the present study, we show that fortification of the main meals with free leucine did not 
attenuate muscle disuse atrophy or muscle strength during 7 days of leg immobilization in 
healthy adults. 
The skeletal muscle loss experienced during short successive periods of muscle disuse (e.g. 
following injury or during recovery from illness) has been hypothesized to be partly 
responsible for the loss of muscle mass throughout the lifespan [4, 5, 47]. Most periods of 
forced muscle disuse are of relative short duration, lasting less than one week [4, 50]. 
Whereas ample studies have shown that long-term disuse leads to considerable muscle loss 
[18, 51-53], only a limited number of short-term disuse studies have been performed [43, 
54]. In the current study, we show that as little as 7 days of muscle disuse leads to 
considerable loss of muscle mass. We observed a 6% decline in muscle cross-sectional area 
of the upper leg (Figure 5.1), which was accompanied by a 9% decline in leg strength (Figure 
5.2) in healthy males. These findings are in line with previous work from our  group [4, 10, 
43, 47] as well as others [55] and underline the impact of even a short period of muscle 
disuse. Disuse atrophy is accompanied by numerous negative health consequences such as 
reduced functional capacity, increased risk of post-surgery complications and co-
morbidities, and less successful rehabilitation upon hospital discharge [20, 56-59]. Clearly, 
effective strategies are needed to prevent or attenuate muscle mass and strength loss 
during such short periods of muscle disuse in both health and disease. 
The loss of muscle mass during a period of disuse has been, at least partly, attributed to a 
decline in the muscle protein synthetic response to meal ingestion, now coined anabolic 
resistance [60, 61]. Increasing protein intake [62] or co-ingesting free leucine [63, 64] has 
previously been shown to increase the postprandial muscle protein synthetic response to 
protein ingestion, implying that free leucine supplementation or food fortification with 
leucine may represent effective strategies to compensate for anabolic resistance and, as 
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such, may be used to attenuate muscle mass loss [65]. Therefore, we hypothesized that free 
leucine supplementation with each main meal (3 * 2.5 g per day) would compensate for 
anabolic resistance and attenuate muscle loss during 7 days of muscle disuse. However, 
muscle loss did not differ between the leucine and control groups (-479±75 and -447±71 
mm2, respectively; P=0.77). In line with the loss of muscle mass, muscle strength loss did 
not differ between groups (-8.2±2.0 and -3.2±1.2 kg, respectively; P=0.52).  
A recent study from English et al. assessed the effects of leucine supplementation during 2 
weeks of bedrest in young individuals [66]. Their study seemed to support our hypothesis 
as leucine supplementation (4.4 g leucine per meal, 13.2 g per day) attenuated lean mass 
loss following 7 days of bedrest (-1.5±0.3 and -0.8±0.3 kg lean mass loss in the control and 
leucine group, respectively). However, this attenuated loss of lean mass was no longer 
evident following 2 weeks of bedrest (-1.5±0.3 and -1.0±0.3 kg lean mass loss, respectively). 
Our data show no benefits of leucine in either preserving muscle mass or strength following 
one week of limb immobilization. Whether the apparent discrepancy between our data and 
those by English et al. is attributed to the disuse model used (limb immobilization vs 
bedrest) or the amount of leucine provided (7.5 vs 13.2 g per day) remains unclear. 
Nonetheless, our work is in line with previous work in our group as we have been unable to 
detect net changes in muscle mass, strength, or glucose homeostasis following 3 and 6 
months of leucine supplementation in healthy individuals [67] and type 2 diabetes patients 
[68], respectively. In the latter publication, we hypothesised that free leucine 
supplementation may be more relevant under more clinically compromised conditions 
where muscle atrophy is apparent. However, based upon the present data we can only 
conclude that under well-fed conditions, local anabolic resistance due to limb 
immobilization [24] is not compensated for by free leucine co-ingestion. We need to stress 
that in our study, healthy subjects were fed in energy balance, with a dietary protein intake 
of 1.1±0.1 g protein·kg-1 body weight per day being well in excess of the Recommended 
Dietary Allowance (RDA) [69]. As dietary protein intake does not meet the RDA in a large 
proportion of institutionalized older people or more clinically comprised individuals 
admitted to hospital [70], these results may not necessarily represent the impact of leucine 
supplementation on preserving skeletal muscle mass during disuse under malnourished 
conditions.  
In conclusion, free leucine ingestion with each main meal (3*2.5 g leucine per day) does not 
attenuate the loss of leg muscle mass and leg strength during a short period of limb 
immobilization in healthy, young males.  
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Abstract 
 
Background: A few days of bed rest or immobilization following injury, disease, or surgery 
can lead to considerable loss of skeletal muscle mass and strength. It has been speculated 
that such short, successive periods of muscle disuse may be largely responsible for the age-
related loss of muscle mass throughout the lifespan. 
Objective: To assess whether a single intramuscular injection of nandrolone decanoate 
prior to immobilization can attenuate subsequent muscle loss in healthy men. 
Methods: Thirty healthy (22±1y) men were subjected to 7 d of one-legged knee 
immobilization by means of a full leg cast with (NAD, n=15) or without (CON, n=13) an 
intramuscular nandrolone decanoate injection (200 mg). Prior to and immediately after 
immobilization, quadriceps muscle cross-sectional area (CT) and leg strength (1-RM) were 
assessed. Furthermore, muscle biopsies were taken in both groups before and after 
immobilization to assess changes in type I and type II muscle fiber CSA. 
Results: Quadriceps muscle cross-sectional area (CSA) decreased during immobilization in 
both CON and NAD (Time P<0.01) with no difference between the groups (-6±1% in both 
groups, Time x Treatment P=0.95). 1-RM significantly declined in both groups (-7±3% and -
6±2%, resp, Time P<0.01), with no difference between the groups (Time x Treatment 
P=0.55). Muscle fiber size and distribution did not change over time and no differences were 
observed between groups (P>0.05). 
Conclusion: This is the first study to report that nandrolone decanoate administration does 
not preserve skeletal muscle mass and strength during a short period of leg immobilization 
in vivo in humans.  
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Introduction 
 
Muscle disuse, such as forced upon following injury or during illness can lead to substantial 
loss of skeletal muscle mass and strength and has numerous negative side effects. Most 
periods of muscle disuse tend to be short, lasting less than 7 days (1, 2). Recently, it has 
been shown that even a few days of muscle disuse can lead to a substantial decline in 
muscle mass and strength (3). It has been speculated that such short successive periods of 
bed rest or immobilization can contribute largely to the loss of muscle mass throughout the 
lifespan (1, 4). Obviously, effective strategies are required to prevent or attenuate muscle 
loss during short periods of muscle disuse (5). 
Skeletal muscle disuse is accompanied by a decline in basal muscle protein synthesis rates, 
an increase in protein breakdown, and the development of anabolic resistance to feeding 
(1, 6). The anabolic steroid nandrolone, with nandrolone decanoate as one of its esters (7-
10) has been shown to increase protein synthesis and decrease proteolysis in mice (11, 12). 
Prolonged nandrolone decanoate administration (ranging from 25-600 mg for a period 
between 1-6 months) has been shown to increase fat free mass, muscle cross-sectional area 
and/or strength in several pathological conditions in vivo in humans (13-23). Based on these 
findings it could be speculated that nandrolone decanoate administration may represent an 
effective adjuvant pharmaceutical strategy to prevent or attenuate disuse atrophy.  
We hypothesize that intramuscular administration of a single dose of nandrolone decanoate 
attenuates muscle mass and strength loss during short-term leg immobilization. To test this 
hypothesis, we selected 30 healthy, young males who were subjected to 7 days of one-
legged knee immobilization. One group (n=15) received a single intramuscular nandrolone 
decanoate injection (200 mg) at the start of the immobilization period, whereas the other 
group (n=15) acted as controls. Skeletal muscle mass and function were assessed before 
and after immobilization.  
 
Methods 
 
Subjects 
Thirty young (18-35 y) healthy males (18.5 < BMI < 30 kg/m2) participated in this experiment. 
Participants’ characteristics are presented in Table 6.1. All subjects were screened and 
excluded in case one or more of the following criteria were met: a history of 
thromboembolic events, smoker, history of participating in regular resistance type exercise 
training,  back/leg/knee/shoulder complaints that could interfere with the use of crutches, 
systematic use of corticosteroids, anabolic steroids, growth hormone, testosterone, 
immunosuppressants, insulin, or blood glucose lowering medication, pre-existing renal 
disease or potential risk for renal dysfunction (diabetes, hypertension, reduced glomerular 
filtration rate), liver disease, heart failure or migraines. All participants were informed about 
the purpose of the study, the experimental procedures, and all its possible risks prior to 
providing written consent to participate. This study was approved by the Medical Ethics 
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Committee from the Academic Hospital Maastricht and Maastricht University (MUMC+). 
The procedures followed were in accordance with the ethical standards of the responsible 
institutional or regional committee on human experimentation or in accordance with the 
Declaration of Helsinki of 1975 as revised in 1983. 
 
Experimental outline 
After inclusion into the study, subjects were allocated to either the control (CON, n=15) or 
the nandrolone decanoate (NAD, n=15) group. Both groups were subjected to 7 d of muscle 
disuse induced by way of a full leg cast. The immobilized leg was randomly allocated and 
counter-balanced between left and right. Two days prior to casting and directly after cast 
removal, a series of measurements were performed. Single-slice computed tomography 
(CT) scans were performed at the mid-thigh of both legs to assess muscle mass. After that, 
a single muscle biopsy was taken from the immobilized leg to assess changes in muscle fiber 
size and distribution, a venous blood sample was collected to assess changes in serum 
testosterone and nandrolone, and knee extension strength (1 repetition maximum; 1-RM) 
was assessed for both legs separately. 
 
Pretesting/ screening 
Body weight, height, blood pressure and heart rate were measured. Subsequently, a 
familiarization session was performed on the leg extension machine (Technogym, 
Rotterdam, the Netherlands) to estimate the subjects’ single-leg one repetition maximum 
(1-RM) as described previously (24, 25). 
 
Muscle mass, biopsies and strength 
Subjects participated in two identical experimental test days, before and immediately after 
the immobilization period. Two days prior to the immobilization period, subjects arrived at 
the laboratory after an overnight fast. Body weight was measured with a digital balance 
with an accuracy of 0.1 kg (SECA GmbH, Hamburg, Germany). Thereafter, a single-slice CT 
scan (Philips Brilliance 64; Philips Medical Systems, Best, the Netherlands) was performed 
to assess quadriceps muscle and whole upper leg muscle anatomical cross-sectional area 
(CSA) in both legs. The scanning characteristics were as follows: 120 kV, 300 mA, rotation 
time of 0.75 s and a field of view of 500 mm. With subjects lying supine with their legs 
extended and feet secured, a 3-mm thick axial image was taken 15 cm proximal to the top 
of the patella. The precise scan position was marked with semi-permanent ink for the 7 d 
of immobilization to ensure accurate repeated measurements at the second test day. 
Muscle area of the leg was selected between -29 and 150 Hounsfield units, after which the 
quadriceps muscle was selected by manual tracing using ImageJ software (version 1.46d; 
National Institute of Health, Bethesda, MD, USA) (26).  
Subsequently, a blood sample was collected from the antecubital vein by venipuncture in 
SST containing tubes (SSTTM Tube with Silica Clot Activator). After 30 min clotting time, blood 
Nandrolone and disuse atrophy 
87 
tubes were centrifuged at 1550 X g for 15 minutes at 21 °C. Aliquots of serum were frozen 
in liquid nitrogen and stored at -80 °C until analysis. 
Thereafter, a muscle biopsy was collected from the vastus lateralis muscle of the leg 
identified as the leg to become immobilized (or the previously immobilized leg in the case 
of the second visit). Muscle biopsy samples were obtained from the middle region of the 
vastus lateralis, ~1–3 cm below the level that the CT scan was performed, and ~3 cm below 
entry through the fascia, by using the percutaneous needle biopsy technique (27). Any 
visible non-muscle tissue was removed immediately, after which the biopsy sample was 
embedded in Tissue-Tec (Sakura Finetek, Zoeterwoude, the Netherlands) before being 
frozen in liquid nitrogen-cooled isopentane. Muscle samples were subsequently stored at -
80 °C until further analyses. Thereafter, subject’s single-leg one repetition maximum (1-RM) 
was assessed. The estimations obtained during the screening visit were used to determine 
1-RM (25). Finally, subjects were instructed on, and familiarized with, the use of crutches.  
On the second test day, post-immobilization, the cast was removed before the 
measurements described above (CT scan, muscle biopsy, blood draw and 1-RM leg strength) 
were performed again.  
 
Limb immobilization protocol 
Two days after the first test day, subjects reported at 8 am at the Casting Room at 
Maastricht University Medical Centre, to have a full leg cast fitted. The casting procedure 
has been described previously (3, 24). In short, the circular leg cast extended from the ankle 
to ~25 cm above the patella. The knee was casted at a 30° angle of flexion to prevent 
subjects performing any weight bearing activities with the casted leg. Subjects were 
provided with crutches for proper ambulation. All subjects were instructed to perform a 
series of simple ankle exercises (i.e. plantar and dorsal flexion, and circular movements of 
the entire foot) to keep the calf muscle activated in the immobilized leg, thereby minimizing 
the risk of developing deep vein thrombosis. After 7 d of immobilization and prior to the 
start of the second test day, subjects visited the Casting Room again to have the cast 
removed. Thereafter, subjects were taken by wheelchair to conduct the CT scan and the 
muscle biopsies before any weight bearing exercise was performed.  
 
Nandrolone decanoate injection 
Subjects in the NAD group were administered 200 mg nandrolon-17β-decanoaat (Deca-
Durabolin) by intramuscular injection in the M. gluteus maximus just before casting.  
 
Diet and activity 
On the evening prior to both test days, subjects received a standardized meal containing 
2.9 MJ providing 51 energy% (En%) as carbohydrate, 32 En% as fat and 17 En% as protein. 
Subjects were asked to maintain their habitual food intake during the study and to refrain 
from consuming alcohol in the 48 h leading up to a test day. All volunteers refrained from 
any sort of heavy physical exercise from 48 h before the first test until the end of the study.  
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Blood analyses 
Nandrolone was measured by Liquid Chromatography/Tandem Mass Spectrometry 
(LC/MS/MS) using a diethyl ether liquid/liquid extraction preparation step to isolate the 
non-conjugated steroid fraction. CV of quality control (CV) samples was < 10%. 
Total testosterone was measured by electrochemiluminescence immunoassay (ECLIA) 
(Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim) using the COBAS 
8000 modular system. CV of QC samples were <20%.  
 
Muscle analyses  
Frozen muscle biopsies were cut into 5-µm-thick cryosections using a cryostat at -20 °C, and 
thaw mounted on uncoated pre-cleaned glass slides. Samples from pre- and post-
immobilization were mounted together on the same glass slide. Care was taken to properly 
align the samples for cross-sectional fiber analyses. Muscle biopsies were stained for muscle 
fiber typing (FT). First antibodies were directed against laminin (polyclonal rabbit 
antilaminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands) and myosin heavy chain 
(MHC)-I (A4.840, dilution 1:25; Developmental Studies Hybridoma Bank, Iowa City, IA, USA). 
Appropriate secondary antibodies were applied: goat anti-rabbit IgG AlexaFluor647 and 
goat antimouse IgM AlexaFluor555 (dilution 1:400 and 1:500, respectively; Molecular 
Probes, Invitrogen, Breda, the Netherlands). All primary and secondary antibodies were 
diluted in 0.1% bovine serum albumin (BSA) in 0.1% Tween–phosphate-buffered saline 
(PBS). All incubations took place at room temperature, unless otherwise stated. Staining 
procedures were as follows. 
After fixation (5 min acetone), slides were air-dried and incubated at room temperature for 
30 min with 3% BSA in 0.1% Tween-PBS. Slides were then washed (5 min PBS). Thereafter, 
primary antibodies against laminin and MHC-I were applied for 45 min. Slides were then 
washed and incubated with the appropriate secondary antibodies. After a final washing 
step, slides were mounted with cover glasses using Mowiol (Calbiochem, Amsterdam, the 
Netherlands). Images were visualized and automatically captured at 109 magnification with 
a fluorescent microscope equipped with an automatic stage (IX81 motorized inverted 
microscope; Olympus, Hamburg, Germany) EXi Aqua CCD camera (Q Imaging, Surrey, 
Canada). 
Micromanager 1.4 software was used for image acquisition (28). Quantitative analyses were 
carried out using Image J software package (version 1.45d, National Institute of Health; 
(26)). All image recordings and analyses were performed by an investigator blinded to 
subject coding. Mean muscle fiber size was calculated for the type I and type II muscle fibers 
separately. To assess fiber circularity, form factors were calculated by using the following 
formula: (4π·CSA)/(perimeter)2. Fiber circularity did not change over time or between 
groups. Mean numbers of 115±12 and 175±16 fibers were analyzed in pre- and post-
immobilization samples, respectively.  
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Statistics 
All data are expressed as mean±SEM. Baseline values between groups were compared by 
means of an independent samples t-test. Pre- versus post-immobilization data were 
analyzed using Repeated Measures ANOVA with treatment (CON vs NAD) as between-
subjects factor and time (pre- vs post-immobilization) as within-subjects factor. A P-value 
of <0.05 was used to determine significance. All data were analyzed using SPSS version 22.0 
(SPSS, IBM Corp., Armonk, NY, USA). 
 
Results 
 
Subjects and dietary intake 
Subjects’ characteristics are provided in Table 6.1. No differences were observed for age, 
height, weight, BMI, whole thigh and quadriceps CSA and strength between the control 
(CON) and nandrolone decanoate (NAD) groups. Two subjects from CON withdrew prior to 
immobilization due to time constraints.  
 
Table 6.1: Subjects’ characteristics 
 Control  
(n=13) 
Nandrolone  
(n=15) 
Age (y) 22 ± 1 22 ± 1 
Body mass (kg) 73.4 ± 2.8 70.1 ± 2.6 
Height (m) 1.77 ± 0.02 1.72 ± 0.02 
BMI (kg/m2) 23.5 ± 0.8 22.8 ± 0.6 
Leg strength (kg) 56 ± 4 64 ± 3 
Whole-thigh CSA (mm2) 14204 ± 469 14471 ± 386 
Quadriceps CSA (mm2) 7603 ± 301 7805 ± 221 
Values are means ± SEM. Abbreviations: BMI, Body Mass Index; CSA, Cross-sectional area. No 
differences were observed between groups (P>0.05) 
 
Muscle mass and strength 
Quadriceps muscle cross-sectional area (CSA) is displayed in Figure 6.1. At baseline, no 
differences were observed in quadriceps muscle CSA between groups (P=0.59). Seven days 
of immobilization caused a significant decline in muscle mass of the quadriceps (from 
7603±301 to 7156±279 mm2 vs from 7805±221 to 7352±202 mm2 in the CON and NAD 
group, respectively (Time P<0.01)) with a similar loss in CON (5.8±0.8%) and NAD (5.8±0.7%; 
P>0.05). Leg muscle strength data are presented in Figure 6.2. Maximal leg muscle strength 
had decreased following immobilization from 56±4 kg to 53±4 kg (5.6±2.2%) and from 64±3 
kg to 60±3 kg (6.9±2.6%) in the CON and NAD group, respectively (Time, P<0.01), with no 
differences between groups (Time x Treatment P=0.55). 
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Figure 6.1A: Cross-sectional area (CSA) of the quadriceps muscle in the Control and Nandrolone group 
before and after 7 days of one-legged knee immobilization. Figure 6.1B: Individual changes in 
quadriceps CSA following 7 days of one-legged knee immobilization. Data were analyzed using 
repeated measures ANOVA. Data are expressed as means±SEM. Immobilization resulted in a 
significant decline in quadriceps CSA in both groups (*), with no differences between groups.  
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Figure 6.2A: One-repetition maximum (1-RM) leg muscle strength in the Control and Nandrolone 
group before and after 7 days of one-legged knee immobilization. Figure 2B: Individual changes in 1-
RM leg muscle strength following 7 days of one-legged knee immobilization. Data were analyzed using 
repeated measures ANOVA. Data are expressed as means±SEM. Immobilization resulted in a 
significant decline in muscle strength in both groups (*), with no differences between groups.  
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Blood analyses 
Serum NAD concentrations significantly increased in the NAD group (0.04±0.002 and 
13.83±0.98 nmol/L) compared with the CON group (0.04±0.003 and 0.04±0.01 nmol/L), pre- 
and post-immobilization, respectively (Time x Treatment P<0.01). Serum testosterone 
concentrations increased more in the NAD group (from 22.75±1.85 to 42.87±2.22 nmol/L) 
than the CON group (from 21.82±1.46 to 21.09±1.43 nmol/L), pre and post immobilization, 
respectively (Time x Treatment P<0.01).  
 
Muscle fiber characteristics 
Muscle fiber characteristics are displayed in Table 6.2. At baseline, no differences between 
groups were observed for any of the variables. No measurable changes in muscle fiber CSA 
or distribution were observed following immobilization (P>0.05). No differences over time 
were observed between groups (P>0.05). 
  
Table 6.2: Muscle fiber characteristics of healthy young men before (pre) and after (post) 7 d of leg 
immobilization in the control and nandrolone group  
  Control Nandrolone 
 Fiber 
type 
Pre Post Pre Post 
Muscle fiber CSA  I 6034 ± 501 6620 ± 508 6014 ± 283 6188 ± 253 
(µm2) II 7202 ± 640 7540 ± 587 6587 ± 512 6594 ± 311 
% Fiber I 38 ± 4 33 ± 3 40 ± 3 40 ± 4 
 II 62 ± 4 67 ± 3 60 ± 3 60 ± 4 
% Fiber (area) I 46 ± 1 47 ± 1 48 ± 1 48 ± 1 
 II 54 ± 1 53 ± 1 52 ± 1 52 ± 1 
Nuclei (n/fiber) I 3.6 ± 0.3 3.7 ± 0.2 4.4 ± 0.4 4.5 ± 0.2 
 II 4.2 ± 0.4 4.0 ± 0.2 4.5 ± 0.5 4.7 ± 0.3 
Myonuclear  I 1697 ± 87 1786 ± 88 1484 ± 108 1401 ±69 
domain (µm2) II 1764 ± 89 1883 ± 101 1562 ± 114 1454 ± 68 
SC (n/fiber) I 0.128 ± 0.016 0.103 ± 0.012 0.056 ± 0.011 0.057 ± 0.008 
 II 0.083 ± 0.011 0.081 ± 0.008 0.047 ± 0.008 0.055 ± 0.010 
Data represent means±SEM. Abbreviations: CSA, Cross-sectional area, SC, Satellite Cell. No 
interaction- or time effect was found in any of the variables (P>0.05).  
 
Discussion 
 
In the present study, we demonstrated that nandrolone decanoate administration does not 
attenuate muscle disuse atrophy during 7 days of leg immobilization in healthy adults. Also, 
nandrolone decanoate administration did not prevent the decline in muscle strength during 
this short period of disuse.  
A period of prolonged muscle disuse or successive short episodes of muscle disuse reduce 
skeletal muscle mass and strength and cause numerous negative health outcomes (29-33). 
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As a consequence, it has been proposed that such short successive periods of muscle disuse 
due to injury or disease may be largely responsible for the loss of muscle mass throughout 
the lifespan (1, 4). In the present study, we report that merely 7 d of muscle disuse leads to 
substantial loss of muscle mass (6%; Fig. 2A), which translates to ~260 g lean muscle from a 
single leg. The 6% decline in quadriceps cross-sectional area was accompanied by a similar 
(6%) decline in leg strength (Fig. 3A) in healthy males. These observations are in line with 
recent data from our group (3, 34) as well as others (35) reporting similar declines in both 
muscle mass and strength in both young and older individuals. These data are of important 
clinical relevance as hospitalization following acute illness or injury is generally 
accompanied by an average hospital stay of one week (2). The loss of muscle mass and 
strength during such short (successive) periods of muscle disuse impairs functional capacity, 
increases the risk of developing chronic metabolic disease, and hinders the subsequent 
rehabilitation upon discharge (36). Clearly, effective interventional strategies need to be 
developed to prevent or attenuate muscle mass and strength loss during short periods of 
muscle disuse due to injury, disease and/or surgery. 
Prolonged anabolic steroid administration (ranging from 25-600 mg during 1-6 months of 
intervention) has previously been shown to increase fat free mass, muscle cross-sectional 
area and/or strength in several pathological conditions (13-23) and in athletes (37). In the 
present study, we administered one single intramuscular dose (200 mg) of nandrolone at 
the day of immobilization. The injection was well received and no major adverse events 
were reported following nandrolone administration during the subsequent immobilization 
period. In our study, nandrolone decanoate administration did not attenuate muscle or 
strength loss.  
In the present study, we chose to provide nandrolone on the day of immobilization as 
opposed to several days or weeks prior to bed rest or immobilization, as it presents a 
practical and clinically relevant strategy for more clinically compromised patients being 
hospitalized following both acute injury as well as scheduled surgery. As demonstrated in 
previous work, a single injection of nandrolone shows a peak in serum concentrations 72 
hours after intramuscular injection, with the half-life of 7-12 days (7). As a consequence, we 
believe that the treatment strategy applied in the present study should be effective to 
increase circulating steroid levels during the entire 7 days immobilization protocol. Indeed, 
after 7 days of immobilization, serum testosterone levels were still significantly increased 
compared to pre-immobilization 
In conclusion, administration of a single bolus of nandrolone decanoate prior to a short 
period of disuse does not attenuate muscle atrophy nor does it preserve muscle strength.   
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Abstract 
 
Background Dietary induced weight loss is generally accompanied by a decline in skeletal 
muscle mass. The loss of muscle mass leads to a decline in muscle strength and impairs 
physical performance. A high dietary protein intake has been suggested to allow muscle 
mass preservation during energy intake restriction.   
Objective To investigate the impact of increasing dietary protein intake on lean body mass, 
strength and physical performance during 12 weeks of energy intake restriction in 
overweight older adults. 
Design Sixty-one overweight and obese men and women (63±5 y) were randomly assigned 
to either a high protein diet (HP; 1.7 g/kg/d; n=31) or normal protein diet (NP; 0.9 g/kg/d; 
n=30) during a 12 week 25% energy intake restriction. During this controlled dietary 
intervention, 90% of the diet was provided by the university. At baseline and after the 
intervention, body weight, lean body mass (DXA), leg strength (1-RM), physical performance 
(SPPB, 400 m) and habitual physical activity (actigraph) were assessed.  
Results Body weight declined in both groups with no differences between the HP and NP 
groups (-8.9±2.9 kg vs -9.1±3.4 kg, respectively; P=0.584). Lean body mass declined by 
1.8±2.2 and 2.1±1.4 kg, respectively, with no significant differences between groups 
(P=0.213). Leg strength had decreased during the intervention by 8.8±14.0 and 8.9±12.8 kg, 
with no differences between groups (P=0.689). Physical performance as measured by 400 
m walking speed improved in both groups, with no differences between groups (P=0.219).  
Conclusion Increasing protein intake above habitual intake levels (0.9 g/kg/d) does not 
preserve lean body mass or muscle strength during prolonged energy intake restriction in 
overweight older adults.  
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Introduction  
 
Muscle mass and strength are main predictors of physical function and health status in older 
adults. During a period of energy intake restriction, the decline in body weight is 
accompanied by a significant loss of muscle mass and strength (1, 2). This decline in muscle 
mass and strength may even offset the metabolic benefits of the reduction of excess body 
fat. Novel strategies to preserve muscle mass during energy intake restriction are 
warranted.  
It has been well established that nutrition is an important factor in regulating muscle mass 
maintenance (3, 4). Dietary protein intake stimulates muscle protein synthesis and allows 
post-prandial muscle protein accretion (5). It has been suggested that increasing the protein 
content of the diet might be an effective interventional strategy to preserve muscle mass 
during prolonged energy intake restriction, thereby maintaining strength and physical 
performance. Whereas several intervention studies show that increasing protein intake 
during a period of energy intake restriction can alleviate the loss of lean body mass (LBM) 
or increase the loss of fat mass (FM) (6-8), other studies have failed to confirm these findings 
(9, 10). The discrepancy in the literature may be attributed to differences in the selected 
study population, the applied nutritional intervention and/or compliance and adherence of 
the subjects to the diet.  
Most of the previous work investigating the impact of different protein intakes on LBM 
preservation during energy intake restriction have been conducted in young to middle-aged 
adults (7, 8, 11-16). However, the results of these studies may not be translated to the older 
population due to differences in muscle mass and the prevalence of anabolic resistance (17-
19). Another explanation for the discrepancy in the literature is the protein content of the 
applied intervention diets. Previous studies have compared the impact of a wide variety of 
protein intakes on LBM preservation during prolonged energy intake restriction, ranging 
from 0.6 - 0.8 versus 1.1 – 2.4 g protein per kg body weight per day (8, 9, 20, 21). 
Furthermore, the compliance and adherence to a dietary intervention requires careful 
attention, with nutrition being provided and consumed under strict supervision (22, 23).  
In the present study, we investigate the impact of an increase in dietary protein intake on 
the preservation of muscle mass during prolonged energy intake restriction in overweight, 
older adults. Maintenance of habitual protein intake (0.9 – 1.0 g/kg/d) has previously been 
shown to be required for muscle mass preservation (24, 25). Therefore, we assess the 
impact of energy intake restriction on LBM preservation with protein intakes being set at 
1.7 versus 0.9 g/kg/d. We hypothesize that a high protein intake can preserve LBM during 
energy intake restriction in overweight, older adults. To ensure proper compliance and 
adherence to the intervention diet, a strictly controlled dietary intervention is performed. 
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Methods 
 
Subjects 
In total, 61 overweight and obese men (n=36) and women (n=25) were included in the study 
(Supplemental Figure 7.1). All subjects were aged between 55 and 70 y, with a BMI between 
27 and 40 kg/m2 and a waist circumference of ≥102 cm for men and ≥88 cm for women (26). 
Subjects were excluded if they suffered from renal insufficiency (MDRD eGFR > 
60mL/min/1.73 m2) (27), type 1 or type 2 diabetes (fasting glucose levels ≥7 mmol/L) (28), 
cancer, COPD, allergy to milk products or underwent a gastric bypass. Subjects were also 
excluded if they had severe loss of appetite, participated in a weight loss or heavy 
resistance-type exercise program 3 months before the intervention, or if they used 
supplements or drugs known to interfere with energy balance. Women could only 
participate if they were postmenopausal (last period one year previous to study start). 
Written informed consent was obtained from all the subjects.  
 
Design 
The study is a randomized, fully controlled dietary intervention trial of 12 weeks. In total, 
76 subjects were screened for current medical status, medical history, BMI, waist 
circumference, fasting glucose and renal insufficiency. In addition, the 1 repetition 
maximum (1-RM) was estimated during the screening as a familiarization session. Subjects 
were randomly allocated to either the high protein group or the normal protein group. 
Randomization was carried out with permuted blocks, stratified by gender and BMI. After 
randomization, the following measurements were performed: Body composition, the Short 
Physical Performance Battery (SPPB), handgrip strength, 400 m walk test, leg strength (1-
RM leg press and leg extension), blood pressure, body weight and habitual physical activity. 
Subsequently, the subjects enrolled in the dietary intervention period that lasted for 13 
weeks, consisting of one run-in week and 12 weeks of intervention. The subjects were not 
aware of the exact aim of the study to limit any possible effect on the outcome measures. 
The study is in accordance with the ethical standards with the Helsinki Declaration of 1975 
as revised in 1983 and approved by the Medical Ethical Committee of Wageningen 
University. The design and aim of the study was registered in the NIH clinical trial database 
(ClinicalTrials.gov number: NCT01915030).  
 
Dietary intervention 
One week after baseline measurements, subjects started with the run-in week. During the 
run-in week, subjects consumed 100% of their habitual energy intake (protein 14 Energy% 
(En%), fat 31 En%, carbohydrate 51 En%). Habitual energy intake was calculated from a 
validated 177-item food frequency questionnaire (29) and estimated by the Schofield 
formula in combination with a standard PAL (physical activity level) of 1.6 (30). Menus were 
designed for 10 levels of energy intake, ranging from 7-16 MJ/d. Procedures during the run-
in week were the same as during the intervention to familiarize the subjects with the 
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intervention procedures and to standardize dietary conditions among groups. Moreover, if 
subjects lost or gained body weight during the run-in week, energy intake was adjusted to 
attain an adequate estimation of the habitual energy intake for the rest of the intervention. 
Directly after the run-in week, subjects enrolled in the dietary intervention.  
The intervention diets were isocaloric compared to each other and energy intake restricted 
by 25% from baseline energy intake. Ninety percent of the diet was provided by the 
university and 10% was chosen by the subjects from a restricted list. Food products were 
weighed for each subject individually. The high protein (HP) diet contained 1.7 g 
protein/kg/d and the normal protein (NP) diet contained 0.9 g/kg/d. Protein was replaced 
by carbohydrates in the NP group, the fat content was equal in both diets. Subjects 
consumed a supplement twice a day, containing either 20 g protein for the HP group (50% 
whey, 40% casein, 10% soy) or 25 g carbohydrate for the NP group. The intervention diets 
were designed and calculated by experienced research dieticians using the Dutch food 
composition table (31). On weekdays, subjects came to the university to consume their hot 
meal (during afternoon or evening). The rest of the diet (breakfast, bread meal, snacks and 
beverages) and all meals for Saturdays and Sundays were provided in take-home packages, 
together with the meal planning. Subjects were carefully instructed how to prepare the hot 
meals for the weekend. Protein intake was evenly divided over the day with on average 
34±4 g (ranging from 25-41 g) protein per meal in the HP group and 16±1 g (ranging from 
15-18 g) protein per meal in the NP group. A sample daily meal plan and an overview of the 
macronutrient distribution are provided in the supplemental material. To cover the 
remaining 10% of daily energy intake, subjects were obliged to choose foods that were low 
in fat and protein content (max 0.6 g protein per portion) from a list with allowed food 
products. They recorded these foods in a diary in which they also noted any deviations from 
the study protocol, illnesses and use of drugs.  
 
Dietary analysis 
To analyze the amount of energy and macronutrients in the diet as provided by the 
university, one complete diet for each group was collected throughout the intervention. 
The collected duplicates were stored at -20 °C until analysis. After the study, all duplicate 
meals were pooled, homogenized and analyzed. Total energy, fat, protein, dry matter, ash, 
and fiber were analyzed and available carbohydrates were calculated. The nutrient 
composition of the remaining 10% of energy intake was calculated from the food dairies.  
 
Compliance 
Compliance was assured via daily contact (weekdays) with the investigators and dieticians. 
Dieticians supervised during meal time to ensure that the complete meal was consumed. 
Food diaries were discussed once per 2 weeks to ensure that the remaining 10% of energy 
intake was properly consumed. Body weight was measured twice a week on a digital 
balance with indoor clothing, without shoes and with empty pockets. If body weight 
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changed more than two kilogram within the first weeks of the intervention, energy intake 
was adjusted.  
 
Body composition  
Fasted body weight was measured at baseline and at the end of the study to the nearest 
0.1 kg using a digital balance (Seca, Bascule MT, USA) with indoor clothing, without shoes 
and with empty pockets. Waist circumference was measured between the lower rib margin 
and the iliac crest, accurate to 0.5 cm, using a non-stretchable tape. Height was measured 
to the nearest 0.1 cm using a microtoise. Total LBM (primary outcome), appendicular LBM 
and FM was determined using dual energy X-ray absorptiometry (DXA, model DPX-L, Lunar 
Radiation Corp, Madison WI, software version 1.31).  
 
Muscle strength 
Maximum leg strength was assessed by 1-RM strength tests on leg press and leg extension 
machines (Technogym, Rotterdam, The Netherlands). During a first familiarization session 
during the screening, the proper lifting technique was demonstrated and practiced, after 
which maximum strength was estimated using the multiple repetitions testing procedure 
for leg press and leg extension. Handgrip strength of the dominant hand was measured 
using a hydraulic hand dynamometer (Jamar, Jackson, MI). Three consecutive measures of 
handgrip strength were recorded to the nearest 0.5 kg with subjects sitting in an upward 
position and the arm in a 90-degree angle. The maximum strength effort was reported.  
 
Physical performance 
Physical performance was assessed by two different tests, the Short Physical Performance 
Battery (SPPB) and a 400 m walk test. The SPPB consists of three components: balance, gait 
speed and chair rise ability. Scores of 0 to 4 were based on categories of performance in the 
balance test, on the time necessary to complete the walk, and on the time needed to 
perform the chair rise test. A summary performance score of 0 to 12 was calculated by 
summing the scores of the tests. The 400 m walk test assessed the time it takes to walk 400 
m. Directly after finishing the test, subjects had to score the rate of perceived exertion (RPE) 
from 6 to 200 points.     
 
Physical activity 
Subjects were asked to maintain their habitual physical activity level during the 
intervention. Physical activity was measured in counts per min (CPM) using a small-sized 
triaxial accelerometer (Actigraph GT3X Actigraph LLC, Pensacola FL, USA), worn on the 
waist. Subjects wore the actigraph during wakefulness for 7 consecutive days and were 
instructed not to wear them while bathing or swimming. The actigraph method enables a 
reliable and objective assessment of daily physical activity (32-34). Activity counts were 
assessed at 1-min intervals. Data were included if subjects wore the actigraph for a 
minimum of 5 days and at least 10 h per day. 
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Blood pressure 
Blood pressure was measured in the morning after 10 min of rest with an Omron HEM-907 
(Omron Healthcare, Lake Forest, IL, USA) device. At baseline and end, four measurements 
were done, with an interval of 2 min, of which the first measurement was discarded. The 
mean value of the three subsequent measurements for systolic and diastolic blood pressure 
was taken. 
 
Statistics 
The sample size was based upon a power calculation with an expected difference in lean 
body mass of 1.4±1.6 kg between the HP and NP group(35). With a power of 80% and a 
significance level (α) of 0.05, at least 23 participants are required per group. Sixty-one 
subjects were included to allow for drop-outs. 
Data are presented as means±standard deviations (SD). To check if there were baseline 
differences between the groups, an independent sampled t-test was used. A paired t-test 
was used to locate if parameters changed over time. After checking the assumptions, 
Analysis of Covariance (ANCOVA) was applied to assess the differences between groups 
over time with diet group as independent variable, end parameters as dependent variable 
and BMI, gender and baseline parameters as covariates. Data were analyzed using SPSS 
version 21 (SPSS Incl Chicago, IL). Results were considered statistically significant at the 0.05 
level. 
 
Results 
Subjects  
An overview of the subjects’ baseline characteristics is presented in Table 7.1. A total of 61 
subjects participated in the intervention with a mean age of 63±4.8 y and BMI of 31.2±3.0 
kg/m2. One person in the high protein group withdrew during the run-in week, because of 
the time constraints of the intervention (Supplemental material Figure 7.1). No significant 
differences were observed in baseline values between groups.  
 
Dietary intake 
The actual composition of the intervention diets based on chemical analysis of the duplicate 
meals, food diaries and supplements is presented in Table 7.2. The HP diet group consumed 
on average 7.93 MJ/d with 27 En% from fat, 35 En% from carbohydrates and 34 En% from 
protein (1.69 g protein/kg/day). The NP diet group consumed on average 7.80 MJ/d with 24 
En% from fat, 51 En% from carbohydrate and 19 En% from protein (0.92 g protein/kg/d). 
Habitual dietary protein intake measured by the FFQ was 1.1±0.4 g/kg/d. 
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Table 7.1 Baseline subjects’ characteristics.  
 High protein group 
n=31 
Normal protein group 
n=30 
Male/Female (n) 18/13 18/12 
Age (y) 63 ± 4.8 62 ± 4.8 
Body weight (kg) 92.8 ± 11.0 90.5 ± 10.0 
BMI (kg/m2) 31.3 ± 3.0 31.0 ± 2.9 
Lean body mass (kg) 54.8 ± 12.2 54.5 ± 9.3 
Fat mass (%) 37.7 ± 8.4 36.1 ± 8.0 
Fat mass (kg) 34.4 ± 7.2 32.5 ± 8.2 
Waist circumference (cm) 108 ± 8.4 107 ± 6.6 
Fasting glucose (mmol/L) 5.7 ± 0.5 5.8 ± 0.5 
Data represented as means±SD. No baseline differences between groups are observed with an 
independent sampled t-test. BMI: Body Mass Index. 
 
 
Table 7.2 Diet composition  
 High protein group 
n=31 
Normal protein group 
n=30 
(g/d) (En%) (g/d) (En%) 
Energy (MJ/d) 7.93 100 7.80  100 
Energy (kcal/d) 1894 100 1863 100 
Total fat 57 27 51 24 
Total carbohydrate 170 35 236 51 
Total protein 157 34 84 19 
Protein (in g/kg/d) 1.69 34 0.92 19 
Fiber (g/d) 21.3 2 33.9 4 
Alcohol (g/d) 7.7 3 7.1 3 
 
Body composition 
Body weight declined over time for both groups (HP: 92.8±11.0 to 83.9±10.1 kg; P<0.01; NP: 
90.5±10.0 to 81.5±9.7 kg; P<0.01). However, no significant differences in weight loss were 
detected between the diet groups (P=0.584). Waist circumference declined from 108±8 to 
97±7 cm (P<0.01) in the HP group and from 107±7 to 97±7 cm in the NP group (P<0.01), 
with no significant differences observed between groups (P=0.921). Similarly, BMI 
decreased in both groups; from 31.3±3.0 to 27.5±5.8 kg/m2 (P<0.01) in the HP group and 
from 31.0±2.9 to 27.9±3.1 kg/m2 (P<0.01) in the NP group. No significant difference 
between the diet groups was found (P=0.395). LBM also changed, as it declined over time 
in both the HP group (from 54.8±12.2 to 53.1±11.4 kg; P<0.01) and in the NP group (from 
54.5±9.3 to 52.4±9.1 kg; P<0.01), without a significant difference between the two groups 
(P=0.213). In both groups, appendicular LBM decreased; from 23.8±5.5 to 23.1±5.4 kg and 
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from 23.8±4.8 to 22.8±4.6 kg in the HP and NP group respectively (P<0.01), without a 
significant difference between the two diet groups (P=0.122). Changes in body composition 
are presented in Figure 7.1 and Figure 7.2. 
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Figure 7.1 Body composition changes after 12 weeks in the normal protein and high protein group. 
Paired t-tests showed that body weight, fat mass and lean body mass all changed over time. No 
differences are found between groups, as indicated by an ANCOVA. No differences in loss of lean body 
mass are found between men and women (P=0.50) and between overweight and obese subjects 
(P=0.52). Data are represented as mean±SD. 
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Figure 7.2 Individual changes in appendicular lean body mass following 12 weeks of energy intake 
restriction with or without an increase in protein intake. Appendicular lean body mass changed over 
time, indicated by a paired t-test. ANCOVA testing showed no significant differences between groups. 
Data are represented as mean±SD. 
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Muscle strength 
Leg strength declined over time in both groups, without a significant difference between 
the groups (for leg press P=0.689; for leg extension P=0.296). In accordance, handgrip 
strength declined over time in the HP group (P=0.013), but not in the NP group (P=0.215), 
with no significant differences observed between groups (P=0.210). Strength and physical 
performance data are presented in Table 7.3. 
 
Physical performance  
The total scores of the SPPB did not change over time (11.5±0.7 to 11.6±0.5 points; P=0.132) 
and no significant differences were observed between groups (P=0.483). The 400 m walking 
velocity increased from 1.45±0.19 to 1.49±0.21 ms-1 (P<0.01) without a difference between 
the two groups (P=0.219). Strength and physical performance data are presented in Table 
7.3. 
 
Table 7.3 Muscle strength and physical performance before and after intervention  
 High protein group Normal protein group 
 n Baseline End Δ n Baseline End Δ 
1-RM Leg  
Press (kg) 
28 152±44 143±39 - 9±14* 25 157±33 148±30 - 9±13* 
1-RM Leg 
Extension (kg) 
27 93±31 91±29 - 2±8 26 98±25 94±25 - 4±4* 
Handgrip 
strength (kg) 
30 40±11 37±9 - 3±6* 30 41±10 40±11 - 1±5 
SPPB (score) 30 11.6±0.7 11.7±0.5 0.1±0.7 30 11.4±0.9 11.6±0.6 0.1±0.7 
400 m walk 
(m/s) 
30 1.46±0.19 1.50±0.20 0.05±0.09* 29 1.45±0.19 1.47±0.22 0.02±0.08 
Data represented as means ± SD. Data with * represent significant differences over time (P<0.01), indicated 
with a paired t-test. ANCOVA testing showed no significant differences between groups. 1-RM: 1 repetition 
maximum, SPPB: Short Physical Performance Battery 
 
Physical activity 
Habitual physical activity did not change over time in the HP group (P=0.748; baseline value 
916±203 CPM) or the NP (P=0.176; baseline value 825±258 CPM). No significant differences 
in habitual physical activity were observed between groups (P=0.685).  
 
Blood pressure 
Systolic blood pressure decreased over time from 139±18 to 132±15 mmHg (P<0.01) in both 
groups. Diastolic blood pressure decreased from 82±9 to 77±8 mmHg (P<0.01) in both 
groups. No significant differences between groups were observed for systolic (P=0.279) 
and diastolic (P=0.170) blood pressure. 
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Discussion 
 
In the present study we observed a nearly 10 kg reduction in body weight following 12 
weeks of 25% energy intake restriction in overweight, older adults. The reduction in body 
mass was accompanied by a 2 kg decline in lean body mass and as much as a 10% decline 
in leg strength. Increasing dietary protein intake from 0.9 to 1.7 g/kg/d during the 
intervention did not preserve lean body mass nor did it prevent the decline in muscle 
strength associated with prolonged energy intake restriction. 
Twelve weeks of energy intake restriction (25%) successfully reduced body weight by 
9.0±3.1 kg in this group overweight older adults (P<0.01; Figure 7.1). These results are in 
line with previous work showing that 12 weeks of 20-33% energy intake reduction induced 
a 7-10 kg decline in body weight in overweight and obese adults (6, 12, 20, 36). The loss of 
body weight in the present study was attributed to a decline in both fat mass (7.0±2.5 kg) 
and lean body mass (2.0±1.8 kg; P<0.01; Figure 7.1). The changes in lean body mass were 
correlated with the changes in appendicular lean body mass (R=0.697; P<0.01), the latter 
ranging from as much -3.8 to +1.9 kg (Figure 7.2). The overall decline in lean body mass was 
accompanied by a concomitant -8.9±13.3 kg decline in leg strength (-42 to +16 kg; P<0.01). 
Despite the reduction in leg strength, physical performance assessed with the 400 m 
walking speed test showed a significant improvement following dietary intervention (Table 
7.3). This was at least partly attributed to the decline in fat mass (R= -0.243; P=0.06). The 
SPPB score did not change over time, probably because the high baseline scores that limit 
the range for improvement (average score 11.5±0.7 of 12 points maximum). Energy intake 
restriction improved blood pressure, BMI and waist circumference in both groups.  
Despite the benefits of prolonged energy intake restriction to reduce body fat mass and 
improve metabolic function, the loss of skeletal muscle mass and strength is particularly 
undesirable in an older population prone to sarcopenia (37). Therefore, effective dietary 
strategies should be developed to preserve muscle mass during a period of energy intake 
restriction. During a period of energy intake restriction, muscle protein synthesis rates 
usually decrease (8), which would lead to the loss of lean body mass. However, this decline 
in muscle protein synthesis rates can be attenuated by the intake of 27 g whey protein (38). 
Increasing the protein content of the diet might therefore be an effective strategy to 
preserve muscle mass during prolonged energy intake restriction, thereby preserving 
strength and physical performance. This is confirmed by previous work showing that a high 
protein diet can preserve lean body mass during prolonged energy intake restriction (6-8, 
11, 12). In the present study we tested our hypothesis that a higher protein intake preserves 
lean body mass during prolonged energy intake restriction in overweight, older adults. We 
compared the impact of a higher protein diet (1.7 g protein/kg/d; 34 En% protein) with a 
normal protein diet (0.9 g protein/kg/d; 19 En% protein) on lean body mass, muscle strength 
and physical performance (Table 7.2). Despite substantial declines in lean body mass in both 
the normal and high protein groups (2.1±1.4 and 1.8±2.2 kg, respectively), we observed no 
differences between groups (P=0.213; Figure 7.2). These findings are in contrast with some 
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(6-8) but certainly not all (9, 10) studies. The apparent discrepancy may be attributed to 
differences in the level of dietary control (7-9, 11-16, 18, 20), the protein content in the 
diets (15, 16, 18), the duration of the intervention period (7, 8, 11, 39), the level of physical 
activity (10, 13, 35) or the specific population that is studied (7-9, 11-16, 20).  
Through our strict dietary control, whereby we provided all subjects with 90% of their 
prescribed energy intake, the influence of possible confounders is limited. Dietary 
compliance was assured by daily contact (on weekdays) with the investigators and dieticians 
and body weight measurements performed twice weekly. No subject failed to consume the 
supplement more than twice during the entire intervention period as reported in the food 
intake diaries. Moreover, the results confirm the high level of compliance of the subjects in 
both groups showing a 10% reduction in body weight with a concomitant decrease in waist 
circumference of 10.3±4.3 cm. In addition, by collecting duplicate meals, we were also able 
to analyze the actual macronutrient composition of the diets, thereby knowing the exact 
protein content of diets consumed in both intervention groups. Furthermore, people 
generally reduce overall energy intake when the level of dietary protein is increased (40), 
due to the satiating effect of protein (41). By providing the subjects with nearly their entire 
diet in the current study, energy intake remained equal in both intervention groups (7.66 
MJ/d in the high protein group, 7.38 MJ/d in the normal protein group). Consequently, the 
normal protein and high protein diet groups lost exactly the same amount of body weight 
(-9.1±3.4 and 8.9±2.9 kg, respectively). In addition, it is well known that underreporting of 
energy intake is common in dietary interventions (23, 42). Overweight subjects typically 
underestimate energy (and macronutrient) intake, which can make data interpretation 
difficult (43). The results of the current study cannot be influenced by underreporting 
because intake of energy and macronutrients does not rely on food intake diaries, but is 
based on macronutrient analyses of the diet as provided by the university. 
The current study aimed to investigate the additional effect of a high protein diet over a 
normal protein diet containing 0.9 g/kg/d, the latter representing habitual protein intake 
(24, 25). Several previous studies consider intakes of 1.1 g/kg/d as a high protein diet (9, 20, 
44), and intakes of 0.8 g/kg/d or lower as normal to low protein diets (7, 8, 14, 16, 20). The 
present study demonstrates 20% loss of lean body mass expressed as a proportion of total 
weight lost in the high protein group – an effect also observed in the comparable literature 
(6, 12). Surprisingly, we demonstrate that the normal protein group experienced a lower 
percentage of lean body mass loss (23% of total weight lost) compared with the results of 
the aforementioned studies showing a 35% loss of lean body mass with similar protein 
intakes of 18% (6, 13). Thus, comparing our data with the literature suggests that 
maintaining habitual protein intake may be more important than increasing protein intake 
beyond habitual protein intake levels as a means to preserve lean body mass during energy 
intake restriction. It is hereby important that protein intake during energy intake restriction 
is expressed in En% as well as in g/kg/d. When energy intake is reduced and protein intake 
is expressed only in En%, protein intake might falsely be defined as normal while absolute 
protein intake is decreased. 
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The protein intake in the current study was on average 34 g per meal and evenly distributed 
throughout the day, which is in accordance to the current guidelines for elderly (45, 46). 
Specifically during energy restriction, an evenly distributed protein intake with lower 
protein amounts per meal appears to be more effective or as good as a skewed protein 
intake pattern in preserving muscle protein synthesis rates or lean body mass (47, 48). 
Details about the food products and macronutrient distribution are provided in 
Supplemental Tables 7.1-7.3. The current study had an intervention period of 12 weeks and 
is therefore in line with previous work that showed a positive effect of a high protein diet 
on lean body mass (6, 12, 13). A recent meta-analysis (18) concluded that an intervention 
period of 12 weeks or longer is required to show any measurable intervention effect on lean 
body mass preservation. Thus, the current study is most likely of sufficient duration to be 
able to detect any possible differences between diets.  
The present study only focuses on the effect of a dietary intervention on lean body mass. 
However, concurrent changes in physical activity level may interact with the impact of 
dietary intervention. To account for individual variability in physical activity levels, the 
physical activity status of each subject was measured before and at the end of the 
intervention period. The measurements indicate that habitual physical activity levels did not 
change over time in either group. Therefore, we can safely assume that changes in physical 
activity levels did not impact the outcome of the present study. Studies that included 
exercise as a co-intervention generally show a greater effect of a higher protein intake diet 
on lean body mass preservation, which has been confirmed by an RCT and systematic review 
(10, 21, 35, 49, 50).  
The study population of the current work are older men and women (55-70 y) whereas most 
previous work has been performed in young to middle-aged adults (7, 8, 11-16). Although 
weight loss shows clear health benefits for overweight and obese adults, recent studies 
indicate that weight loss is not beneficial per se in an older population (51). A key 
determinant of healthy weight loss in the elderly is the amount of fat and not lean mass loss 
(51). The present study confirms that weight loss causes a substantial decline in muscle 
mass and strength. Therefore, interventions that limit the loss of muscle mass and strength 
during weight loss are of particular clinical relevance for the older adults (37).  
Our observations imply that it is important to maintain a sufficient amount of protein intake 
during weight loss. Thus, decreases in energy intake should be derived mainly from 
decreases in carbohydrates and fat intake. Future studies could aim to optimize protein 
distribution throughout the day. However, current literature shows that total preservation 
of lean body mass is not possible with only a dietary intervention. The combination of 
exercise and energy intake restriction is generally more effective in preserving lean body 
mass (35, 52).  
In conclusion, increasing dietary protein intake above habitual intake levels does not 
preserve lean body mass or muscle strength during prolonged energy intake restriction in 
overweight older adults. 
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Supplemental Figure 7.1 Flow chart of the recruitment of subjects 
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Advertisements 
 
416 people 
interested 
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Not eligible (n=190) 
Not interested (n=130) 
Other (n=20)
61 subjects 
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eGRF (n=4) 
Diabetic (n=5) 
Other (n=6) 
High Protein:  
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completed 
Normal Protein: 
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completed 
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Supplemental Table 7.1: Example of a daily meal plan*  
  High Protein diet Normal Protein diet 
 Food product Food 
product (g) 
Protein 
amount (g) 
Food 
product (g) 
Protein 
amount (g) 
Breakfast Bread  
Cheese  
Meat  
Sweet topping  
Milk  
105  
32 
17  
- 
160  
 70 
16  
- 
16 
141 
 
  
  
 33 17 
Snack Cheese  60   16  
 Supplement  20   25   
 Bread  -  35  
   35  9 
Lunch Bread  70  70  
 Cheese  16   -  
Meat  34   17  
Cream cheese  -  17  
Dessert  179   130  
   32  16 
Snack Dessert  -  130 14 
Dinner Rice  129  85  
 Meat  80   70  
Sauce  45   45  
Cooked vegetables  150   150  
 Uncooked 
vegetables  
100   100  
 Dressing  15   12  
   35  17 
Snack Supplement  20   25   
 Dessert  -  75   
   20  7 
Subjects 
decision of time 
to consume 
Low-fat margarine  20   25  
 Fruit (portion) 1  2  
Egg (per week) 3 -  
Other** Points from list with 
allowed food 
products 
20 - 20 - 
   4  3 
*Based on a subject with a body weight of 90 kg and an energy intake of 8 MJ/d (1911 kcal/d) during the 
intervention. **‘Other’ consists of the 10% of energy that the subjects could choose themselves from a 
restricted list, timing of those products was chosen by the subjects. 
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Supplemental Table 7.2: Macronutrients per meal in the Normal Protein group* 
 Breakfast Snack Lunch Snack Dinner Snack Other** 
Energy (kJ) 1417  972  1227  305 1546  678 1666 
Energy (kcal) 339 232 293 73 369 162 398 
Total fat (g) 10 5 8 1 16 4 9 
Total 
carbohydrates (g) 
41 37 33 4 35 25 59 
Total protein (g) 17 9 16 14 17 7 3 
Fiber (g/d) 7 3 8 0 10 0 0 
Alcohol (g/d) 0 0 0 0 0 0 7 
*Based on a subject with a body weight of 90 kg and an energy intake of 8 MJ/d (1911 kcal/d) during 
the intervention. **‘Other’ consists of the 10% of energy that the subjects could choose themselves 
from a restricted list, timing of those products was chosen by the subjects. 
 
Supplemental Table 7.3: Macronutrients per meal in the High Protein group* 
 Breakfast Snack Lunch Snack Dinner Snack Other** 
Energy (kJ) 1938 955 1477   1911 417  1427 
Energy (kcal) 463 228 353  457 100 341 
Total fat (g) 16 9 9  15 0 10 
Total 
carbohydrates (g) 
42 5 32  41 4 43 
Total protein (g) 33 35 32  35 20 4 
Fiber (g/d) 6 0 5  7 0 2 
Alcohol (g/d) 0 0 0  0 0 8 
*Based on a subject with a body weight of 90 kg and an energy intake of 8 MJ/d (1911 kcal/d) during 
the intervention. **‘Other’ consists of the 10% of energy that the subjects could choose themselves 
from a restricted list, timing of those products was chosen by the subjects. 
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Muscle mass is the main predictor for muscle strength and physical function. For athletes, 
it is important to maintain muscle mass during a period of disuse, since the loss of muscle 
is associated with decreased muscle strength, decreased physical performance and a longer 
recovery period (1, 2). In the older and more clinically compromised populations, the 
consequences of muscle disuse can substantially impact metabolic health (3-5), physical 
functioning (6), quality of life (7) and mortality rates (8, 9). In this thesis, we evaluated 
nutritional interventions to support muscle mass maintenance. Although an adequate 
serum vitamin D concentration is considered important for maintenance of muscle mass 
and function, we uncovered that a high percentage of Dutch athletes have a low vitamin D 
status (chapter 2 and 3). During a period of muscle disuse, supplementing creatine (chapter 
4) or leucine (chapter 5) did not prevent or attenuate the loss of muscle mass and strength, 
neither did a single injection of an anabolic steroid (nandrolone decanoate) (chapter 6). 
During a period of weight loss in older, overweight subjects, simply increasing protein intake 
did not attenuate the loss of muscle mass and function (chapter 7).   
 
Vitamin D  
 
The effect of vitamin D intake on bone health is well-described (10), however, the effect of 
vitamin D on muscle mass and function has only recently received attention from the 
scientific community. Cross-sectional studies have shown that vitamin D status (commonly 
assessed as serum 25-hydroxyvitamin D (25(OH)D) concentration) is positively correlated 
with skeletal muscle mass and function (11-13). Prospective studies have indicated that, in 
the older population, serum 25(OH)D concentrations below 25 or 50 nmol/L are associated 
with an increased fall risk (14), muscle weakness (15), and a greater muscle mass loss (15, 
16) when compared to  serum concentrations above 50 nmol/L. Yet, the limited evidence 
from intervention trials show only small or no positive effects of vitamin D supplementation 
on the preservation of muscle strength in older adults (17-19).  
Although optimal muscle function is essential for athletes, they are currently an 
underrepresented group in vitamin D research (11-16). Until now, only a limited number of 
studies have focused specifically on the effect of vitamin D supplementation on exercise 
performance in athletes (20-24). A daily vitamin D dosage of 5000 IU/d for 8 weeks 
improved 10 meter sprint time and vertical jump performance compared to the placebo 
group (20). In a separate study, provision of 2000 IU/d vitamin D for 4 months increased 
isometric muscular strength by 19% and vertical jump height by 7% in ballet dancers (21). 
The same study also reported that the vitamin D supplemented group suffered fewer 
injuries than the athletes in the control group (21). Another recent study assessed the 
effects of 4000 IU/d vitamin D for 6 weeks and showed a 14% improvement in functional 
recovery from eccentric exercise at 48h and 7 days post-exercise compared to a placebo 
group (22). Important to note, these studies tend to have a small sample size (n=10-24) and 
other studies failed to find an effect of vitamin D supplementation on athletic performance 
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(23, 24). Although more studies are needed to firmly establish the effect of vitamin D 
supplementation on muscle mass and function, previous work suggests that an adequate 
serum vitamin D concentration can enhance muscle mass and function in athletes. 
Individuals with baseline serum 25(OH)D concentrations below <50 nmol/L show greater 
benefits of vitamin D supplementation on muscle mass and function compared to 
individuals with higher vitamin D concentrations at baseline (25, 26). Our study showed that 
a considerable 34% of the athletes had deficient (<50 nmol/L) 25(OH)D concentrations at 
the end of the winter (chapter 3). Only 30% of the highly-trained Dutch athletes had a 
sufficient (>75 nmol/L) total serum 25(OH)D concentration and the other 36% of the 
athletes were vitamin D insufficient (50-75 nmol/L) (chapter 3). We also showed that 
25(OH)D concentrations fluctuate throughout the year, with ~36% lower concentrations in 
March compared to September (chapter 2). Thus, athletes with a sufficient 25(OH)D 
concentration in summer, still have a high risk (20%) of being deficient (<50 nmol/L) in late 
winter (chapter 2). Given the considerable number of deficient athletes and the seasonal 
fluctuations in 25(OH)D concentrations, it is important to assess an athlete’s 25(OH)D 
concentration on a regular basis.  
The interpretation of our results clearly depends on the definition of vitamin D deficiency. 
We defined vitamin D deficiency as serum total 25(OH)D concentrations below 50 nmol/L, 
as traditionally used for bone health and calcium metabolism (27). However, at this point, 
the 25(OH)D concentration that optimally supports training ability and sports performance 
is still under debate (28). Whereas some researchers suggest that 25(OH)D concentrations 
above 50 nmol/L do not have additional benefits, others consider 25(OH)D concentrations 
above 125 nmol/L to be optimal for musculoskeletal health and function (29). The lack of 
consensus among researchers can be partly explained by differences in outcome (bone 
health vs sports performance) and partly by the limited number of randomized controlled 
trials linking 25(OH)D concentrations with functional performance measures (20, 21, 30, 
31). Most of the work on vitamin D supplementation shows positive findings of vitamin D 
supplements when 25(OH)D concentrations are increased from <50 nmol/L to >75 nmol/L 
(20, 22, 32). Therefore, we chose to define total serum 25(OH)D concentrations above 75 
nmol/L as sufficient.  
By defining 25(OH)D concentrations above 75 nmol/L as sufficient, 70% of the athletes in 
our study had an insufficient or deficient serum 25(OH)D concentration at the end of the 
winter season (chapter 3). Supplementing with 2200 IU (55 μg/d) vitamin D per day was 
effective to achieve and maintain a sufficient serum 25(OH)D concentration throughout the 
entire year (chapter 3). However, a daily dosage of 2200 IU/d is much higher than the 
current guidelines of the Netherlands Health Council (33) and the Institute of Medicine 
(IOM) (27). The Netherlands Health Council recommends only 400 IU/d and the Institute of 
Medicine (IOM) recommends 600 IU/d for individuals with minimum or no sunlight 
exposure (27, 33). Individuals with sufficient sunlight exposure are advised to take 
supplements in a lower dosage or no supplements at all. The difference between our data 
and current guidelines is mainly attributable to the difference in target level. Current 
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recommendations are set to maintain 25(OH)D concentrations at 30-50 nmol/L (27, 33), 
whereas our target was to increase 25(OH)D concentrations above 75 nmol/L. Our data are 
therefore more in line with the Endocrine Society (34) and the International Osteoporosis 
Foundation (35), both stating that a vitamin D intake up to 2000 IU/d is needed to increase 
25(OH)D concentrations above 75 nmol/L. 
Although our work did not focus on the effect of an improved 25(OH)D concentration on 
muscle hypertrophy or atrophy, previous work suggests a potential role of vitamin D on 
regulating muscle mass. Currently, only in vitro and in vivo studies using rodents have shown 
an effect of vitamin D on muscle atrophy. More specifically, myocytes treated with the 
active form of vitamin D, 1,25(OH)2D, demonstrates inhibited expression of MAFbx and 
MuRF1, thereby potentially slowing the rate of muscle protein breakdown (36, 37). 
Although some of these findings have already been confirmed in vivo in animals (36, 38-40), 
no human studies are performed to assess the effects of vitamin D supplementation on 
muscle mass preservation. Interestingly, a study in older women with limited mobility and 
a serum 25(OH)D concentration below 60 nmol/L at baseline, increased muscle fiber size by 
a substantial 10% in 4 months while receiving vitamin D supplementation (4000 IU/d) (41). 
These pilot data suggest that vitamin D supplementation can have anabolic effects, even in 
the absence of an exercise intervention. Thus, vitamin D supplementation may also help to 
attenuate disuse-induced muscle atrophy. Until now, we propose that athletes should aim 
to prevent vitamin D deficiency throughout the year to allow optimal muscle mass and 
function. More studies are needed to provide evidence for the effect of vitamin D 
supplementation on muscle mass and function during muscle maintenance and during 
muscle atrophic-conditions. Also, since 25(OH)D concentrations are positively associated 
with the rehabilitation after surgery (42, 43), the effects of vitamin D supplementation after 
a period of injury or disuse remains to be established.   
 
Creatine, leucine and nandrolone 
  
Unlike for vitamin D, there is ample evidence for creatine, leucine and nandrolone 
decanoate to enhance muscle mass gains in combination with or without exercise. 
However, far less is known about the capacity of these compounds to attenuate muscle 
atrophy. To induce muscle atrophy, we used a 7-day single-leg immobilization model in 
healthy young men in order to assess the effects of three different strategies to preserve 
muscle mass: two nutritional strategies, creatine supplementation prior to and during 
disuse and leucine supplementation during disuse, and one pharmacological strategy 
involving nandrolone decanoate, administered once at the beginning of the disuse period. 
None of the compounds attenuated the loss of muscle mass during 7 days of single-leg 
immobilization in healthy, young men. 
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Creatine monohydrate 
Creatine supplementation has been considered as one of the most promising nutritional 
strategies to preserve muscle mass during disuse (44, 45). Previous speculation is based on 
the fact that creatine supplementation can enhance muscle mass and strength gains in the 
presence as well as in the absence of resistance-type exercise training (46-49). The increase 
in lean mass following creatine supplementation has, at least partly, been attributed to 
water retention in muscle tissue (50, 51). The greater osmotic pressure following the 
increase in intramuscular creatine content has been suggested to result in muscle cell 
swelling, which is considered to be a key stimulus for cell growth (50, 52). In addition, 
previous work showed that creatine supplementation can directly activate myogenic 
regulatory factors (MRFs), IGF-1 or other myogenic cofactors, which are known to initiate 
muscle fiber hypertrophy or attenuate muscle protein breakdown (53-55). One study in 
particular assessed muscle protein synthesis and whole body protein breakdown after a 5-
day creatine loading phase (20 g/d) (56). In this study, creatine loading did not increase 
whole body or muscle protein synthesis rates (56). Creatine loading did, however, reduce 
whole body protein breakdown by 7.5% compared to a placebo group, suggesting 
anticatabolic effects of creatine (56). Creatine supplementation has also been shown to 
stimulate satellite cell proliferation and upregulate genes that promote protein synthesis, 
thereby possibly enhancing muscle mass gains over a prolonged supplementation period 
(55, 57-61). 
Despite the biological plausibility, creatine supplementation did not prevent nor attenuate 
the decline in muscle mass or strength during short term disuse in our study (chapter 4). 
Our findings are in line with a previous study by Hespel et al., showing that creatine 
supplementation during a 14-day immobilization period did not preserve muscle mass 
(placebo: -850 vs creatine: -1020 mm2 CSA of the quadriceps muscle) (53). However, this 
study did not include a creatine loading phase to increase total muscle creatine content 
before the start of the disuse period. In our study, the 5-day creatine loading phase (20 g/d) 
allowed the total muscle creatine content to increase from 90±9 to 107±4 mmol per kg dry 
muscle prior to disuse. Still, the increased muscle creatine content before the start of the 
disuse period did not attenuate the loss of muscle mass. The only previous study that 
showed that creatine supplementation attenuates the loss of lean mass applied a 7-day 
period of upper arm immobilization (-3.7 vs +0.9% for the placebo and creatine group) (62). 
However, this study assessed muscle mass using DEXA scans, which includes total body 
water content in the assessment of lean tissue mass (63). Therefore, the observed 
preservation of lean body mass in the creatine group might be attributed to the increase in 
body water content resulting from creatine supplementation. 
Although the anabolic effects of creatine supplementation in active young men are well 
established (46-48), our data demonstrates that creatine supplementation prior to and 
during disuse does not prevent the loss of muscle mass or strength. It is likely that creatine 
supplementation has a greater anabolic effect on muscle mass when combined with regular 
muscle contraction (46-49). Therefore, creatine supplementation might serve to enhance 
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the regain of muscle mass after a period of disuse when applied in combination with a 
resistance-exercise program. This suggestion is supported by the study of Hespel et al., 
which showed that CSA of the quadriceps muscle increased to a greater extent with creatine 
loading (21%) compared to a placebo (14%) after 10 weeks of rehabilitation (53). Therefore, 
although creatine supplementation does not preserve muscle mass during disuse, it may 
still be useful during rehabilitation from injury. 
 
Leucine 
Leucine has been found to be the most potent amino acid to stimulate muscle protein 
synthesis and inhibit muscle protein degradation (64-67). Leucine increases muscle protein 
synthesis rates via the direct or indirect regulation of the mTOR pathway (68-72). In 
addition, leucine supplementation can decrease muscle protein breakdown by inhibiting 
the ubiquitin pathway, which involves MuRF, MAFbx and FOXO proteins (73). So far, 3 
animal studies have assessed the muscle preserving effect of leucine in an atrophy model 
of which 2 studies show a beneficial effect of leucine (74-76). A recent study from English 
et al. assessed the effects of leucine supplementation during 2 weeks of bed rest in young 
men (77). Interestingly, this study showed that leucine supplementation preserved lean 
body mass after 7 days of bed rest (-1.5±0.3 and -0.8±0.3 kg in the control and leucine group, 
respectively), but this effect was no longer evident after 14 days of bed rest (respectively -
1.5±0.3 and -1.0±0.3 kg). In contrast, our data show no effect of leucine on the preservation 
of muscle mass following one week of limb immobilization (chapter 5). The apparent 
discrepancy between our data and those by English et al. could be attributed to the disuse 
model (limb immobilization vs bed rest) or the amount of leucine provided (7.5 vs 13.2 g 
per day). Whether leucine only exerts an effect during bed rest remains to be established, 
but we postulate that the difference is more likely attributed to the dosage of leucine. 
English et al. provided 13.2 g leucine per day, divided over 3 meals (4.4 g/meal), with each 
meal containing more than 20 g protein. We chose to give 7.5 g leucine per day, divided 
over 3 times per day, thus 2.5 g leucine ingested with each meal. The ingestion of 2.5 g 
leucine in combination with a meal-like amount of protein (20 g) has been shown to increase 
muscle protein synthesis rates by 22% more than the protein bolus alone (78). However, 
this previous work is conducted in active, young males and the question remains what 
dosage is needed during disuse. During disuse, the anabolic response to food intake is 
diminished by ~30-70% (79-81). Due to this reduced capacity to respond to anabolic stimuli, 
a higher dosage of leucine might be required to overcome this anabolic resistance and 
maximally stimulate muscle protein synthesis rates during disuse. Thus, despite the fact that 
2.5 g leucine stimulates muscle protein synthesis rates in active young males, it is possible 
that this amount does not stimulate muscle protein synthesis rates (markedly) in a disuse 
model.  
Moreover, the anabolic impact of leucine supplementation may be determined by habitual 
levels of protein intake (66, 82). More specifically, leucine can enhance muscle protein 
synthesis rates when protein intake is suboptimal (~6 g protein) (66). Therefore, in 
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individuals with a suboptimal protein intake, such as in older adults or during hospitalization 
(83), the addition of leucine could be effective in maximizing muscle protein synthesis rates 
without the need to ingest larger protein boluses. In our study, healthy subjects were fed in 
energy balance, with a dietary protein intake of 1.1±0.1 g/kg/d, which is well above the 
Recommended Daily Allowance (RDA) of 0.8 g/kg/d (84). In this regard, our findings may 
not necessarily represent the impact of leucine supplementation on preserving skeletal 
muscle mass during disuse under malnourished conditions.  
 
Nandrolone decanoate 
Besides creatine and leucine supplementation, we also tested the effect of the anabolic 
steroid, nandrolone decanoate, on muscle mass preservation during disuse. In resistance-
trained subjects, anabolic steroid administration has been shown to increase lean mass by 
2-5 kg (85, 86) and is therefore a more potent stimulus for muscle mass gains than what has 
been reported in most nutritional interventions (~1-3 kg) (87, 88). Nandrolone decanoate, 
or 19-nortestosterone, is a synthetic anabolic steroid that has a chemical structure similar 
to testosterone, although it does not show the same androgenic (masculinization) effects 
(89). Anabolic steroid administration, such as nandrolone decanoate, has been shown to 
increase fat free mass, muscle cross-sectional area and/or muscle strength in healthy 
subjects and in several patient groups (86, 90-92). In agreement, administration of 
nandrolone decanoate and testosterone has been shown to increase protein synthesis 
twofold (via IGF-1 and Akt/mTORC1 signalling) and decrease proteolysis (expression of 
FOXO transcriptional genes) (93-95). Based on these findings, we hypothesized that 
nandrolone decanoate administration may represent an effective pharmaceutical strategy 
to prevent or attenuate muscle disuse atrophy. However, as presented in chapter 6, 
nandrolone decanoate did not attenuate muscle disuse atrophy during 7 days of leg 
immobilization in healthy adults. Our study is the first to assess the effects of nandrolone 
decanoate administration prior to a period of disuse in vivo in humans. Based on our 
findings, we can speculate that the absence of any effect of nandrolone decanoate in our 
study is due to the rate of muscle loss and/or the duration of the study protocol. Firstly, 
although nandrolone has been shown to prevent the loss of muscle mass in several patient 
groups (96-98), these patients were not completely inactive, as was the case in our disuse 
model. The rate of muscle loss in our study was also much more rapid (0.8 % per day) 
compared to what has been described in these patient groups (96-98). Thus, it could be 
speculated that the complete absence of muscle contraction, and the accompanied rapid 
rate of muscle loss, overpowers the anabolic effect of nandrolone administration. Secondly, 
to our knowledge, all previous studies administered repeated injections of (50-600 mg) 
nandrolone over a period of 1-6 months (86, 90-92, 96-99), whereas we administered only 
one single injection of 200 mg nandrolone. Although serum nandrolone and total 
testosterone concentrations in our study were still elevated after 7 days of immobilization, 
the period might be too short for nandrolone to attenuate the loss of muscle mass. Our 
study protocol was designed to represent a practical and clinically relevant strategy for 
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patients being hospitalized following both acute injury as well as scheduled surgery. 
However, it appears that a single dose of nandrolone is not effective in preventing or 
attenuating muscle loss over 7 days of complete muscle disuse. We suggest that muscle is 
lost at such a rapid rate (0.8 % per day) during the first days of muscle disuse that even a 
pharmacological intervention is not strong enough to counteract this loss of muscle mass.  
 
Protein 
 
The intake of dietary protein stimulates muscle protein synthesis and inhibits muscle 
protein breakdown rates, thereby allowing net muscle protein accretion (100). Therefore, 
simply increasing dietary protein intake could potentially alleviate the decline in basal (81, 
101-106) and postprandial (79-81) rates of muscle protein synthesis that is observed during 
disuse. Although some studies show that supplementation of protein or essential amino 
acids can preserve muscle mass during disuse (107), not all studies confirm this finding (108, 
109). It remains to be established whether the apparent discrepancy between these studies 
is attributed to the duration of disuse (ranging from 5 to 28 days), the disuse model (bed 
rest vs limb immobilization), the level of protein intake (0.8 vs 1.1 g/kg/d) or the study 
population (old vs young, men vs women). 
Similar to periods of muscle disuse, energy intake restriction lowers the anabolic response 
to protein ingestion (110-112), contributing to the loss of muscle mass. Consequently, it has 
been previously speculated that an increased protein intake can attenuate the loss of 
muscle mass during periods of weight loss (113, 114). In chapter 7, we assessed the effects 
of an increased dietary protein intake (from 0.9 g/kg/d to 1.7 g/kg/d) on the preservation 
of muscle mass during energy intake restriction in overweight, older adults. After 12 weeks 
of 25% energy intake restriction, we observed a 10% decrease in body weight. The reduction 
in body weight was accompanied by a 2 kg decline in lean body mass and as much as a 10% 
decline in leg strength. Increasing dietary protein intake did not preserve lean body mass 
nor did it prevent the decline in muscle strength associated with prolonged energy intake 
restriction. We therefore conclude that increasing protein intake does not attenuate the 
loss of muscle mass during energy intake restriction. Our findings are in line with some (115, 
116), but not all previous studies (110, 117, 118). Two major differences in study design 
between our study and previous work could explain these findings. Firstly, our study 
compared an increase in protein intake (1.7 g/kg/d) to a diet that maintained habitual 
protein intake levels (0.9 g/kg/d), while other studies compared a high protein diet to a 
group that decreased their protein intake (0.8 g/kg/d or lower) (110, 118-121). Whereas our 
high protein group demonstrated the same loss of lean body mass (20% of total weight lost) 
compared to other studies (117, 122), our normal protein group experienced a lower 
percentage of lean body mass loss (23% of total weight lost) compared with the results of 
the aforementioned studies (35%) (117, 123). Thus, increasing protein intake above habitual 
intake levels does not attenuate the loss of lean mass, but a decrease in protein intake 
during energy intake restriction could possibly enhance lean mass loss. Secondly, most of 
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the previous studies that observed a muscle-preserving effect of a high-protein diet, 
combined a dietary intervention with resistance training (124, 125). These studies show that 
the combination of a dietary intervention with resistance-type exercise training can even 
completely prevent the loss of muscle mass (124, 125). Thus, based on our study and 
current literature, total preservation of muscle mass during a period of energy intake 
restriction appears to be possible when protein intake is maintained (or increased) and 
combined with resistance-type exercise training (124, 125). During energy intake 
restriction, maintenance of protein intake is only possible when the protein density of the 
diet is increased. The protein density of a diet can be enhanced with food products that are 
naturally high in protein such as dairy products, by using protein supplements and/or by 
using protein enriched food products. The benefit of using protein supplements is that the 
protein density of the diet can be easily increased while overall energy intake is restricted. 
For example, during energy intake restriction, an individual can lower overall energy 
(including the protein) from their existing diet, but simultaneously increase protein density 
of the diet through protein supplementation. Moreover, protein supplements are effective 
for easily distributing protein intake over the day. Recent studies have reported that most 
individuals ingest protein in a skewed fashion throughout the day, with a low protein intake 
at breakfast and higher intakes at dinner. However, an equal protein distribution has been 
shown to allow a greater stimulation of 24 h muscle net balance (126-128), which might 
prevent muscle mass loss over a longer period (129). Protein supplements represent a 
convenient way to increase protein intake at breakfast and lunch to balance protein intake 
over the day. However, when protein supplements are consumed for prolonged periods, 
the compliance generally declines because of the limited number of different flavors and 
textures (130, 131). Protein enriched food products, such as bread, soup or fruit juices, can 
increase protein intake without changing eating habits or increasing portion sizes. Indeed, 
recent studies show that including familiar protein enriched foods and drinks increase 
protein intake in institutionalized and community-dwelling older adults (132, 133). 
 
Methodological considerations 
 
Although the presented studies were diverse in nature, some generic methodological issues 
and considerations regarding the models for muscle atrophy, study population and 
investigated nutritional compounds need to be discussed.  
 
Models of muscle atrophy 
This thesis presents two models to induce muscle atrophy: single-leg immobilization and 
energy intake restriction. Both models induced a substantial loss of muscle mass, 6% during 
7 days of leg immobilization and 2 kg lean mass (representing 3.5%) during 12 weeks of 
energy intake restriction. Both models are applicable to real-life settings such as the 
recovery from injury, illness and/or during periods of weight loss.  
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In chapter 4, 5 and 6, we chose for a short-period (7 days) of limb immobilization to model 
the typical length of hospitalization or recovery from sports injuries, which ranges from 5-7 
days (134-136). In this short period, the nutritional interventions tested were not strong 
enough to counteract the loss of muscle mass and strength. In the studies presented, we 
show that young, healthy men lose ~6% muscle mass during 7 days of leg immobilization. 
To put this into perspective, the same amount of muscle mass can be gained during 12 
weeks of resistance type exercise training (137). Thus, it is likely that much more time and 
effort is required to regain the muscle mass that is lost during short periods of disuse. 
Confirming this, in the absence of a resistance training program, the young men in our study 
regained only 1.8% muscle mass after one week of recovery, representing 26% of the 
muscle mass lost (chapter 4). Older adults appear unable to fully regain the loss of muscle 
mass after a 4-wk rehabilitation program including resistance-type exercise 3 times per 
week (138). Due to the rapid loss of muscle mass during short periods of disuse and the 
difficulty to regain muscle mass, it has been previously hypothesized that successive short 
periods of disuse throughout the lifespan will enhance the development of sarcopenia 
(Figure 1 of general introduction). Therefore, there is a great need for effective strategies 
to prevent the loss of muscle mass during short periods of disuse.  
In chapter 7, we conducted a fully controlled dietary intervention for 12 weeks to assess 
the effect of a high protein diet on the preservation of lean mass during energy intake 
restriction. We chose for an intervention period of 12 weeks since this is the period required 
to show any detectable effect on the preservation of lean body mass (139). The strictly 
controlled nature of the study enhanced compliance of the subjects and allowed us to 
assess the efficacy of the dietary intervention without the possible effects of an increased 
protein intake on satiety and thus energy intake. This is confirmed by the similar decline in 
body weight in both intervention groups (high protein group: -8.9±2.9 kg vs normal protein 
group: -9.1±3.4 kg). However, we acknowledge that this level of control is not always 
possible in real-life. 
 
Study population 
In this thesis, many different populations have been studied. The first chapters (chapter 2 
and 3) were performed in male and female athletes. We continued with studies in young, 
healthy males (chapter 4, 5 and 6), and the last chapter (chapter 7) was conducted in 
overweight, older men and women. Thus, most subjects included in our studies were 
healthy and young (18-35 y) except for the subjects in chapter 7 (55-70 y). We did not find 
a muscle-preserving effect of the nutritional compounds that we tested (chapter 4, 5, 6 and 
7), which might be partly attributed to the characteristics of the study population chosen. 
We chose to include young healthy males in chapters 4 to 6 to study the effects of our 
nutritional interventions since they generally show a greater loss of muscle mass compared 
to older adults. However, they were not nutritionally compromised at baseline as indicated 
by a protein intake of 1.1±0.1 g/kg/d, which is well above the RDA as currently set at only 
0.8 g/kg/d (84). We conclude that neither additional leucine, nor additional protein beyond 
General discussion 
129 
habitual intakes preserve muscle mass in the populations that we studied. However, we 
acknowledge that our findings cannot be directly translated to an older and/or clinically 
compromised population with a protein intake much lower than 1.1 g/kg/d (83) and a higher 
chance of being malnourished, possibly making them more responsive to an increased 
protein or leucine intake. Furthermore, muscle phosphocreatine levels are generally 5% 
lower in the elderly population (140) than those found in younger adults. Given such lower 
muscle creatine content levels, which are suggested to contribute to the loss of muscle mass 
during aging (140), creatine loading may represent a more effective strategy for preserving 
muscle mass during disuse in the older population. However, whether the nutritional 
compounds that we tested in this thesis (creatine, leucine, protein) can indeed preserve 
muscle mass and strength during disuse in an older population remains to be established. 
 
Nutritional compounds 
When combined with resistance type exercise training, there is prior evidence for all of the 
compounds (creatine, leucine, nandrolone, protein) studied in this thesis to be effective in 
augmenting muscle mass and strength gains (46, 47, 86, 87, 90-92). Furthermore, it is well 
established that protein and leucine stimulate muscle protein synthesis rates in an acute 
setting (78, 100, 141). Therefore, it was surprising to find that none of these compounds 
prevented or attenuated muscle loss during disuse or energy intake restriction.  
The dosages of the nutritional compounds that we provided were in line with current 
recommendations and best estimates based on current evidence (78, 142-144). However, 
as dose-finding studies are lacking and considering the development of anabolic resistance 
during disuse, it is possible that a higher dosage of our nutritional compounds is required. 
Therefore, future nutritional studies on the preservation of muscle mass during disuse 
should include dose-dependent effects of these compounds. 
These studies might involve other novel nutritional compounds such as ursolic acid, 
phosphatidic acid, omega-3 fatty acids and resveratrol which appear to affect anabolic 
mechanisms alternative to those affected by the compounds in this thesis. Although these 
lesser-studied compounds have only been tested in myocytes or animals models (145-148), 
they might be able to prevent muscle mass during disuse in humans. Furthermore, 
combinations of two or more nutritional compounds may have complimentary or 
synergistic effects in the preservation of muscle mass during disuse. Future research could 
focus on administering multiple nutritional compounds known to affect different 
mechanisms, for example stimulating muscle protein synthesis and lowering breakdown 
simultaneously, or reducing inflammation or insulin sensitivity. By modulating different 
mechanisms, a combination of nutritional compounds may have stronger effects on muscle 
mass preservation than a single compound has.  
Also, the combination of nutrition with an exercise mimetic, such as neuromuscular 
electrical stimulation (NMES) may be more effective than a nutritional intervention only. 
Involuntary muscle contractions by NMES has been shown to prevent the loss of muscle 
mass (but not muscle strength) during 5 days of leg immobilization (149). The combination 
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of NMES with a nutritional intervention (creatine or leucine) might be able to effectively 
attenuate or even prevent the decline in both muscle mass and strength.  
Moreover, since the nutritional compounds that we tested are effective in combination with 
resistance type exercise training, they might contribute to the regain in muscle mass and 
strength after a period of muscle loss. As such, protein, creatine and leucine 
supplementation may be (more) effective during clinical rehabilitation as they likely 
augment the skeletal muscle adaptive response to rehabilitative training. However, it 
should be noted that muscle loss during disuse occurs at a rate that is several-fold greater 
than muscle (re)gain during resistance type exercise training. Therefore, it is imperative that 
we continue our endeavors to identify nutritional or pharmaceutical compounds that may 
help in preventing or attenuating disuse atrophy (150). 
 
Future research 
 
 Although the first studies show promising results, more studies are needed to establish 
the effects of vitamin D supplements on muscle mass and function in athletes. 
 The effect of vitamin D supplementation on the preservation of disuse-induced atrophy 
remains to be established. 
 More studies are needed to establish whether creatine or leucine can prevent or 
attenuate the loss of muscle mass and strength during disuse in an older population.   
 The effect of nutritional interventions in combination with an exercise mimetic, such as 
NMES, on the preservation of muscle mass during a period of disuse remains to be 
established. 
 The effects of nutritional compounds such as ursolic acid, phosphatidic acid, omega-3 
fatty acids and resveratrol on muscle mass preservation during disuse remain to be 
assessed.  
 It remains to be established if nutritional interventions can enhance the regain of 
muscle mass and strength following a period of disuse. 
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Muscle mass is the main predictor for muscle strength and physical function. The amount of 
muscle mass can decline rapidly during periods of reduced physical activity or during periods 
of energy intake restriction. For athletes, it is important to maintain muscle mass, since the 
loss of muscle is associated with decreased muscle strength, decreased physical performance 
and a longer recovery period. In the older and more clinically compromised populations, the 
consequences of muscle loss can substantially impact metabolic health, physical functioning, 
quality of life and mortality rates. In this thesis, the effects of different nutritional interventions 
on the preservation of muscle mass are being evaluated. 
Vitamin D deficiency (serum 25-hydroxyvitamin D or 25(OH)D) has been associated with 
increased muscle loss and reduced muscle strength. In chapter 2, we identified seasonal 
changes in 25(OH)D concentration in elite athletes. We observed that 25(OH)D concentrations 
were highest at the end of summer (113±26 nmol/L), and lowest at the end of winter (78±30 
nmol/L). Athletes that had a sufficient 25(OH)D concentration (>75 nmol/L) at the start of the 
study, still had a high risk (20%) of being deficient (<50 nmol/L) in late winter. Thus, a sufficient 
25(OH)D concentration in summer does not guarantee a sufficient status in winter. In chapter 
3, we assessed 25(OH)D concentrations in 128 highly-trained athletes and found that 70% had 
a deficient or insufficient 25(OH)D concentration at the end of the winter season. 
Supplementation with 2200 IU/d vitamin D resulted in a sufficient 25(OH)D concentration in 
80% of the athletes after 12 months and was therefore a better dosage to improve 25(OH)D 
concentration than 400 or 1100 IU/d.  
In the following chapters, we assessed the effects of creatine supplementation (chapter 4), 
leucine supplementation (chapter 5) and nandrolone administration (chapter 6) on the 
preservation of muscle mass during a short period of muscle disuse. For all of these compounds 
there is prior evidence for their efficacy in augmenting muscle mass and strength gains in 
combination with resistance-type exercise training and all have been suggested to attenuate 
the loss of muscle mass during a period of muscle disuse. During 7 days of single-leg 
immobilization, muscle mass decreased by ~6% and muscle strength decreased by ~8%. 
Surprisingly, none of the tested compounds attenuated the loss of muscle mass during 7 days 
of single-leg immobilization in healthy, young men.  
In chapter 7, we performed a fully controlled dietary intervention to assess the impact of a 
high protein intake on the preservation of lean body mass during 12 weeks of energy intake 
restriction. Sixty-one overweight and obese men and women were randomly assigned to either 
a high protein diet (1.7 g/kg/d) or a normal protein diet (0.9 g/kg/d) during 12 weeks of 25% 
energy intake restriction. During the dietary intervention, subjects lost 9±3 kg body weight 
with a concomitant 2±2 kg decline in lean body mass with no differences between the two 
intervention groups. Thus, increasing protein intake above habitual intake levels (0.9 g/kg/d) 
did not preserve lean body mass during a period of energy intake restriction.  
Finally, in chapter 8 we reflected on the main findings described in this thesis. In this chapter, 
we point out that the populations studied were all healthy and well-nourished. We conclude 
that in these populations, additional creatine, leucine and protein beyond habitual intakes did 
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not preserve muscle mass. Older and/or malnourished individuals might be more responsive 
to these nutritional interventions. Future research could also focus on the combined effects of 
two or more nutritional compounds during disuse that are known to affect different 
mechanisms. Moreover, we speculate that the tested nutritional compounds could be 
effective in accelerating the regain of muscle mass and strength after a period of muscle loss. 
However, it should be noted that muscle loss during disuse occurs at a rate that is several-fold 
greater than muscle (re)gain during resistance type exercise training. Therefore, it is 
imperative that we continue our endeavors to identify nutritional or pharmaceutical 
compounds or exercise mimetics that may help to prevent or attenuate disuse atrophy. 
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Spiermassa is de belangrijkste voorspeller van spierkracht en lichamelijk functioneren. De 
hoeveelheid spiermassa kan snel afnemen tijdens een periode van verminderde 
lichamelijke activiteit of verlaagde energie-inname. Voor sporters is het belangrijk om de 
hoeveelheid spiermassa te behouden omdat een afname van spiermassa geassocieerd is 
met een afname in spierkracht, verminderde sportprestaties en een langere herstelperiode 
na een blessure. In ouderen of kwetsbare populaties kan een afname van spiermassa leiden 
tot een verminderde metabole gezondheid, functionele capaciteit, kwaliteit van leven en 
levensverwachting. Het is dus belangrijk om spiermassa te behouden. In dit proefschrift is 
de invloed van verschillende voedingsinterventies getest op het behoud van de spiermassa.  
Een vitamine D tekort (aangeduid als serum 25-hydroxyvitamine D of 25(OH)D concentratie) 
is geassocieerd met een verhoogd spiermassaverlies en een afname van de spierkracht. In 
hoofdstuk 2 hebben we de seizoensvariatie in 25(OH)D concentratie gemeten bij sporters. 
We zagen dat de 25(OH)D concentratie in het bloed het hoogst was aan het einde van de 
zomer (113±26 nmol/L) en het laagst aan het einde van de winter (78±30 nmol/L). Sporters 
met een voldoende 25(OH)D concentratie (>75 nmol/L) aan de start van de studie, hadden 
toch een hoog risico (20%) op het ontwikkelen van een vitamine D tekort (<50 nmol/L) aan 
het einde van de winter. Een voldoende vitamine D concentratie in de zomer garandeert 
dus geen voldoende vitamine D concentratie in de winter. In hoofdstuk 3 hebben we de 
25(OH)D concentratie bij 128 topsporters gemeten en we observeerden dat 70% van de 
sporters aan het eind van de winter een lage vitamine D concentratie (<75 nmol/L) hadden. 
Vitamine D suppletie van 2200 IE/d resulteert in een voldoende 25(OH)D concentratie in 
80% van de sporters na 12 maanden en was daardoor een betere dosis om de vitamine D 
concentratie te verhogen dan 400 of 1100 IE/d. In de hoofdstukken die daarop volgen 
hebben we de effecten van creatine supplementen (hoofdstuk 4), leucine supplementen 
(hoofdstuk 5) en het toedienen van nandrolon (hoofdstuk 6) onderzocht op het behoud 
van spiermassa tijdens een korte periode van inactiviteit. Voor al deze componenten is 
bewijs uit eerdere studies dat ze de toename in spiermassa en spierkracht kunnen vergroten 
als ze in combinatie met krachttraining worden gebruikt. Mede daardoor wordt er 
gespeculeerd dat deze componenten mogelijk ook spiermassaverlies kunnen tegengaan 
tijdens een periode van inactiviteit. Gedurende een periode van 7 dagen immobilisatie van 
één been zagen we een afname in spiermassa van ~6% en een afname in spierkracht van 
~8%. Opvallend is dat geen van de onderzochte componenten (creatine, leucine en 
nandrolon) de afname van spiermassa konden tegengaan in jonge, gezonde mannen tijdens 
een 7-daagse gipsbehandeling van het been.  
In hoofdstuk 7 staat beschreven dat we een volledig gecontroleerde voedingsinterventie 
hebben uitgevoerd om het effect te meten van een verhoogde eiwitinname op het behoud 
van spiermassa gedurende een 12-weekse periode van een verlaagde energie-inname (-
25%). Eenenzestig mannen en vrouwen met overgewicht of obesitas zijn door middel van 
randomisatie toegewezen aan een hoog eiwit-dieet (1.7 g/kg/d) of aan een dieet met een 
normale eiwitinname (0.9 g/kg/d). Tijdens deze voedingsinterventie verloren de 
deelnemers gemiddeld 9±3 kg lichaamsgewicht, wat gepaard ging met een verlies van 2±2 
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kg spiermassa. Omdat beide groepen evenveel spiermassa verloren, concluderen wij dat 
een verhoogde eiwitinname geen effect heeft op de afname van spiermassa tijdens een 
periode van een verlaagde energie-inname. Ten slotte hebben we in hoofdstuk 8 de 
belangrijkste bevindingen in dit proefschrift bediscussieerd. In dat hoofdstuk beschrijven 
we o.a. dat de bestudeerde populaties allemaal gezond zijn en niet ondervoed. We 
concluderen dat extra creatine, leucine en eiwit bovenop de dagelijkse inname in onze 
gezonde onderzoekspopulatie niet resulteert in een behoud van spiermassa tijdens een 
periode van immobilisatie van een ledemaat. Echter, het is mogelijk dat ouderen en 
ondervoede personen gevoeliger zijn voor voedingsinterventies. Toekomstig onderzoek zou 
zich ook kunnen richten op de combinatie van meerdere voedingscomponenten tegelijk op 
het behoud van spiermassa. We speculeren dat de onderzochte voedingsinterventies 
mogelijk wel een effect hebben op het herstel van spiermassa na een periode van 
spiermassaverlies. Echter, we benadrukken dat spierverlies veel sneller plaatsvindt dan het 
aanmaken van spiermassa. Het is daarom essentieel dat we blijven zoeken naar strategieën 
zoals voedings- en farmacologische componenten die spiermassaverlies kunnen tegengaan. 
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